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Abstract
Of the threats faced by current and future generations, man-made climate change is perhaps the 
greatest.  In order to combat climate change, chemists must contribute to reducing the environmental 
impact of synthetic chemistry.  Biocatalysis could be a useful tool with which to combat climate change, 
since environmentally benign syntheses of complex molecules can be achieved through its use.
Benzoate dioxygenase (BZDO) enzymes allow access to arene ipso,ortho-diols through the 
dearomatisation of sodium benzoate (scheme A-01).  This enantiopure building block has previously
shown utility in the synthesis of natural products and cyclitols.
This thesis sought to expand on the known chemistry of arene ipso,ortho-diol A-01 through the 
synthesis of arene diol derived heterocycles and asymmetric epoxidation organocatalysts (scheme A-
01).  In addition to these themes, the microbial oxidation of sodium 4-fluorobenzoate has been 
achieved, providing fluoro-arene ipso,ortho-diol  A-02. The reactivity of fluoro-arene diol A-02 has 
been probed through a number of oxidative transformations.
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Introduction to microbial dearomatisation chemistry
The importance of catalysis in synthesis
The diminishing supply of fossil fuels and of catalytically valuable transition metals, and the ever-
increasing threat of man-made climate change are two of the greatest challenges faced by current and 
future generations. Current synthetic methods are highly reliant on the use of transition metals for 
catalysis and often require reagents which are known to pose significant environmental risks.  Over 
previous decades, synthetic chemists have conducted vital research to help mitigate the risks posed
by these environmental issues, however the development of environmentally benign synthetic 
methodologies remains of vital importance.
In addition to environmental concerns, there is also a continuing demand to synthesise novel organic 
molecules for a variety of applications. This demand is partly pharmaceutically driven due to, for 
example, the increasing prevalence of antibiotic resistance1-3 and the ongoing challenge to find 
effective treatments for cancer.4, 5 As such, it is necessary that routes to novel organic compounds are 
also thoroughly researched.
Catalysis – the increase in rate of a reaction by the addition of a reagent that is not itself consumed –
allows reactions to be conducted efficiently and economically on multi-tonne scales.  The 
pharmaceutical, polymer and petroleum industries consequently rely heavily on catalysis, which is 
evident from 90% of industrially produced chemicals requiring at least one catalytic reaction to 
synthesise.6 Many catalytic reactions currently in use, however, cannot be considered as being 
environmentally benign processes, since they fail to fulfil several criteria of green chemistry (figure I-
01).7
Figure I-01: Principles of green chemistry.7
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Biocatalysis is the application of enzymes to catalyse chemical reactions and offers many benefits over 
more traditional catalytic methods.8, 9 Biocatalysts tend to be non-toxic, environmentally benign and 
used under ambient reaction conditions.  Furthermore, enzymes are also highly regio- and stereo-
selective whilst offering extremely high catalytic turnovers, with reactions requiring typical catalyst 
loadings of between 10-6 and 10-9 mol%.  The low environmental footprint of biocatalysts coupled with 
their high selectivity make them an attractive candidate for use in industrial scales syntheses.
Biocatalysis can be conducted using either isolated enzymes or whole-cells, with each method offering 
contrasting advantages and disadvantages.9 Enzyme extracts are often favoured over whole-cells for 
use in biocatalysis, since reactions with enzymes involve simple apparatus and tolerate higher 
substrate concentrations.  However, use of isolated enzymes requires the addition of cofactors. 
Additionally, not all enzymes are isolable since denaturation can occur on removal from their parent 
cell. In contrast to this, whole-cell biotransformations do not require addition of supplementary 
cofactors, however specialist equipment is often necessary and substrate concentrations are often 
reduced when compared to using isolated enzymes.  Substrate and product solubility can also be 
problematic when using whole cells, as biotransformations must be conducted in aqueous media.
One of the successes of biocatalysis in pharmaceutical synthesis is in the manufacture of Sitagliptin.6, 
10 Sitagliptin – the active ingredient in Januvia™ - is used in the management of type 2 diabetes and 
made sales of $4.1 billion for Merck in the calendar year of 2012.  A transaminase was used in the 
synthesis of Sitagliptin to enantio- and chemo-selectively convert ketone I-01 to amine containing 
Sitagliptin in >99% e.e. (scheme I-01).  The transaminase used was developed through 11 rounds of 
directed evolution using extensive high-throughput screening, resulting in an enzyme that possessed 
4 orders of magnitude greater activity than the original transaminase.  Other desirable features were 
also present in the enzyme, such as its ability to endure substrate concentrations as high as 100 g/L.  
This biocatalytic reaction was judged to make the overall synthesis of Sitagliptin superior to the 
previous route, which utilised rhodium-catalysed asymmetric hydrogenation, and earned Merck and 
Codexis the ‘Presidential Green Chemistry Challenge Award’ in 2010.
Scheme I-01: Transaminase reaction used in the synthesis of Sitagliptin.  a) Arthrobacter transaminase, 




Dearomatisation chemistry allows the synthesis of highly functionalised organic molecules from simple 
aromatics, which themselves are often inexpensive and abundant.  The clear utility of dearomatisation 
chemistry has led to efforts by several research groups to develop chemical methodologies to achieve 
this.  However, whilst the oxidation of alkenes can be achieved readily using a variety of reagents, the 
oxidation of aromatic compounds remains challenging on account of their conjugated, aromatic π-
system possessing high stability.  A comprehensive review on chemical dearomatisation methods has 
been recently published by Sarlah.11
Dearomatisation methods for monocyclic arenes can be broadly categorised into reductive, oxidative, 
transition metal-mediated and cycloaddition-based methodologies.11 The Birch reduction, first 
reported in 1944, effects the sodium mediated dearomatisation of arenes to cyclohexa-1,4-dienes,12
whilst arenes may also be reductively dearomatized through metal hydrogenation. Metal catalysed 
procedures for dearomatisation employ stoichiometric quantities of metals in order to form η2-aryl 
metal complexes, destabilising the aromatic character of the arene and facilitating its reaction with 
electrophiles.13
One procedure for oxidative dearomatisation was reported by Motherwell in 1995.14 Motherwell
reported the oxidative dearomatisation of benzene, allowing the synthesis of a range of 
polyoxygenated cyclohexanes and cyclohexenes.  Motherwell found that, upon treating benzene with 
a stoichiometric quantity of OsO4 and irradiating the resulting solution with UV light, charge-transfer 
between the arene and OsO4 could be induced, ultimately resulting in the dihydroxylation of benzene.  
In 1997, Motherwell went on to synthesise (±)-Pinitol using this chemistry (scheme I-02), however only 
a catalytic quantity of OsO4 was required in this instance.15 Despite the utility of this chemistry, the 
use of OsO4 in this reaction precludes its use for large scale, industrial application.
Scheme I-02: Synthesis of (±)-Pinitol reported by Motherwell.15 a) OsO4, hv, NaBrO3.  b) pTSA, acetone, water.  
c) K2CO3, MeOH.  d) Al2O3, MeOH.  e) HCl, THF, water.
In addition to Motherwell’s research, the oxidation of 2-substituted phenols has also been shown to 
result in dearomatisation of their aromatic π-systems.  This chemistry has been used by both Stoltz16
and Quideau17 in the synthesis of (±)-grandifloracin, a compound that has shown anti-austerity activity 
against pancreatic cancer cells.18 Upon treating salicyl alcohol I-02 with NaIO4, Stoltz and co-workers 
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report that epoxide I-03 forms as a transient species before spontaneously dimerising to form 
(bis)epoxide I-04 (scheme I-03).  I-04 may then be converted to (±)-grandifloracin and analogues 
thereof.
Scheme I-03: Dearomatising oxidation of salicyl alcohol en route to (±)-Grandifloracin.16 a) NaIO4, water.
Bugg et al. have further explored the reaction of salicyl alcohols with NaIO4, resulting in the isolation 
of several epoxides similar in structure to transient epoxide I-03 (scheme I-03).19 Whilst dimerization 
of the 5-substituted epoxides was also reported by Bugg, the rate of dimerization differed depending 
on the substituted group.  Following their isolation and characterisation, epoxides were treated with 
Aspergillus niger epoxide hydrolase to give diols, before being converted to substituted tropolones
(scheme I-04). 
Scheme I-04: Synthesis of substituted tropolones from salicyl alcohols using a chemical dearomatisation 
strategy.19 a) NaIO4, water.  b) A. niger epoxide hydrolase.
In 2016, Sarlah et al. reported the photochemically induced dearomatisation of a range of aromatic 
compounds.20 It was discovered that, upon treating arenes such as t-butyl benzene with MTAD and 
exposing the solution to visible light, a [4+2] cycloaddition could be induced (scheme I-05).  OsO4
catalysed dihydroxylation of the resulting diene I-05 occurred exclusively at the non-substituted alkene 
to give isolable diol I-06.  Acetonide protection of the diol and removal of the MTAD group furnished 
diene I-07. Through using this approach, Sarlah synthesised a range of cyclitols and aminocyclitols.
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Scheme I-05: Photochemical dearomatisation of t-butyl benzene, resulting in diene I-07.20 a) MTAD, hv, CH2Cl2.  





Microbial ortho,meta-dihydroxylation of arenes
Due to the many benefits conferred by biocatalytic approaches to synthesis, it is of great interest to 
utilise biocatalysis for dearomative chemistry.  In 1968, Gibson first reported arene diol I-08 as an 
intermediate in the conversion of benzene to catechol by a strain of Pseudomonas putida (scheme I-
06).21 Later, it was found the a chloro-arene ortho,meta-diol accumulated when chlorobenzene was 
fed to the wild-type strain of Pseudomonas putida.22 Further to this work, Gibson subsequently 
reported the isolation of arene diol I-08, which was found to accumulate in cells of a mutant strain of 
P. putida – P. putida 39/D.23 Gibson and co-workers suggested that the accumulation of arene diol I-
08 was caused by deactivation of the dihydrodiol dehydrogenase of the wild-type organism.  In 
addition to the microbial dearomatisation of benzene, P. putida 39/D was also found to dihydroxylate
toluene enantioselectively to furnish arene diol I-09 (scheme I-06). 
Scheme I-06: Biosynthesis of catechol from benzene (top)21 and microbial oxidation of toluene to arene diol II-
09 (bottom).23
Following Gibson’s pioneering research, several other dioxygenase enzymes have been reported to 
dearomatize aromatics, with each being classified based on the substrate it was first reported to 
metabolise. Consequentially, the dioxygenase enzyme present in P. putida 39/D is classified as toluene 
dioxygenase (TDO), however this enzyme has also been shown to dearomatize ethylbenzene,24
chlorobenzene and para-halotoluenes (scheme I-07).25 Other known arene dioxygenases include
naphthalene dioxygenase (NDO),26 biphenyl dioxygenase (BPDO)27 and benzoate dioxygenase 
(BZDO).28
Scheme I-07: Microbial oxidation of chlorobenzene (left) and 4-fluorotoluene (right).25
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In 1993, Boyd et al. developed a widely applicable predictive model for the enantio- and regio-
selectivity of microbial arene ortho,meta-dihydroxylations (scheme I-08).29,30 Boyd found that, in the 
case of 1,4-disubstituted benzenes, dihydroxylation occurs ortho,meta- to the more sterically 
demanding substituent.  It was additionally found that, where RL is significantly more sterically 
demanding than RS, the enantioselectivity of the reaction was greater, whereas enantioselectivity 
decreases on convergence of the steric profile of the substituents.
Scheme I-08: General selectivity observed in the ortho,meta-dihydroxylation of aromatics with arene 
dioxygenases.29, 30
Due to the substrate promiscuity of TDO, NDO and BPDO, as well as the commercial availability of 
arene diols arising from their use, there are numerous examples of arene ortho,meta-diols being used 
in synthesis.  Imperial Chemical Industries PLC were the first company to report the use of an arene 
diol in synthesis, using an arene diol to synthesise polyphenylene in 1983.31 Gibson later reported the 
cis-dihydroxylation of indole, the product of which was a transient intermediate in the biocatalytic 
synthesis of indigo (scheme I-09).32
Scheme I-09: Synthesis of indigo through the microbial dihydroxylation of indole.32
Cyclitol synthesis is of great interest to synthetic chemists, primarily as they are a class of compounds 
known for possessing a diverse range of biological activity.33-35 In the 1980s, Ley reported the use of 
microbial arene oxidation chemistry in the synthesis of several cyclitols from benzene.36, 37 Synthesised 
cyclitols included (+)-Pinitol and (+)-Conduritol F (figure I-02).  In addition to cyclitols, Hudlický has
reported the synthesis of aminocyclitols from benzene,38 whilst Boyd has demonstrated the synthesis 
of carbasugars,39 providing a library of highly functionalized, enantiopure cyclohexanes that can be
easily accessed from arenes using biocatalysis.
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Figure I-02: Cyclitols and aminocyclitols synthesised using microbial arene oxidation.
Aside from highly functionalised cyclohexanes, arene ortho,meta-diols have also been used extensively 
in the synthesis of natural products and biologically active compounds. In 2015, Banwell achieved the 
total synthesis of the terpenoid (–)-Platencin from I-10.40 The core carbocyclic structure of (–)-
Platencin is synthesised in the first 3 steps of its synthesis through Stille coupling between dienyl iodide 
I-10 and stannane I-11, followed by oxidation of the alcohol to give I-12 and finally an intramolecular 
cycloaddition to give I-13.  Overall, Banwell achieved the synthesis of (–)-Platencin in 16 steps from 
arene diol derived diene I-10 (scheme I-10).  This particular synthesis is of note because (–)-Platencin 
has been proven to be a potent inhibitor of enzymes involved in bacterial fatty acid biosynthesis and 
has shown potent in vitro activity against a range of bacteria, including methicillin-resistant 
Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus faecalis (VREF).  
Scheme I-10: Banwell’s synthesis of (–)-Platencin.40 a) Pd(Ph3)4, CuI, CsF, DMF.  b) DMP, pyridine, CH2Cl2.  c) 
toluene, reflux.
Several alkaloids have also been synthesised using arene ortho,meta-diols as starting materials, 
including (+)-Brunsvigine41 and (+)-Montabuphine.42 However, one of the most intriguing total 
syntheses of an alkaloid is that of Codeine by Hudlický in 2009.  Hudlický was able to demonstrate how
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both enantiomers of Codeine could be synthesised from a single arene ortho,meta-diol.43 Following 
the microbial oxidation of arene I-14 by E. coli JM109 (pDTG601) – a recombinant strain of E. coli that 
overexpresses the TDO enzyme – diol I-16 was synthesised from arene diol I-15 in 5 steps (scheme I-
11).  Diol I-16 was the point of enantio-divergence in the synthesis of both enantiomers of Codeine.  
Scheme I-11: Initial steps in Hudlický’s synthesis of Codeine.43 a) PAD, AcOH, MeOH, 0oC.  b) Ac2O, NEt3, DMAP, 
CH2Cl2, 0oC.  c) MeNH2, K2CO3, THF, -40oC to RT.  d) Boc2O, DMAP, CH2Cl2, RT.  e) MeONa, MeOH, RT.
In the synthesis of Codeine ent-2, the least hindered alcohol of diol I-16 is initially protected as a TBDMS
ether, followed by Mitsunobu inversion of the remaining non-protected alcohol, using 2-bromo-3-
hydroxy-4-methoxybenzaldehyde as a nucleophile, to give I-17 (scheme I-12).43 Following the 
construction of the carbocyclic scaffold of Codeine, the alcohol of I-18, previously introduced during
the microbial oxidation, is inverted to give alcohol I-19 (scheme I-12).  Further derivatisation of I-19
gives Codeine ent-I-20, the non-natural enantiomer.
Scheme I-12: Key steps in the synthesis of Codeine ent-I-20 from diol I-16.43 a) TBDMSCl, imidazole, 
CH2Cl2, -78oC to RT.  b) n-Bu3P, DIAD, 2-bromo-3-hydroxy-4-methoxybenzaldehyde, THF, 0oC to RT.  c) IBX, DMF, 
RT.  d) NaBH4, CeCl3.H2O, MeOH, 0oC.
In the synthesis of the natural enantiomer of Codeine, a modified strategy was required to obtain the 
desired stereochemistry (scheme I-13).  Following the Mitsunobu inversion and tosylation of diol I-16, 
an epoxide was formed by reacting I-21 with sodium methoxide.  Epoxide opening of I-22 with 
Potassium 2-bromo-3-formyl-6-methoxyphenolate gave I-23, which was then subjected to similar 
conditions to those employed in the synthesis of Codeine ent-I-20 to furnish Codeine I-20, the natural 
enantiomer of Codeine. Hudlický’s comprehensive research demonstrates how the stereochemistry 
Chapter 1
11
obtained from the microbial oxidation of arenes may be manipulated in order to gain access to valuable 
compounds.
Scheme I-13: Synthesis of Codeine I-20 as reported by Hudlický.43 a) DIAD, PPh3, 4-nitrobenzoic acid, THF, 0oC.  
b) TsCl, NEt3, DMAP, CH2Cl2, 0oC to RT.  c) NaOMe, MeOH, THF, 0oC.  d) Potassium 2-bromo-3-formyl-6-
methoxyphenolate, 18-crown-6, DME, DMF, 80oC.
The anti-influenza agent oseltamivir phosphate (Tamiflu®) generated sales of $3.6 billion in 2009. Due 
to its clinical success, three separate research groups – led by Fang, Banwell and Hudlický – have made 
efforts to synthesise oseltamivir phosphate from arene ortho,meta-diols.44-46 The first synthesis of
oseltamivir phosphate from an arene diol was reported by Fang in 2008, using bromo-arene diol I-24
as a (commercially available) starting material. Fang achieved the enantioselective synthesis of 
oseltamivir phosphate in 11 steps and in a yield of 21% from bromo-arene diol I-24 (scheme I-14).
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Scheme I-14: Fang’s synthesis of oseltamivir phosphate.44 a) pTSA, 2,2-DMP, acetone, 0oC to RT.  b) SnBr4, NBA, 
water, MeCN, 0oC.  c) LHMDS, THF, -10oC to 0oC.  d) 3-pentanol, BF3.Et2O, -10oC to 0oC.  e) HCl, MeOH, 50oC.  f) 
α-acetoxy-isobutyryl bromide, THF, 0oC to RT.  g) LiBHEt3, THF, 0oC to RT.  h) DDQ, PPh3, nBu4NOCN, MeCN, RT; 
then tBuOH, reflux.  i) CuI, KI, DMEDA, nBuOH, 120oC.  j) Pd(OAc)2, CO, NaOAc, EtOH, RT.  k) H3PO4, EtOH, 50oC.
Due to the impressive substrate scope of wild-type arene ortho,meta-dioxygenase enzymes,  there has 
been little need to conduct engineering on the enzymes to increase their substrate promiscuity.  
Consequentially, there has only been one reported effort to engineer the TDO enzyme, conducted by 
Carrera, Rodríguez-Giordane and co-workers in 2017.47 The authors cited the lack of regio- and stereo-
diversity of dioxygenase catalysed oxidations as motivation for researching this area.  Three mutant 
TDO enzymes – I324F, T365N, F366V – were generated and tested in the microbial oxidation of four 
mono-substituted areas and indene.  Whilst in the majority of cases the activity of the mutant enzymes 
did not differ greatly from the wild-type enzyme, in the oxidation of styrene with mutant T365N a 
notable difference in regioselectivity was reported (scheme I-15). Due to the proven success of arene 
ortho,meta-diols in synthesis, it is likely that research into engineering the TDO enzyme will continue 
to be conducted in the future.
Scheme I-15: Microbial oxidation of styrene using wild-type TDO and TDO mutant T365N.47
In addition to the uses of arene ortho,meta-diols in the synthesis of natural products, efforts have also 
been made to synthesise organocatalysts, chiral auxiliaries and  ligands from arene ortho,meta-diols. 




Microbial ipso,ortho-dihydroxylation of benzoic acid
The biosynthesis of catechol through the oxidation of benzoic acid has been a known biosynthetic 
pathway  since 1948.51 In 1971 Reiner and Hegeman reported the accumulation of an intermediate in 
this pathway, arene ipso,ortho-diol I-27 (scheme I-16), in a mutant strain of Ralstonia eutropha 
(formerly classified as Alcaligenes eutrophus).52 The oxygenase enzyme present in Ralstonia eutropha 
B9 was therefore termed benzoate dioxygenase (BZDO).  In addition to non-substituted benzoic acids, 
the microbial of oxidation of several substituted benzoic acids has also been reported using Ralstonia 
eutropha B9.53-55
Scheme I-16: Microbial oxidation of benzoic acid using Ralstonia eutropha B9.52
Through conducting isotopic labelling experiments using 18O2, Reiner and Hegeman suggested that the 
formation of arene diol I-27 occurs through a peroxide intermediate.28 In 2015, Lipscomb and co-
workers conducted a more detailed mechanistic study into the mode of action of the BZDO enzyme.56
Lipscomb ascertained the roles of the Rieske iron-sulfur cluster and the mononuclear Fe(II) located in 
the active site of BZDO through the use of single turnover enzyme experiments and computational 
chemistry.
In comparison to arene ortho,meta-diols, synthetic uses of arene ipso,ortho-diols have been less 
comprehensively studied. A number of factors are likely to have contributed to this, including the 
limited substrate scope of the BZDO enzyme and the low stability of arene ipso,ortho-diols.52, 53, 55, 56
Nonetheless, the microbial ipso,ortho-dihydroxylation of benzoic acid remains highly valuable due to 
the generation of an enantiopure, tetra-substituted carbon from an inexpensive starting material.
Furthermore, the number of synthetic transformations one may perform on arene diol I-27 is vast
(figure I-03). As such, the ipso,ortho-dihydroxylation of benzoic acid has still been shown to be of 
great utility in the synthesis of an array of enantiopure compounds. 
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Figure I-03: Illustration of possible reactions that may be performed on arene diol I-27, taken from a review 
paper by Lewis.57
In 2001, Myers demonstrated the versatility of arene diol I-27 through the synthesis of a range of highly 
functionalised, enantiopure molecules, focussing on oxidative and rearrangement chemistry.58 Myers 
also showed that, when functionalising derivatives of arene diol I-27, the diastereo- and regio-
selectivity could be controlled through making subtle modifications to the substrate.  For example, 
epoxide I-29 was produced as the sole product in the epoxidation of diene I-28 with mCPBA, whereas 
in the epoxidation of acetonide protected diene I-30, the stereoisomeric epoxide I-31 predominated 
as the major product, with a minor quantity of its regioisomer I-32 also being formed (scheme I-17).
Myers further reported the synthesis of several lactones, whose syntheses are detailed in the 
introduction to chapter 2, “Synthesis of enantiopure heterocycles from an arene ipso,ortho-diol”. The 
strategies devised by Myers for controlling the diastereoselectivity of reactions on arene ipso,ortho-
diols have subsequently been employed by multiple groups in the synthesis enantiopure compounds 
from arene diol I-27.
Scheme I-17:  Epoxidation of dienes I-28 and I-30 as reported by Myers.58 a) CH2N2, Et2O, 0oC.  b) mCPBA, 
CH2Cl2, RT.  c) pTSA, 2,2-DMP, acetone, RT.  d) mCPBA, CH2Cl2, RT.
Cyclitols – carbocyclic rings bearing multiple hydroxyl groups – are known to possess a diverse range 
of biological activities.33-35 In Parker’s 2004 synthesis of the cyclitol carba-β-L-fructopyranose, an 
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acetonide group was employed to control the diastereoselectivity of dihydroxylation. Dihydroxylation 
of diene I-30 afforded regioisomeric diols I-33 and I-34, which were separable by column 
chromatography (scheme I-18).  Further transformations afforded carba-β-L-fructopyranose in 7 steps 
from arene diol I-35.
Scheme I-18: Synthesis of carba-β-L-fructopyranose I-36.  a) OsO4, NMO, acetone, water, RT.  b) H2, Pd/C, 
EtOAc, RT.  c) HCl, 2,2-DMP, acetone, RT.  d) DIBAL-H, THF, 0oC to RT.  e) TFA, water, RT.
Widdowson reported the first intermolecular Diels–Alder reactions on an arene ipso,ortho-diol derived 
diene in 1995.59 Widdowson found that the diastereoselectivity of cycloadditions on such dienes could
also be controlled through modification of the diol.  When reacting diene I-28 with PTAD, a mixture of 
2 products were formed which were inseparable by column chromatography (scheme I-19).  Acetonide 
protection of the mixture provided diastereomers which were separable, allowing characterisation of 
the major product as I-36.  Conversely, upon reacting diene I-30 with PTAD, cycloadduct I-37 was 
formed exclusively (scheme I-19).  Protecting the diol as an acetonide group seemingly blocks attack 
of dienophiles from its residing face, allowing for diastereoselective cycloadditions to be performed.
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Scheme I-19: Diels–Alder reaction between dienes I-28 and I-30 and PTAD.59 a) PTAD, acetone, RT.  b) pTSA, 
2,2-DMP, RT.
Widdowson also tested nitrosobenzene as a dienophile, which introduced the issue of regioselectivity 
in its cycloaddition with diene I-30 and I-40 (scheme I-20).59 Widdowson suggested that steric effects 
between the incipient PTAD group and methyl ester could impart a degree of regioselectivity on this 
cycloaddition reaction, resulting in I-38 forming as the major product.  In contrast to this, the opposite 
regioselectivity could be induced through converting the methyl ester to a primary alcohol prior to 
exposing it to nitrosobenzene, providing I-42 as the major product.  
Scheme I-20: Diels–Alder reaction of dienes I-30 and I-40 with nitrosobenzene.59 a) ONPh, toluene, RT.  b) 
LiAlH4, Et2O, 0oC to RT.
The Diels–Alder chemistry of arene ipso,ortho-diol derived dienes has subsequently been utilised by 
Lewis et al. in the synthesis of several enantiopure, poly-functionalised carbocycles.60-63 In 2011, Lewis 
reported the synthesis of two inosaminoacids, from arene diol I-27, using a Diels–Alder reaction 
between diene I-43 and benzyl N-hydroxycarbamate (oxidised in situ to form an acylnitroso dienophile)
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to install an amine group onto the carbocyclic framework (scheme I-21).60 Following further 
functionalisation, inosaminoacid I-45 was synthesised. Enantiopure inosaminoacids are of interest in 
peptide chemistry, since the incorporation of cyclic amino acids into peptide chains can impart changes 
in a peptide’s secondary structure.64, 65 Aminocyclitols have also been synthesised by Lewis through a 
similar strategy.62
Scheme I-21: Synthesis of inosaminoacid I-45 from arene diol I-27.60 a) pTSA, 2,2-DMP, acetone, RT.  b) BnBr, 
NEt3, DMF, RT.  c) Bu4NIO4, benzyl N-hydroxycarbamate, CH2Cl2, -78oC.  d) OsO4, NMO, acetone, water, RT.  e) 
H2, Pd/C, MeOH, RT.  f) HCl, water, RT.
An alternative strategy for nitrogen incorporation onto the carbocyclic scaffold of arene ipso,ortho-
diols was developed by Carrera in 2017.66 Following the isolation of the mixed sodium/potassium salt 
arene diol I-46, acetonide protection was conducted followed by reaction with para-toluenesulfonyl 
isocyanate to give amide I-47 (scheme I-22). Treating amide I-47 with NBS afforded β-lactam I-48 as 




Scheme I-22: Carrera’s synthesis of β-amino-γ-hydroxyester I-49.66 a) TFA, 2,2-DMP, 0oC to RT.  b) pTsNCO, 
NEt3, THF, RT.  c) NBS, NaHCO3, MeCN, 0oC to RT.  d) KCN, MeOH, DMF, RT.  e) NaHSO3, acetone, water, 75oC.
The diverse biological activity of cyclitols has also prompted Lewis to investigate their synthesis from 
arene ipso,ortho-diol I-27.33-35 A singlet oxygen cycloaddition was performed upon diene I-50 by Lewis 
and co-workers for this purpose.  After reductive cleavage of the resulting endoperoxide I-51, diol I-52
was furnished, which was then elaborated to cyclitol I-53 (scheme I-23).63
Scheme I-23: Synthesis of cyclitol I-53 from diene I-40.  a) TBDMSOTf, NEt3, CH2Cl2, -78oC to RT.  b) O2, TPP, hv, 
CCl4, 10oC.  c) Thiourea, CH2Cl2, MeOH, RT.  d) MOMCl, DIPEA, CH2Cl2, RT.  e) OsO4, NMO, acetone, water, RT.  f) 
HCl, water, RT.  g) Ac2O, pyridine, 0oC.  h) NH3, MeOH, RT.
Lewis and co-workers also exploited singlet oxygen cyclo-addition chemistry in the synthesis of 
zeylenols and zeylenones.61 Both enantiomers of zeylenol can be isolated from a variety of sources, 
such as Uvaria zeylanica and Boesenbergia kaempferia,67, 68 however only (–)-zeylenone has been
isolated from nature to date. Lewis conducted a Kornblum–DeLaMare rearrangement on 
endoperoxide I-55 in an attempt to synthesise a (+)-zeylenone congener (scheme I-24).  Whilst this 
route to a zeylenone was ultimately unsuccessful, it is a demonstration of how γ-hydroxyenones can
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be easily synthesised from arene diol I-27.  Instead, Lewis and co-workers found success in the 
synthesis of a zeylenone through a route that reductively cleaved the endoperoxide bridge of I-55.
Lewis has also previously reported the synthesis of a (bis)epoxide from an arene diol derived 
endoperoxide.63
Scheme I-24: Kornblum–DeLaMare rearrangement of endoperoxide I-55.  a) LiBH4, THF, 0oC.  b) BzCl, NEt3, 
CH2Cl2, RT.  c) O2, TPP, hv, CCl4, 10oC.  d) DIPEA, CH2Cl2, RT.
The synthesis of several other natural products from arene ipso,ortho-diols have also been reported 
over the previous decade.  In 2011, Hudlický achieved the enantiopure synthesis of (–)-Idesolide from 
arene diol I-27.69 (–)-Idesolide is known to possess potent anti-inflammatory activity, making its 
synthesis of interest to the scientific community.70 Treating diene I-28 with potassium 
azodicarboxylate and AcOH was found to effect the hydrogenation of only a single alkene of its diene, 
giving a mixture of alkenes I-57 and I-58 (scheme I-25).  Subsequent oxidation of the secondary alcohol
of I-58 gave ketone I-59, which upon treatment with NaHCO3 resulted in its dimerization to give (–)-
Idesolide (scheme I-25).69
Scheme I-25: Hudlický’s synthesis of (–)-Idesolide.69 a) PAD, AcOH, MeOH, RT, 5oC.  b) IBX, DMSO, RT.  c) 
NaHCO3, CHCl3, RT.
Hudlický has recently reported the synthesis of the hydroxylated cyclohexanone moiety of xylosmin 
from arene diol I-27.71 Xylosmin is a natural product which, along with flacourtosides, can be found in 
extracts of Flacoutia indica.  These extracts have been examined for their β-hematin inhibitory activity
and as antimalarial agents.72, 73 The potential biological activity of xylosmin has inspired interest in its 
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synthesis.  Hudlický’s enantioselective synthesis of the hydroxylated cyclohexanone moiety of xylosmin 
was completed in just 7 steps from arene ipso,ortho-diol I-27 (scheme I-26). 
Scheme I-26: Structure of free hydroxyl derivative of xylosmin and Hudlický’s synthesis of the cyclohexanone 
fragment of xylosmin.71 a) para-nitrobenzoyl chloride, NEt3, CH2Cl2, RT.  b) mCPBA, CH2Cl2, RT.  c) Bi(OTf)3, 
MeCN, water, RT.  d) DDQ, dioxane, 85oC.  e) K2CO3, MeOH, RT.  f) K2CO3, water, RT.
Piper cubeb and Uvaria rufa extracts have been shown to contain several polyoxygenated compounds 
which possess a range of biological activities, including anti-leukemic and anti-tumour activities.74, 75
Found in extracts of Piper cubeb, Piperenol B is a polyoxygenated cyclohexene that was targeted for 
synthesis by Mihovilovic in 2015.76, 77 Not only did Mihovilovic achieve the synthesis of Piperenol B in 
8 steps from benzoic acid (scheme I-27), the synthesis unambiguously confirmed the stereochemistry 
of Piperenol B found in extracts of Piper cubeb.
Scheme I-27: Mihovilovic’s synthesis of Piperenol B.76 a) BzCl, NEt3, Et2O, 0oC to RT.  b) OsO4, NMO, acetone, 
water, RT.  c) HCl, THF, 40oC.
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First isolated from Uvaria grandiflora in 1997, (–)-grandifloracin has been found to be cytotoxic against 
pancreatic cancer cells (figure I-04).78 Later, in 2012, Awale established the enantiomeric (+)-
grandifloracin to be an anti-austerity agent against human pancreatic cancer cell lines.18 Due to the 
biological activity of grandifloracin, Quideau and Stoltz have both reported its racemic synthesis from 
inexpensive, aromatic starting materials.16, 17 Lewis and co-workers have achieved the enantioselective 
total synthesis of (+)-grandifloracin from arene ipso,ortho-diol I-21,79 utilizing a strategy which employs 
iron complexation chemistry that had been previously developed in the group.80, 81
Figure I-04: Structures of (+)- and (–)-grandifloracin.
In 1958, Pauson reported the first example of a tricarbonyl(cyclohexadiene)iron complex.82 In 2010, 
Lewis demonstrated that, when reacting arene diol I-28 with nonacarbonyldiiron, a similar 
tricarbonyl(cyclohexadiene)iron complex could be accessed (scheme I-28).81 The product of the 
reaction of arene diol I-28 with nonacarbonyldiiron gave an enantiomerically pure product, which was 
shown to be I-60 by X-ray crystallography. The observed selectivity seemingly arises as a result of the 
cis-diol directing coordination of the iron to the back face of the diene.
Scheme I-28: Synthesis of tricarbonyl(cyclohexadiene)iron complex I-60.80 a) Fe2(CO)9, THF, RT.
Following complexation of diene I-28 to iron, iron complex I-60 can be treated with DIBAL-H and the 
resulting alcohol benzoylated to give I-61 (scheme I-29).83 Subsequent oxidation of the secondary 
alcohol using manganese dioxide then gave iron bound dienone I-62 (scheme I-29).  Upon de-
complexation of iron, spontaneous dimerization occurs furnishing (+)-grandifloracin (scheme I-29). 
This is the first reported enantioselective synthesis of (+)-grandifloracin.
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Scheme I-29: Lewis’ enantioselective synthesis of (+)-grandifloracin.83 a) DIBAL-H, THF, CH2Cl2, -78oC to RT.  b) 
BzCl, 2,4,6-collidine, THF, RT.  c) MnO2, CH2Cl2, RT.  d) Ceric ammonium nitrate, acetone, 0oC. 
Subsequent studies by Lewis and co-workers into the iron complexation chemistry of arene diols
resulted in the discovery of a novel rearrangement reaction.81 In an attempt to achieve iron 
complexation to the face of the diene anti to the diol, diol I-28 was protected to give acetonide I-30.  
It was envisaged that iron complexation would then result in iron complex I-63.  However, upon 
reaction of diene I-30 with nonacarbonyldiiron, iron complex I-64 was instead formed (scheme I-30).
This discovery is noteworthy since it provides access to the opposite enantiomer to that obtained when 
synthesising arene ortho,meta-diols using TDO expressing bacteria. In addition to iron complexation 
chemistry of arene ipso,ortho-diols, Lewis has also investigated cobalt complexation chemistry.84
Scheme I-30: Rearrangement reaction of diene I-30 when reacted with nonacarbonyldiiron.81 a) Fe2(CO)9, THF, 
RT.
Research into the synthesis of enantiopure heterocycles from arene ipso,ortho-diols has been 
previously explored by several research groups.58, 66, 85-87 A detailed account of this research can be 
found in the introduction to chapter 2, “Synthesis of enantiopure heterocycles from an arene 
ipso,ortho-diol”. Likewise, a detailed account of the chemistry of substituted arene ipso,ortho-diols 
can be found in the introduction to chapter 4, “Exploiting a fluoro arene ipso,ortho-diol in synthesis”.
The previous research into arene ispo,ortho-diols has demonstrated the great versatility of their use in 
synthesis, however there are a number of research areas that are yet to be exploited.  At the outset of 
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this project, we aimed to to expand the known synthetic chemistry of arene ipso,ortho-diols through 
the synthesis asymmetric epoxidation organocatalysts and enantiopure heterocycles.  In addition to 
these themes, the chemistry of fluoro arene ipso,ortho-diols was also to be investigated. Achieving 
these aims would  greatly expand the known chemistry of arene cis-diols,  whilst potentially offering 
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Synthesis of enantiopure heterocycles from an arene ipso,ortho-diol
Introduction to the synthesis of heterocycles from arene ipso,ortho-diols
Heterocyclic compounds have found extensive use in agricultural chemicals and pharmaceuticals,1, 2
with 80% of the best-selling small molecule drugs of 2010 containing at least 1 heterocycle.3 Indeed, 
bi-heterocyclic Lenalidomide (figure II-01) was the best-selling small molecule pharmaceutical of 
2017.4 The utility of heterocycles demands new strategies be developed to synthesise novel 
heterocyclic compounds so that drug-like chemical space may be expanded.
Figure II-01: Structure of lenalidomide (racemic), which is used in the treatment of multiple myeloma.5
The microbial oxidation of sodium benzoate using BZDO expressing organisms provides access to 
enantiopure arene diol II-01.6, 7 Whilst arene diol  has been used in the synthesis of a variety of 
carbocycles,8-18 its use in the synthesis of heterocycles has been less extensively researched.  Two
examples of heterocycle synthesis from arene diol II-01 were reported by Mihovilovic in 2004 using a 
strategy based on intra-molecular Diels–Alder reactions (scheme II-01).19 Following the synthesis of 
diene II-02, cyclization was affected under microwave conditions to give poly-cyclic II-03, which 
contains an oxygen heterocycle.  Mihovilovic also found that treating diene II-04 with allyl amine at 




Scheme II-01: Mihovilovic’s synthesis of heterocycle containing compounds from arene diol II-01.20 a) NaH, 
Bu4NI, allyl bromide, THF, 0oC.  b) Toluene, 135oC in microwave.  c) PPh3, imidazole, iodine, toluene, reflux.  d) 
Allyl amine, 120oC.
Myers has also reported the synthesis of 2 heterocycles from arene diol II-06 (scheme II-02).16
Acetonide protection of arene diol II-06 afforded II-07.  Upon treating diene II-07 with NBS, formation 
of a bromonium ion on the most hindered alkene of diene II-07 preceded nucleophilic attack of the 
proximal carboxylic acid on the bromonium ion, giving lactone II-08.  Synthesis of lactone II-10, 
however, was achieved through initial epoxidation of arene diol II-06 to give epoxide II-09.  Refluxing 
II-09 in perchloric acid and acetone affected the one-pot epoxide ring opening of II-09, through attack 
of the proximal carboxylic acid, followed by acetonide protection of the resulting diol to afford lactone 
II-10.
Scheme II-02: Myer’s synthesis of lactones II-08 and II-10.16 a) pTSA, 2,2-DMP, acetone, RT.  b) NBS, toluene, 
CH2Cl2, RT.  c) mCPBA, EtOAc, RT. d) HClO4, acetone, reflux.
In 2017, Carrera reported the synthesis of a β-lactam from arene diol II-12 (scheme II-03)21 using a 
similar strategy to that used by Myers in the synthesis of lactone II-08.16 In contrast to the research
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done by Myers, however, intramolecular cyclisation to form β-lactam II-12 proceeded through 
bromination of the least hindered alkene of diene II-11, followed my intramolecular conjugate addition 
of the amide to the resulting allylic bromonium ion. β-lactam II-12 was further derivatised by Carrera 
to give several carbocycles bearing amine groups.  Whilst Mihovilovic’s, Myers’ and Carrera’s research 
do demonstrate the synthesis of heterocycles from arene diol II-01, none of these methods modify the 
original carbocyclic scaffold of the arene diol.
Scheme II-03: Carrera’s synthesis of β-lactam II-12.21 a) pTsNCO, NEt3, THF, RT.  b) NaHCO3, NBS, MeCN, RT.
The only literature example demonstrating modification of the carbocyclic scaffold of arene diol II-01
was reported by Hudlický in 2014 when synthesising a pyrrolidine.22 After derivatising arene diol II-01
as its acetonide protected methyl ester II-13, a cycloaddition reaction with an acylnitroso dienophile 
(generated in situ) was conducted to give inseparable regioisomers II-14 and II-15 (scheme II-04).  A 
similar cycloaddition reaction had been previously reported by Lewis et al.11 Reductive ozonoylsis of 
regioisomers II-14 and II-15 followed by acetylation of the resulting alcohols gave regioisomers II-16
and II-17 (scheme II-04). These regioisomers were separable by column chromatography, allowing II-
16 to be isolated in 22% yield.  The isolated yield of II-17 was not reported.
Scheme II-04: Initials synthetic steps in Hudlický’s synthesis of a pyrrolidine.22 a) NaIO4, t-butyl 
hydroxycarbamate, MeOH, water, 0oC.  b) O3, CH2Cl2, NaBH4, -70oC to RT. c) Ac2O, DMAP, NEt3, CH2Cl2, RT.
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Deprotection of acetyl protected II-16 was achieved with MeOH and K2CO3, after which reductive 
cleavage of the N-O bond was affected using Mo(CO)6 providing acyclic II-18 (scheme II-05).22 NaIO4
mediated glycol cleavage resulted in formation of a 6-membered lactol, which was protected to give 
II-19 (scheme II-05).  Reacting II-19 with MeOH and K2CO3 resulted in lactol ring opening with
subsequent ring closure through formation of imine II-20 (scheme II-05).  Further synthetic steps gave 
poly-hydroxylated pyrrolidine II-21.  Whilst Hudlický’s research demonstrates an ingenious route to 
pyrrolidine II-21, the number of synthetic steps required is significant.
Scheme II-05: Final synthetic steps in Hudlický’s synthesis of a pyrrolidine.22 a) K2CO3, MeOH, RT.  b) Mo(CO)6, 
MeCN, water, RT to reflux. c) NaIO4, CH2Cl2, RT.  d) Ac2O, DMAP, NEt3, CH2Cl2, RT.  e) TFA, CH2Cl2, 0oC to RT.  f) 
K2CO3, MeOH, RT.
Having reviewed the literature in this field, it was considered of great importance to develop synthetic 
strategies that allow rapid access to a diverse range of enantiopure heterocycles from arene diol II-01.  
It was envisaged that achieving this would not only allow access to novel heterocyclic compounds 





Since Reiner’s seminal paper on the microbial oxidation of sodium benzoate (scheme II-07),6 iterative 
improvements to the biotransformation procedure have been made by several research groups.15, 16, 
20 The procedure adopted in our research bears a high similarity to the most successful reported 
procedures, however a noteworthy difference can be found by comparison of the equipment used for 
the biotransformations.  This research reports the microbial oxidation of sodium benzoate using non-
specialist equipment, furnishing carboxylate II-01. This demonstrates how specialist bioreactors are
not compulsory when conducting the microbial oxidation of sodium benzoate, highlighting the 
accessibility of this biotransformation to non-specialist research groups (although it should be 
acknowledged that substrate concentrations achieved when using bioreactors tend be improved by 
between 30% and 50%).
Carboxylate II-01 has been used in the synthesis of various compounds, however there are several 
compounds that may only be accessed from its corresponding acid.  As such, carboxylate II-01 and acid 
II-06 have both been synthesised and used as starting materials in the synthesis of enantiopure 
heterocycles (scheme II-06). 
Scheme II-06: Microbial oxidation of sodium benzoate to afford carboxylate II-01 and acid II-06.  a) conc. aq. 
HCl, water, 0oC. 
Attempted Beckmann rearrangement of an arene diol derived oxime
The Beckmann rearrangement, first reported by Beckmann in 1886,23 allows the synthesis of amides 
from oximes, which themselves can be easily accessed from ketones.  Since its discovery, the 
Beckmann rearrangement has found use in the industrial scale synthesis of ε-caprolactam24 – used as 
a monomer in the synthesis of Nylon-6 – as well as in total synthesis.   For example, the Beckmann 
rearrangement has been used in the synthesis of (+)-codeine (scheme II-07), a clinically used opiate.25
Chapter 2
34
Scheme II-07: Beckmann rearrangement in the total synthesis of (+)-Codeine.  a) HONH2.HCl, NaOAc, MeOH.  b) 
BsCl, triethylamine, DMAP, CH2Cl2.  c) AcOH.
By exploiting the Beckmann rearrangement, we aimed to synthesise a novel, enantiopure lactam from 
arene diol II-01.  As such, it was necessary to synthesise a ketone derived from arene diol II-01.  Lewis
et al. have previously reported the synthesis of saturated methyl ester II-23, which was achieved 
through hydrogenation of acid II-06, followed by methylation of the resulting carboxylic acid II-22 using 
TMS-diazomethane (scheme II-08).12 This method was utilised in the subsequently reported research 
to furnish methyl ester II-23, however it was also established that accessing this compound directly 
from carboxylate II-01 may be preferential owing to the difficulties associated with isolating acid II-06
(partial acid catalysed re-aromatisation of the arene diol is observed upon its acidification).  The 
catalytic hydrogenation of carboxylate II-01 using Pd/C and hydrogen gas was unsuccessful, so 
carboxylate II-01 was first derivatised as its acetonide protected acid II-07 through a procedure 
developed by Hudlický.15 Hydrogenation of this compound then proceeded smoothly to give saturated 
acid II-24, which upon reaction with pTSA in MeOH resulted in one-pot acetonide group deprotection 
and methylation of the carboxylic acid (scheme II-08).  The latter method resulted in the synthesis of 
saturated methyl ester II-23 in 55% yield over 3 steps from carboxylate II-01, compared to a yield of 
24% over 3 steps from carboxylate II-01 for the former procedure.
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Scheme II-08: Synthetic routes to saturated methyl ester II-23.  a) H2, Pd/C, MeOH, RT, 23 hours.  b) TMS-
diazomethane, MeOH, benzene, RT, 20 minutes.  c) TFA (5 equiv.), 2,2-DMP, 0oC to RT, 24 hours.  d) H2, Pd/C, 
EtOAc, RT, 16 hours.  e) pTSA (1 equiv.), MeOH, RT, 5 days.
It was determined that oxidation of the secondary alcohol of II-23 may result in a ketone which could 
be used in a Beckmann rearrangement reaction. Efforts were therefore made to oxidise this 
compound.  Consistent with literature reports, it was found that Ley oxidation conditions resulted in 
glycol cleavage of diol II-23, which is also a known reaction of cis-diols when reacted with Dess–Martin 
periodinane.26 However, reacting diol II-23 with SIBX (stabilised IBX)27 furnished the desired ketone II-
25 in a good yield (scheme II-09).  Interestingly, it was also found that under Swern conditions oxidation 
of the secondary alcohol could only be achieved with simultaneous protection of the tertiary alcohol 
as its methyl-thioacetal, giving II-26 (scheme II-09). The reason for the low yield of this reaction is 
unclear.
Scheme II-09: Oxidation of diol II-23.  a) SIBX (2.0 equiv.), DMSO, 60oC, 3 hours.  b) DMSO (2.0 equiv.), (COCl)2
(1.0 equiv.), NEt3 (5.0 equiv.), CH2Cl2, -78oC, 1 hour.
The synthesis of enone II-28 was first reported by Hudlický in 2011,14 which was achieved through the
rearrangement of diene II-27 catalysed by Grubbs’ 1st generation olefin metathesis catalyst (scheme 
II-10).28 This was thought to be a potential route to achieving the synthesis more highly substituted 
ketones that may be used in Beckmann type reactions.  For this reason, Hudlický’s work was replicated 
to give enone II-28.  Whilst Hudlický and co-workers reported a yield of 45% for this reaction, 
replication of this yield proved challenging – in our hands, a maximum yield of just 10% could be 
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attained. The observed low yields were a result of thermal re-aromatisation of the starting material 
II-27 under the reaction conditions.  Grubbs’ II catalyst and RhCl3.3H2O were also tested as catalysts 
for this transformation. Grubbs’ II catalyst provided enone II-28 in a reduced yield (<3%), whereas 
RhCl3.3H2O failed as a catalyst in this transformation.
Scheme II-10: Rearrangement of diene II-27 to enone II-28 and conjugate addition of ethanethiol to give II-29.
a) TMS-diazomethane, MeOH, benzene, RT, 20 minutes. b) Grubbs’ I catalyst (5 mol%), toluene, reflux, 18 
hours.  c) EtSH (1.1 equiv.), NEt3, CHCl3, 30oC, 22 hours.  
Enone II-28 was treated with ethanethiol and trimethylamine, resulting in the conjugate addition of 
ethanethiol to the enone (scheme II-10).  The reaction was deemed to have succeeded due to the 
absence of any peaks indicative of an alkene in the 1H NMR spectrum of the product, as well as the 
appearance of peaks characteristic of an ethyl chain.   Unsurprisingly, this reaction produced a mix of 
both the S,S and R,S diastereomers of II-29.  NMR analysis of the isomeric mixture of II-29 was 
attempted with a view to establishing the relative ratio of each diastereomer in the mixture.
The presence of 2 overlapping singlets at δ = 3.80 and 3.79 ppm (H12) in the 1H NMR spectrum suggest
that the methyl ester has been conserved during the thiolation reaction, as well as suggesting the 
presence of 2 diastereomers.  Furthermore, the presence of a multiplet at δ = 1.30-1.20 ppm (H14) in 
the 1H NMR spectrum suggested the successful addition of ethanethiol to the enone.  Using HSQC, 
peaks at δ = 14.9 and 14.7 ppm (C14) could be assigned in the 13C NMR spectrum, giving further 
confirmation of diastereomers.  HMBC indicated an interaction of the multiplet at δ = 1.30-1.20 ppm
(H14) with the carbon peak at δ = 24.6 ppm (C15) as well.  HSQC allowed the assignment of the multiplet
at δ = 2.62-2.49 ppm (H15) as a result, which was confirmed by coupling interactions observed by COSY 
between the multiplet at δ = 1.30-1.20 ppm (H14) and δ = 2.62-2.49 ppm (H15). Due to the characteristic 
chemical shifts of carbonyls, the peak at δ = 204.5 ppm (C5) was assigned as the ketone in both 
diastereomers.  Peaks at δ = 171.2 and 170.1 ppm (C9) in the 13C spectrum were assigned as the ester 
carbonyls for each diastereomer.  Carbon peaks at δ = 80.2 and 80.1 ppm (C6) were assigned as the 
tetra-substituted carbon peaks for each diastereomer. These peaks suggest the conservation of key 
functional groups within II-29.
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Figure II-02: 1H NMR spectrum (top) and 13C NMR spectrum (bottom) of mixture of diastereomers II-29.
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Whilst assigning the methyl ester and ethanethiol peaks in the NMR spectra was relatively 
straightforward, assigning the ring protons and carbons for diastereomeric mixture II-29 proved more 
challenging.  This was due to a complicated 1H spectrum arising from 7 different ring proton 
environments for each diastereomer, with each proton showing a complex splitting pattern.
Scheme II-11: Possible chair conformations for both diastereomers of II-29.
Consideration of the relative occupations of each possible chair conformation for diastereomers II-29
(Scheme II-11) was not thought to be of importance in assigning ring protons H1 and H2. Assigning 
these protons would allow, by process of elimination, the peaks that are responsible for the remaining 
ring protons (H3 and H4) to be established.  
For the major diastereomer (see figure II-03 for 1H and 13C NMR spectra), the carbon peak at δ = 171.2
ppm (C9) shows a 3 bond HMBC interaction with 1 of the protons contributing to the multiplet at δ =
2.26-2.11 ppm (H1).  HSQC allowed the assigning of carbon peak δ = 33.6 ppm (C1) and, as a result, of 
the ddd at δ = 2.42 ppm (C1) in the 1H NMR spectrum.  The COSY spectra permitted assignment of 
multiplet δ = 2.04-1.95 ppm (H2) in the 1H NMR spectrum, whilst HSQC subsequently allowed 
assignment of carbon peak δ = 27.2 ppm (C2) and of another of the protons contributing multiplet δ = 
2.26-2.11 ppm (H2).A similar strategy was employed when assigning the minor diastereomer’s NMR 
spectra (see figure II-04 for 1H and 13C NMR spectra).  A 3 bond HMBC interaction between this 
diastereomer’s ester carbon at δ = 170.1 ppm (C9) and proton td δ = 1.65 ppm (H1) was observed, which 
subsequently allowed assignment of the carbon peak at δ = 35.8 ppm (C1) and proton dt at δ = 2.73
ppm (H1). COSY allowed the final proton contributing to the multiplet at δ = 2.26-2.11 ppm (H2) to be 
assigned, followed by the carbon at δ = 29.3 ppm (C2) and proton dddd at δ = 1.90 ppm (H2). 
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The Karplus equation states that coupling between vicinal protons is maximal when their dihedral 
angle is either 0o or 180o, with a minimum at 90o.29 For this reason, it was envisaged that the observed 
J values for H3 and H4 in the 1H NMR spectrum could be used to assign the stereochemistry of the major 
and minor components of the mixture of diastereomers II-29. In order to do this, however, it is first 
necessary to consider the possible chair conformations of each diastereomer (scheme II-16). 
A values define the propensity of a substituent to preferentially adopt the equatorial position in a 
cyclohexane ring, with the magnitude of the A value being proportional to the steric bulk of the 
substituent.30 In cyclohexane rings with multiple non-hydrogen substituents, a comparison of each 
substituent’s A values can often provide valuable information on the preferred chair conformation 
adopted. Since there is no reported A value for a thioethyl group in the literature, instead the A value 
for a thiomethyl group was used in the comparison of A values in cyclohexane II-29. Reported A values 
for methyl ester, hydroxyl and thiomethyl groups are 1.31, 1.0 and 1.1 kcal/mol respectively.31 Upon 
analysis of these A values, it was determined that the favoured chair conformation for the R,S-
diastereomer II-29 would place both the methyl ester and thioethyl group equatorial, with the hydroxyl 
group axial (conformer A, scheme II-12).  However, the preferred chair conformer for the S,S-
diastereomer II-29 was less straightforward to establish due to the competing preference of the large 
methyl ester group to be equatorial versus both the hydroxyl and thiomethyl groups being equatorial.
Scheme II-12: Predicted chair conformations for diastereomers II-29 based on the reported A-values for each 
substituent.
Computational modelling was conducted by Dr. Matthew Grayson (University of Bath) in order to 
unambiguously determine the preferred chair conformations for each diastereomer. DFT calculations 
were performed using Gaussian 16 (Revision A.03) to assess the relative free energies of the different 
conformers of the R,S- and S,S-diastereomers II-29.32, 33 Contrary to the predictions made based on 
the substituents’ A values, the energy difference between chair conformers A and B of the R,S-
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diastereomer II-29 was zero (scheme II-13).  It is proposed that this is a result of a favourable hydrogen 
bond being established between the hydroxyl and ketone moieties in conformer B of the R,S-
diastereomer which cannot be formed in conformer A, thus lowering the energy of conformer B
relative to conformer A. This same interaction contributes to conformer B of the S,S-diastereomer 
being lower in energy than conformer A. With the relative energies of each conformer having been 
calculated, the ratio of each at RT (298.15 K) was calculated using the Gibb’s free energy equation
(scheme II-13).  
As the computational investigation indicated that the ratio of conformers A and B for the R,S-
diastereomer is 50:50 at RT and the ratio of conformers A and B of the S,S-diastereomer is 67:33 at RT, 
it was not possible to accurately assign stereochemistry of each component in the diastereomeric 
mixture based purely on its NMR spectra.
Scheme II-13: Energies of each chair conformer for diastereomers of II-29 as calculated by DFT (reported 
energies relative to chair conformer B for S,S-diastereomer). 
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Figure II-05: 1H spectrum of the major (top) and minor (bottom) diastereomer of II-29 with complete labelling.
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After complete assignment of the 1H NMR spectra of each diastereomer in the isomeric mixture of II-
29 (figure II-05), it was nonetheless possible to determine the ratio of products using the relative 
integrals in the 1H NMR spectrum.  The ratio of major:minor products was thus calculated as 64:36, 
showing that the conjugate addition of ethanethiol to enone II-28 proceeded with a minor degree of
diastereocontrol.
Despite a degree of selectivity being observed in the conjugate addition of ethanethiol to enone II-28, 
the low yielding route to the enone necessitates a more efficient isomerization reaction be developed 
in order to test more nucleophiles in this reaction.  Since a degree of diastereoselectivity has already 
been observed, it may be expedient to examine how this selectivity changes when modifying the 
reaction conditions, substrate or nucleophile. Researching this topic more thoroughly could lead to a 
range of selective conjugate addition reactions to a microbially derived enone, providing the 
opportunity to synthesise multiple enantiopure, novel compounds. 
With ketones II-25 and II-29 in hand, the synthesis of an oxime was attempted.  The reaction of ketone 
II-25 with hydroxylamine furnished oxime II-30 in a yield of 36% (scheme II-14).  The observed low yield 
could be a result of loss of product during recrystallisation, which may necessitate an improved method 
for purification of oxime II-30 should it prove to be of value. 1H NMR of the oxime suggested a single 
product was formed from this reaction, which was confirmed by X-ray crystallography to be the E-
oxime. This was a desirable outcome, because successful Beckmann rearrangement of a geometrically 
pure oxime should theoretically be more likely to give rise to a single lactam product. 
Scheme II-14: Synthesis of oxime II-30 and its crystal structure. a) HONH2.HCl (3 equiv.), NaOAc (10 equiv.), 
MeOH, RT, 16 hours.
The Beckmann rearrangement of oxime II-30 was subsequently attempted, with the aim of 
synthesising lactam II-31.  It is reported in the literature that Beckmann rearrangement often fails
when the oxime moiety is located α to a tetra-substituted carbon, however in most cases at least a 
minor quantity of lactam is formed.34 In such cases, a competing Beckmann fragmentation also occurs,
resulting in C-C bond cleavage and the formation of a nitrile as the major product.  When reacting 
oxime II-30 with thionyl chloride, this fragmentation occurred to give acyclic nitrile II-32 exclusively
(scheme II-15).  
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Scheme II-15: Attempted Beckmann rearrangement of oxime II-30. a) thionyl chloride (10 equiv.), THF, 0oC, 3 
hours.
Indeed, a literature search of reactions that treat α-hydroxy oximes with thionyl chloride shows that 
Beckmann fragmentation occurs exclusively when exposing them to Beckmann rearrangement 
conditions.35, 36 Based on the reported mechanism of Beckmann fragmentation, an argument can be 
made that these oximes may be yet more prone to fragmentation than their non-hydroxylated 
analogues. This is due to the alcohol – α to the oxime – promoting C-C bond cleavage through its 
deprotonation, resulting in formation of ketone II-32 (scheme II-16).
Scheme II-16: Proposed mechanism of Beckmann fragmentation of II-30.  a) thionyl chloride (10 equiv.), THF, 
0oC, 3 hours.
Due to Beckmann fragmentation, it was necessary to synthesise a ketone from arene diol II-01 where 
the ketone moiety was not α to the tetra-substituted carbon.  Two strategies were contrived to achieve
this.  The first was based on an epoxide ring opening reaction using a source of hydride and the second 
on the Kornblum–DeLaMare rearrangement of an endo-peroxide. As such, epoxide II-34 and endo-
peroxide II-35 were synthesised (scheme II-17), with a view to using these compounds in the synthesis 
of ketones.  The synthesis of endo-peroxides from arene diol II-01 has been previously reported by 
Lewis et al..10, 12
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Scheme II-17: Synthesis of epoxide II-34 and endoperoxide II-35.  a) TMS-diazomethane, MeOH, benzene, RT, 
20 minutes.  b) LiBH4 (2.0 equiv.), THF, 0oC to RT, 16 hours.  c) TBDMSOTf (1.05 equiv.), NEt3 (1.2 equiv.), CH2Cl2, 
-78oC to RT, 16 hours.  d) mCPBA (1.4 equiv.), CH2Cl2, RT, 19 hours.  e) O2, TPP, CH2Cl2, 0oC, 8 hours.
The reaction of epoxide II-34 with LiAlH4 did induce epoxide ring opening, however TBDMS 
deprotection was also observed to give diol II-36 (scheme II-18).  Epoxide ring opening was found to 
occur exclusively at C4, which can be rationalised through sterics (C3 is more sterically encumbered by 
the acetonide group than C4).  TBDMS deprotection was an unexpected result, which prevented 
continued research into this strategy.  Furthermore, Kornblum–DeLaMare rearrangement of endo-
peroxide II-35 to give derived γ-hydroxy-enone II-37 was also unsuccessful (scheme II-18).  Lewis et al. 
had previously reported the successful synthesis of similar γ-hydroxyenones, however it was also 
noted that difficulties were encountered due to the tendency of these γ-hydroxyenones to undergo a 
multitude of side reactions.10 Careful modification of reaction conditions – for example reaction 
temperature, time or base – may have supressed unwanted side reactions, however this has not yet 
been studied.  As such, research into the synthesis of a suitable ketone for Beckmann rearrangement 
is ongoing.  
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Scheme II-18: Epoxide opening of II-34 and attempted Kornblum–DeLaMare rearrangement of endoperoxide II-
35.  a) LiAlH4 (2.0 equiv.), THF, 0oC to RT, 16 hours. b) DIPEA, CH2Cl2, RT.
Synthesis of arene diol derived O-heterocycles
The microbial oxidation of sodium benzoate occurs regio- and enantio-selectively at the ipso, ortho-
position of the aromatic ring, providing an enantiopure tetra-substituted carbon adjacent to a 
secondary alcohol.  Due to the difficulties faced when synthesising chiral compounds, it was envisaged 
that this biotransformation could provide a chiral starting material that could be used in the synthesis 
of an array of enantiopure compounds. To achieve this, oxidative fragmentation of diene II-13 was 
attempted in the hope of accessing dialdehyde II-38.  This would then be examined for its suitability 
as a chiral starting material in synthesis.  However, upon reaction of diene II-13 with OsO4 and NaIO4 a 
product was obtained that contained a single aldehyde group (scheme II-19).  This product was 
tentatively assigned as lactol II-39, which was unstable to column chromatography.
Scheme II-19: One step lactol formation from diene II-13.  a) OsO4 (5 mol%), NaIO4 (2.0 equiv.), dioxane, water, 
RT, 16 hours.
Proposed intermediates in the formation of lactol II-39 are illustrated in scheme II-20.  It was 
hypothesised that formation of diol II-40 would initially occur, followed by rapid NaIO4 mediated glycol 
cleavage to give ene-dialdehyde II-41.  An intramolecular conjugate addition of the aldehyde to the 
enal then proceeds.  It is suggested that at this stage of the reaction, a molecule of water is
incorporated to form lactol II-39. The intermediates of this reaction pathway were targeted for 
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synthesis, as achieving this would not only help to confirm the proposed series of events, but also give 
access to ene-dialdehyde II-41, a molecule which possess a high degree of modifiable functionality.
Scheme II-20: Proposed intermediates in the formation of lactol II-39 from diene II-13.
Synthesis of the diol proved straightforward.  Parker et al. had previously reported the synthesis of 
regioisomeric diols II-40 and II-42 by treating diene II-13 with OsO4 and NMO.17 Dihydroxylation 
favours the least hindered alkene in this reaction, however a mixture of regioisomers is still obtained
(scheme II-21).  Separation of this regioisomeric mixture by column chromatography was successful, 
albeit challenging.  Conversely, dihydroxylation of the analogous TBDMS protected alcohol II-33
proceeded regioselectively to give novel diol II-43 exclusively (scheme II-21).  The regioselectivity of 
this dihydroxylation reaction is confirmed by 1H NMR, whereas the stereo-selectivity is assumed based 
on the stereoselectivity reported in the epoxidation and dihydroxylation of methyl ester II-13.16, 17
Scheme II-21: Dihydroxylation of dienes II-13 and II-33.  a) OsO4 (2.5 mol%), NMO (1.2 equiv.), acetone, water, 
RT, 16 hours.
Reacting diols II-40 and II-43 with NaIO4 in THF gave the desired enantiopure lactols in good to very 
good yields (scheme II-22).  Furthermore, the products were obtained in remarkably good purity, thus 
avoiding the requirement for further purification.  Lactols II-39 and II-44 could therefore be fully 
characterised and their identities confirmed.  Despite the purity of lactols II-39 and II-44, their
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stereochemistry could not be fully established at this point, since the 1H NMR spectra of these 
compounds provided insufficient information to ascertain it.  To the best of our knowledge, this is the 
only example of the one-step synthesis of a lactol from an allylic diol.  Only one other example of the 
reaction of an allylic diol with NaIO4 is reported in the literature, which provides an uncyclized 
dialdehyde in 37% yield.37 No explanation was offered by the authors for the apparent low yield.
Scheme II-22: Formation of lactols II-39 and II-44 from diols II-40 and II-43.  a) NaIO4 (2.0 equiv.), THF, water, 
RT, 16 hours.
The dialdehyde intermediate inferred in the synthesis of lactols II-39 and II-44 proved more challenging 
to isolate.  Because the dihydroxylation of TBDMS containing diene II-33 proceeded regioselectively, 
diol II-43 was chosen as a substrate for testing alternative oxidants to NaIO4.  Due to water being 
necessary for the formation of lactol II-44, conditions for glycol cleavage under an anhydrous 
environment were explored.  Reaction of diol II-43 with Bu4N.NaIO4 in anhydrous CH2Cl2 led to a 
complex mixture of products being formed.  Contrastingly, reacting diol under Ley oxidation conditions 
furnished the unusual α-hydroxydiene-one II-45, with no glycol cleavage being observed (scheme II-
23).  In 2004, Koo et al. reported the glycol cleavage of similar allylic diols using Pb(OAc)4, resulting in 
the formation of dialdehydes.38 Diol II-43 was therefore reacted with Pb(OAc)4 for 50 minutes,
furnishing a product with 1H NMR signals that suggested the successful synthesis of dialdehyde II-46
(figure II-05).  Due to its instability, dialdehyde II-46 was immediately reduced to acyclic diol II-47 and 
fully characterised (scheme II-23).  The low yield of diol II-47 obtained is thought to be a result of the 
instability of intermediate dialdehyde II-46.  
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Scheme II-23: Attempted glycol cleavage reactions on II-43, eventually leading to the proposed dialdehyde
intermediate II-46 in the lactol forming reaction of II-44.  a) TPAP (6 mol%), NMO (0.99 equiv.), CH2Cl2, RT, 3 
hours.  b) Pb(OAc)4 (1.1 equiv.), MeCN, RT, 50 minutes.  c) NaBH4 (10 equiv.), MeOH, RT, 5 hours.
Figure II-05: Crude 1H NMR of dialdehyde II-46.
Interestingly, reacting diol II-43 with Pb(OAc)4 for 16 hours gave a different product – tricyclic II-48
(scheme II-24).  Similarly to the formation of lactol II-44, this product too seems to be a result of 
intramolecular conjugate addition of the aldehyde to the enal.  However, in the absence of water, the 
resulting enolate seemingly attacks the oxonium ion to give II-48.  This observation suggests that enal 
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II-46 is highly reactive towards nucleophiles.  The stereochemistry of the product has been fully 
assigned using X-ray crystallography (figure II-06). 
Scheme II-24: Synthesis of tricyclic II-48 with proposed intermediates.  a) Pb(OAc)4 (1.0 equiv.), MeCN, RT, 16 
hours.
Figure II-06: Crystal structure of poly-cyclic II-48.
Reacting crude dialdehyde II-46 with water in THF did indeed result in the formation of lactol II-44, 
albeit as a minor product when compared to the faster formation of tricyclic II-48 (scheme II-25).  
Whilst this set of experiments does help to confirm the series of intermediates produced in the 
formation of lactol II-44, the non-exclusive formation of lactol II-44 when reacting dialdehyde II-46
with water in THF does suggest that NaIO4 may play an important role in its formation.  
Scheme II-25: Reaction of dialdehyde II-46 with water in THF.  a) water, THF, RT, 16 hours.
In order to unambiguously assign the stereochemistry of lactol II-44 and II-39, efforts were made to 
synthesise an analogous lactol which would be crystalline.  Doing so would allow an X-ray crystal 
structure of this compound to be acquired.  To this end, alcohol II-49 was treated with 4-nitrobenzoyl 
chloride and triethylamine to give ester II-50 (scheme II-26).  Dihydroxylation of this compound 
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subsequently gave diol II-51. Whilst the reaction of diol II-51 with NaIO4 has been conducted, the 
purification of the product by recrystallisation, and subsequent growth of crystals suitable for X-ray 
crystallography, continues to be worked towards.
Scheme II-26: Synthesis of diol II-51. a) 4-nitrobenzoyl chloride (1.1 equiv.), NEt3 (1.2 equiv.), CH2Cl2, 0oC to RT, 
16 hours. b) OsO4 (3 mol%), NMO (1.3 equiv.), acetone, water, RT, 16 hours.
Derivatisation of lactol II-44 has been pursued, however success has not yet been found in this venture
(scheme II-27).  Oxidation of the lactol using DMP and SIBX both gave a mixture of a number of 
compounds, as did Ley oxidation, Swern oxidation and oxidation with PDC.  In addition to this, the 
reaction of lactol II-44 with BF3.Et2O and allyl-TMS also failed to give the desired furan.  It was also 
envisaged that deprotection of the TBDMS group may result in the formation of a second lactol ring, 
however this too gave a mixture of products.  
Scheme II-27: Attempts at derivatising lactol II-44. a) BF3.Et2O (3.1 equiv.), allyl-TMS (2.1 equiv.), CH2Cl2, -78oC 
to RT, 16 hours.  b) TBAF (1.2 equiv.), THF, -78oC to RT, 16 hours.
Reaction of lactol II-44 with MeMgBr, however, led once more to the formation of tricyclic II-48, and 
not to methylation of its aldehyde (scheme II-28). This observation suggests that lactol II-44 may also 
be reversibly dehydrated, on this occasion using MeMgBr, to form an intermediate which may then 
participate in the aforementioned intramolecular conjugate addition to afford bicycle II-48.
Chapter 2
53
Furthermore, it has also been found that, upon attempted purification of lactol II-44 by silica gel 
column chromatography, tricyclic II-48 also forms.
Scheme II-28: Attempted methylation of lactol II-44.  a) MeMgBr (5.0 equiv.), THF, 0oC to RT, 72 hours.
The diverse and densely packed functionality of lactol II-44 is desirable for complex, small molecule 
synthesis, however these features have also presented significant challenges.  In particular, the lability 
of lactol II-44 has proved a challenge when it comes to derivatising it, necessitating further research to 
make this strategy of heterocycle synthesis more viable.
The synthesis of spiro-cyclic epoxides from arene diol II-01 may permit incorporation of various alkyl 
chains at the tetra-substituted carbon atom through epoxide ring opening reactions. Diol II-53 was 
synthesised through TBDMS protection of the secondary alcohol of methyl ester II-23 to give silyl 
protected II-52, followed by reduction of its methyl ester.  Tosylation of the primary alcohol and intra-
molecular attack of the tertiary alcohol gave spiro-cyclic epoxide II-54 (scheme II-29).  Whilst this 
chemistry may be of utility in the future, the synthetic chemistry of epoxide II-54 has not yet been 
explored.
Scheme II-29: Synthesis of spirocyclic epoxide II-54.  a) TBDMSOTf (1.2 equiv.), NEt3 (2.0 equiv.), CH2Cl2, -78oC 
to RT, 90 minutes.  b) LiBH4 (2.2 equiv.), THF, -78oC to RT, 16 hours.  c) pTsCl (1.4 equiv.), DMAP (10 mol%), NEt3
(5.0 equiv.), CH2Cl2, 0oC to RT, 20 hours.  d) K2CO3 (1.0 equiv.), MeOH, 0oC to RT, 2 hours.
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Benzyne cycloaddition chemistry and reductive aminations
Compounds containing β-lactams are ubiquitous in medicinal chemistry, particularly in antibiotics.39
As such, the synthesis of novel, enantiopure β-lactams is of interest to expand the pool of compounds 
that may be useful in medicinal chemistry.  The synthesis of β-lactams from arene diol II-01 was 
therefore targeted.  Two strategies were designed to synthesise β-lactams; the first based on the 
intramolecular attack of an amide on a tosylated alcohol and the second on the intramolecular attack 
of an amide on a bromonium ion (similarly to Myers’ synthesis of lactones from arene diols).16
The cyclic propylphosphonic anhydride T3P® is not reported to effect the formation of esters, however 
it is often used in the synthesis of amides.40 Since two free alcohols are present on substrate II-06, 
T3P® was consequently identified as a suitable coupling agent for the amidation of II-06.  Formation of 
amide II-55 proved difficult due to base catalysed re-aromatisation of the starting material.  
Nonetheless, minor amounts of amide II-55 were synthesised using T3P® (scheme II-30). Other 
coupling agents have not yet been tested in this transformation, however a reagent screen may be 
necessary should amide II-55 be of synthetic utility. In the synthesis of amide II-57, the protection of 
the diol of II-07 allowed a wider range of suitable coupling agents to be considered.  Treating acid II-
07 with benzylamine in the presence of DCC and DMAP gave amide II-57 in a moderate yield (scheme 
II-30).  Following these early stages of research, Carrera et al. published a paper reporting the synthesis 
of a β-lactam from arene diol II-01.21 Consequentially, the synthesis of amides II-56 and II-58 was never 
attempted and this area of research discontinued.
Scheme II-30: Initial research towards the synthesis of β-lactams.  a) T3P® (1.1 equiv.), NMM (3.0 equiv.), 
benzylamine (1.7 equiv.), EtOAc, 0oC to RT, 72 hours.  b) DCC (1.1 equiv.), DMAP (10 mol%), benzylamine (1.1
equiv.), CH2Cl2, RT, 16 hours.
The synthesis of nitrogen containing heterocycles may also be achieved from the reductive amination 
of dialdehydes, such as dialdeyde II-60 (scheme II-31).  Due to the aforementioned lactol formation 
reaction when reacting allylic diol II-43 with NaIO4, it was necessary to first removed the alkene moiety 
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from this compound prior to dialdehyde formation.  To this end, diol II-43 was epoxidized to give II-59 
(scheme II-31).  Reaction of epoxide II-59 with NaIO4, however, proceeded to give a mixture of 
compounds.  Hydrogenation of alkene II-43 was also attempted for this sequence of reactions, 
however hydrogenation was found to proceed extremely slowly under ~1 atmosphere of hydrogen 
gas.  Research by Parker suggests that this reaction may be more successful when conducted under a 
high pressure of hydrogen gas.17 Work in this area is ongoing.
Scheme II-31: Attempted synthesis of dialdehyde II-60.  a) mCPBA (2.4 equiv.), CH2Cl2, RT, 3 days.  b) NaIO4 (2.0
equiv.), THF, water, RT, 6 hours.
Dienes derived from arene diol II-01 have been used in several cycloaddition reactions in the past by 
Widdowson,41 Mihovilovic19, 20 and Lewis.9, 10, 12 However, an emerging trend in synthetic chemistry is 
to conduct cycloaddition reactions with a source of benzyne, which has been used in the synthesis of 
benzofurans,42 benzotriazoles43 and indazoles.44 The cycloaddition of benzyne with an ortho,meta-
arene diol derived diene has previously been reported by Hudlický,45, 46 however such a cycloaddition 
has not yet been attempted on dienes derived from ipso,ortho-arene diols.  Achieving this would give 
access to 1,2-disubstituted aromatic compounds with fascinating 3D architectures.
Investigation into the reaction of arene ipso,ortho-diol derived dienes with benzyne precursors has 
therefore been undertaken, with Carlos Lopez-Alled (former Masters student at the University of Bath)
making a significant contribution to the research.  In the reaction of dienes II-27 and II-13 with 2-
(trimethylsilyl)phenyl trifluoromethanesulfonate, benzyne formation was triggered in situ through 
addition of CsF, which affected an elimination reaction with loss of fluorotrimethylsilane and 
trifluoromethanesulfonate.47 The reaction of free diol II-27 with 2-(trimethylsilyl)phenyl 
trifluoromethanesulfonate failed, resulting in re-aromatised product.  However, the cycloaddition 
between acetonide protected diol II-13 and 2-(trimethylsilyl)phenyl trifluoromethanesulfonate in the 
presence of CsF proceeded as planned, giving II-61 in an excellent yield (scheme II-32). The facial 
selectivity of this reaction was initially assumed based on the previously reported stereoselectivity of
diene II-13 in cyclo-addition reactions, but was later confirmed by X-ray crystallography of derivative 
II-69.9, 10, 13, 41
Chapter 2
56
Scheme II-32: Benzyne cycloaddition reaction with diene II-13.  a) 2-(trimethylsilyl)phenyl 
trifluoromethanesulfonate (2.0 equiv.), CsF (4.0 equiv.), MeCN, RT, 16 hours.
Methyl ester II-61 was subsequently reduced and the resulting alcohol protected as a TBDMS ether to 
give II-62 (scheme II-33).  OsO4 mediated dihydroxylation of diene II-63 gave diol II-64 in a good yield
(scheme II-33).  It was envisaged that oxidative cleavage of the glycol bond of II-64 would give a di-
aldehyde, which may then be suitable to conduct a reductive amination on, resulting in a 7-membered 
N-heterocycle.  As such, diol II-64 was reacted with NaIO4 (scheme II-33).  The resulting di-aldehyde
was not purified or characterised over concerns of epimerisation of the protons α to the aldehydes.  
Consequentially, it was immediately subjected to reductive amination conditions to furnish N-
heterocyclic II-65 in moderate yield (scheme II-33). 
Scheme II-33: Synthesis of N-heterocyclic II-65.  a) LiAlH4 (1.8 equiv.), THF, 0oC to RT, 6 hours.  b) TBDMSOTf
(1.2 equiv.), NEt3 (1.5 equiv.), CH2Cl2, -78oC to RT, 24 hours.  c) OsO4 (5 mol%), NMO (1.5 equiv.), acetone, 
water, 45oC, 16 hours.  d) NaIO4 (2.0 equiv.), THF, water, 3 hours.  e) Benzylamine (1.05 equiv.), NaBH(OAc)3 (5.0
equiv.), CH2Cl2, RT, 16 hours.
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In addition to N-heterocyclic II-65, the synthesis of cyclitols bearing an arene ring has also been 
achieved.  Following synthesis of the MOM protected alcohol II-66, reaction with 2-
(trimethylsilyl)phenyl trifluoromethanesulfonate and CsF furnished II-67, which was subsequently 
dihydroxylated using catalytic OsO4 to give diol II-68 (scheme II-34).  Upon acid catalysed global 
deprotection of diol II-68, tri-cyclic cyclitol II-69 was generated (scheme II-34).  An X-ray crystal 
structure of penta-ol II-69 was acquired, confirming both the assumed diastereoselectivity of the
previous cycloaddition and dihydroxylation reactions (figure II-07).  Bicyclic diol II-70 was also 
synthesised from diol II-68 through its reaction with NaIO4 – resulting in cleavage of the glycol bond –
followed by immediate reduction of the resulting di-aldehyde (scheme II-34).  Whilst global 
deprotection of diol II-70 has not yet been attempted, achieving this would give access to another 
cyclitol bearing an arene ring.
Scheme II-34: Synthesis of penta-ol II-69 and diol II-70 from arene diol derived diene II-66. a) 2-
(trimethylsilyl)phenyl trifluoromethanesulfonate (3.0 equiv.), CsF (6.0 equiv.), MeCN, RT, 16 hours.  b) OsO4 (5 
mol%), NMO (1.0 equiv.), acetone, water, RT, 72 hours.  c) Acidic ion exchange resin (DOWEX 50W-X8, 20-50 
mesh), MeOH, RT, 48 hours.  d) NaIO4 (24 equiv.), MeOH, water, RT, 6 hours.  e) NaBH4 (9.8 equiv.), MeOH, 0oC 
to RT, 24 hours.
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Figure II-07: Crystal structure of cyclitol II-69. 
In an attempt to reduce the number of synthetic steps required to synthesise cyclitol II-69, an 
alternative synthetic route was devised (scheme II-35).  OsO4 mediated dihydroxylation of alkene II-61
was conducted to give diol II-71 in a very good yield.  Reduction of the methyl ester to the primary 
alcohol provided II-72.  This transformation was achieved in a sub-optimal yield of just 33% yield.  The 
reason for the low yield may be a result of the compound’s hydrophilicity; upon aqueous work-up of 
the reaction, the hydrophilicity of triol II-72 may have resulted in inefficient extraction from the
aqueous phase. Acetonide deprotection of triol II-72 to form penta-ol II-72 has not yet been 
attempted, however developing this chemistry would lead to a more straightforward and atom 
efficient route to penta-ol II-72.
Scheme II-35: Synthesis of triol II-72.  a) OsO4 (2.5 mol%), NMO (1.5 equiv.), acetone, water, 65oC, 24 hours.  b) 
LiAlH4 (2.0 equiv.), THF, 0oC to RT, 4 hours.
Polyhydroxylated compounds have previously been synthesised from arene diols by Parker,17 Lewis et 
al.,10, 12 and Myers,16 and the biology of cyclitols well documentated.48, 49 The previously detailed work 
has added to the literature by demonstrating the straightforward synthesis of novel, arene containing
cyclitols that possesses a complex 3D structure, as well as novel N-heterocyclic II-65. 
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Conclusions and future work
The Beckmann rearrangement allows the synthesis of lactams from ketones.23, 50 Ketones II-25 and II-
29 have been synthesised from arene diol II-01 with the aim of using both in Beckmann rearrangement 
reactions.  However, upon exposing geometrically pure oxime II-30 to Beckmann rearrangement 
conditions, Beckmann fragmentation was instead observed to give achiral nitrile II-32 (scheme II-36).  
It is postulated that the failure of this reaction was the result of the ketone being situated α to a 
hydroxyl-bearing tetra-substituted carbon.
Scheme II-36: Synthesis of ketones II-25 and II-29 and the attempted Beckmann rearrangement of oxime II-30.  
a) HONH2.HCl (3.0 equiv.), NaOAc (10 equiv.), MeOH, RT, 16 hours.  b) thionyl chloride (10 equiv.), THF, 0oC, 3 
hours.
Attempts have been made to synthesise ketones from arene diol II-01 where the ketone moiety was
not situated α to a hydroxyl-bearing carbon atom, however difficulties were encountered when trying 
to achieve this. The synthesis of γ-hydroxy-enone II-37 from endoperoxide II-35 was challenging due 
to the innate reactivity of II-37, which resulted in several side reactions occurring.  An alternative, and
relatively straightforward, method to correct this may be to hydrogenate endo-peroxide II-35 prior to 
Kornblum–DeLaMare rearrangement (scheme II-37).  This would circumvent the synthesis of a reactive 
γ-hydroxy-enone Michael acceptor, furnishing instead γ-hydroxy-ketone II-73.  This product would be 
a promising substrate upon which to conduct a Beckmann rearrangement reaction.
Scheme II-37: Proposed route to a ketone suitable for Beckmann rearrangement.
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Lactol II-44 has also been synthesised from diene arene diol II-01 (scheme II-38).  This can be achieved 
in a one-pot reaction from diene II-33 or through a two-step approach, with diol II-43 being synthesised 
prior to glycol cleavage. The two-step strategy furnishes lactol II-44 with remarkable purity, however 
despite full characterisation of the product, the stereochemistry of all stereo-centres in the molecule 
were not possible to assign.  It should be made a priority to establish this stereochemistry, which may 
be achieved through the synthesis of a compound that bears a more crystallisable group in place of 
the sillyl ether.  This would allow an X-ray crystal structure of a similar lactol to II-44 to be obtained.
Tricyclic II-48 has also been synthesised from diol II-43 through its reaction with Pb(OAc)4.
Scheme II-38: Synthesis of lactol II-44 and tricyclic II-48 from diene II-33.  a) OsO4 (2.5 mol%), NMO (1.2 equiv.), 
acetone, water, 16 hours.  b) NaIO4 (2 equiv.), THF, water, 8 hours. c) Pb(OAc)4 (1.0 equiv.), MeCN, RT, 16 
hours.
Derivatisation of lactol II-44 should continue to be explored.  Whilst the synthesis of lactol II-44 has 
been shown to be high yielding, reliable and clean, accessing furans or lactones would greatly diversify 
the number of compounds accessible using this chemistry.  Whilst a number of derivatisation protocols 
have already been attempted, most focus on reactions on the lactol group.  It may instead be necessary 
to protect/derivatise the aldehyde initially, as this may confer greater stability of the product for 
subsequent reactions.  
Furthermore, research into dialdehyde II-46, which is thought to be an intermediate in the formation 
of both lactol II-44 and tricyclic II-48, may be of interest.  Such dialdehydes have been reported 
previously in Baylis–Hillman reactions to form cyclopentenes.38 In addition to this, hydrogenation of 
or conjugate addition to dialdehyde II-46 would shut down the lactol and bi-cycle forming pathways
and give access to compounds which may be used in reductive amination reactions (scheme II-39).  
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The reactivity of dialdehyde II-46 may prove to be of high utility in accessing a wealth of novel, 
enantiopure compounds from microbially derived arene diols.
Scheme II-39: Proposals for the derivatisation of dialdehyde II-46.
Benzyne cyclo-addition chemistry has also been conducted on microbially derived dienes II-13 and II-
67.  Derivatisation of the resulting arene containing compounds has led to the syntheses of N-
heterocyclic II-65, cyclitol II-69 and diol II-70 (scheme II-40). These compounds are of synthetic interest 
due to their complex 3D shape and densely packed functionality.
Scheme II-40: Synthesis of N-heterocyclic II-65, cyclitol II-69 and diol II-70 through the use of a benzyne 
cycloaddition reaction with arene diol derived dienes II-13 and II-66. a) 2-(trimethylsilyl)phenyl 
trifluoromethanesulfonate (2.0 equiv.), CsF (4.0 equiv.), MeCN, RT, 16 hours. b) 2-(trimethylsilyl)phenyl 
trifluoromethanesulfonate (3.0 equiv.), CsF (6.0 equiv.), MeCN, RT, 16 hours.  
Despite the synthesis of multiple novel and enantiopure heterocycles from arene diol II-01, as well as 
several other noteworthy compounds synthesised en route, continued research is necessary to fully 
demonstrate the potential of arene diols in heterocycle synthesis.  Research focussed around uses of 
dialdehyde II-46 in synthesis and the further development of a Beckmann rearrangement reaction of 







A sterile pipette tip was streaked across a frozen glycerol solution of Ralstonia eutropha B9 and added 
to a sterile solution of Hutner’s mineral base (100 mL) and sodium succinate (0.405 g) in an Erlenmeyer 
flask.  The flask was placed on an orbital shaker (250 rpm) at 27oC and shaken for 48 hours.  The 
resulting cloudy suspension was poured into Hutner’s mineral base (1.4 L) contained within an 
Erlenmeyer flask, which was heated to ca. 30oC and through which air was bubbled using an airstone.   
Aqueous D-fructose (10 mL, 10% w/v) was then added, and the culture was left to grow for 24 hours.
Following this, the culture was induced with sodium benzoate (1.0 M, 8.0 mL) and fed a further 
quantity of D-fructose (8.0 mL).  After 16 h, repetitive feeding of sodium benzoate and D-fructose 
began, with a total of 200 mL of sodium benzoate and 200 mL of D-fructose being added to the culture 
over a period of 5 days (40 mL/ 24 h).  A final quantity of D-fructose (20 mL) was then added over the 
next 24 hours in order to ensure full conversion of all the added substrate.  
The culture was centrifuged (5000 rpm, 45 minutes, 4oC) and the supernatant collected.  The volume 
of the supernatant was reduced to ~150 mL through concentration under vacuum.  Isopropanol (850 
mL) was added, which effected precipitation of a brown solid. The solid was then filtered off, re-
dissolved in water (80 mL) and isopropanol (800 mL) added; this was found to aid in the removal of 
residual media salts and excess D-fructose. The product was again isolated by filtration, washed with 
CH2Cl2 and dried under vacuum to give a cream coloured solid (16.4 g), which contained II-01 as the 
mixed sodium/potassium carboxylate salt and a variable proportion of growth medium salts.
1H NMR (500 MHz, DMSO) δ = 5.79 (1H, dd, J = 9.5, 5.2 Hz), 5.75-5.67 (1H, m), 5.61-5.54 (1H, m), 5.51 
(1H, d, J = 9.5 Hz), 4.68-4.63 (1H, m).  Data are in agreement with those previously reported.20
(1S,6R)-1,6-Dihydroxycyclohexa-2,4-diene-1-carboxylic acid II-06
Carboxylate II-01 (16.4 g, 92.1 mmol (assuming solid contains no residual media salts)) was dissolved 
in water (1.0 L). The solution was cooled to ~0oC and carefully acidified to between pH 2.5 and 3.0 
with aq. conc. HCl.  Carboxylic acid II-06 was extracted with EtOAc (10 x 2 L), ensuring the pH of the 
aqueous phase remained between pH 2.5 and 3.0 and each extraction.  The solvent was removed 
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under vacuum (water bath 30oC), and the product triturated with CH2Cl2 (2 x 50 mL) to give pure acid 
diol II-06 as an off-white solid (8.00 g, 51.3 mmol, 56%).
1H NMR (500 MHz, CD3OD) δ = 6.10 (1H, dd, J = 9.7, 5.2 Hz), 5.93 (1H, dddd, J = 9.2, 5.2, 2.8, 1.2 Hz), 
5.83-5.76 (2H, m), 4.87-4.82 (1H, m); 13C NMR (126 MHz, CD3OD) δ = 178.0, 133.6, 127.3, 127.1, 123.5, 
75.4, 72.4.  Data are in agreement with those previously reported.12
(1S,2R)-1,2-Dihydroxycyclohexane-1-carboxylic acid II-22
To acid diol II-06 (5.48 g, 35.1 mmol) and Pd/C (0.700 g) was added MeOH (80 mL).  The suspension 
was stirred under an atmosphere of H2 gas (balloon) for 23 hours, and the suspension then filtered 
through Celite.  The solvent was removed under vacuum, and the product triturated with cold CH2Cl2
(2 x 30 mL) to remove unwanted re-aromatisation products. II-22 was obtained as an off-white solid
(3.49 g, 21.8 mmol, 62%) and was found to be of good purity, meaning that no purification was 
necessary.  
1H NMR (500 MHz, CD3OD) δ = 3.83 (1H, dd, J = 11.5, 4.5 Hz), 1.81-1.27 (8H, m); 13C NMR (126 MHz, 
CD3OD) δ = 179.1, 77.9, 73.6, 35.3, 30.8, 25.4, 21.1.  Data are in agreement with those previously 
reported.12
Methyl (1S,2R)-1,2-dihydroxycyclohexane-1-carboxylate II-23
To a solution of saturated diol acid II-22 (1.28 g, 8.08 mmol) in MeOH (40 mL) and benzene (40 mL) 
was added TMS-CHN2 (~ 12.5 mL, “2M” in hexanes), until a luminous yellow colour persisted in 
solution.  The solution was left to stir for 20 minutes, and the solvent was removed under vacuum.  
The crude product was purified by column chromatography (30% EtOAc, 70% petroleum ether) to give 
II-23 as a white solid (0.975 g, 5.60 mmol, 69%).
1H NMR (500 MHz, CDCl3) δ = 3.87-3.76 (1H, m), 3.81 (3H, s), 3.31 (1H, m, OH), 2.02 (1H, s, OH), 1.91-
1.21 (8H, m). HRMS (ESI+) m/z calculated for (C8H14O4Na)+ 197.0784; found 197.0861. Data are in 




A suspension of diol carboxylate II-01 (1.90 g, 9.69 mmol, 1.0 equiv.) in 2,2-DMP (70 mL) was cooled 
to 0oC and TFA (3.7 mL, 48.4 mmol, 5.0 equiv.) added dropwise over 10 minutes.  The suspension was 
allowed to warm to RT over 24 h and then filtered through a pad of Celite.  The solution was 
concentrated under vacuum and then resuspended in water (50 mL).  The product was extracted with 
CH2Cl2 (2 x 50 mL).  Organic extracts were combined, dried over MgSO4 and the solvent removed to 
give II-07 as a brown oil (1.69 g, 8.62 mmol, 89%).  This brown oil was of acceptable purity to use in 
subsequent synthetic steps.
1H NMR (500 MHz, CDCl3) δ = 6.19-6.12 (2H, m), 6.04-6.00 (1H, m), 5.81-5.78 (1H, m), 4.95 (1H, dd, J = 
4.1, 0.9 Hz), 1.49 (3H, s), 1.43 (3H, s).  HRMS (ESI-) m/z calculated for (C10H11O4)- 195.0663; found 
195.0674. Data are in agreement with those previously reported.21
Methyl (1S,2R)-1,2-dihydroxycyclohexane-1-carboxylate II-23
Through a suspension of acid diene II-07 (0.558 g, 0.285 mmol, 1.0 equiv.) and Pd/C (60 mg) in EtOAc
(20 mL) was bubbled H2 gas for 16 hours.  The suspension was filtered through a pad of Celite and the 
solvent removed to give a brown oil.  This oil was immediately re-dissolved in MeOH (30 mL) and pTSA 
added (56 mg, 0.292 mmol, 1.0 equiv.) and the solution stirred for 5 days.  NaOAc (100 mg) was added 
and the suspension filtered.  The solvent was removed under vacuum to give a brown oil, which was 
purified by column chromatography (50% EtOAc, 50% petroleum ether) to give II-23 as a white solid 
(0.307 g, 0.176 mmol, 62%).
1H NMR (500 MHz, CDCl3) δ = 3.87-3.76 (1H, m), 3.81 (3H, s), 3.31 (1H, m, OH), 2.02 (1H, s, OH), 1.91-
1.21 (8H, m). HRMS (ESI+) m/z calculated for (C8H14O4Na)+ 197.0784; found 197.0861. Data are in 




A suspension of SIBX (45% wt IBX, 3.91 g, 6.28 mmol, 2.0 equiv.) and DMSO (10 mL) was stirred until 
full dissolution of SIBX (~10 minutes).  Alcohol II-23 (0.547 g, 3.14 mmol, 1.0 equiv.) in DMSO (5.0 mL) 
was then added slowly.  After addition of II-23, the solution was heated to 60oC and stirred for 3 h.  
The solution was then allowed to cool to RT, and TFA (0.48 mL, 6.28 mmol, 2.0 equiv.) added.  Stirring 
was continued for a further 2 h.  EtOAc (20 mL) was added to the solution, and the organic layer was 
washed with saturated, aqueous NaHCO3 (2 x 15 mL), aqueous sodium thiosulfate (10%, 2 x 15 mL) 
and brine (2 x 15 mL).  The organic layer was dried over MgSO4 and the solvent removed under vacuum 
to give II-25 as a yellow oil (0.370 g, 2.15 mmol, 68%) of good purity.
Rf = 0.35 (30% EtOAc, 70% petroleum ether); [α]D26 = -99 (CH2Cl2, c. 0.73 g/100 mL); 1H NMR (500 MHz, 
CDCl3) δ = 3.79 (3H, s), 2.78-2.53 (3H, m), 2.11-2.00 (1H, m), 1.98-1.62 (4H, m); 13C NMR (126 MHz, 
CDCl3) δ = 207.4, 170.7, 80.9, 53.1, 39.0, 38.0, 27.2, 22.1; νmax (film) 3458, 2953, 2868, 1716, 1438, 
1249, 1214, 1114, 1093 cm-1; HRMS (ESI+) m/z calculated for (C8H12O4Na)+ 195.0628; found 195.0610.
Methyl (S)-1-((methylthio)methoxy)-2-oxocyclohexane-1-carboxylate II-26
DMSO (90 μL, 1.16 mmol, 2.0 equiv.) in CH2Cl2 (10 mL) was cooled to -78oC and oxalyl chloride (73 μL, 
0.578 mmol, 1.0 equiv.) was added dropwise. Stirring at -78oC continued for 15 minutes, at which point 
diol II-23 (0.100 g, 0.578 mmol, 1.0 equiv.) was added dropwise and the reaction stirred for a further 
15 minutes. Triethylamine (0.400 mL, 2.89 mmol, 5.0 equiv.) was added dropwise, and stirring 
continued for a final 30 minutes. The solution was then warmed to 0oC, stirred for 15 minutes and 
poured into CH2Cl2 (25 mL). The resulting solution was washed with water (20 mL), saturated aqueous 
NH4Cl (20 mL), water (20 mL), saturated aqueous NaHCO3 (20 mL) and brine (20 mL). The organic layer 
was dried over MgSO4 and the solvent removed under vacuum to give an oil. The oil was purified by 
column chromatography (10% EtOAc, 90% Petroleum ether) to give II-26 as a colourless oil (23 mg, 
0.099 mmol, 17%). 
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Rf = 0.53 (25% EtOAc, 75% petroleum ether); [α]D26 = -3.5 (CH2Cl2, c. 1.25 g/100 mL); 1H NMR (500 MHz, 
CDCl3) δ = 4.80 (1H, d, J = 10.9 Hz), 4.67 (1H, d, J = 10.9 Hz), 3.80 (3H, s), 2.76-2.66 (1H, m), 2.52-2.42 
(1H, m), 2.41-2.32 (1H, m), 2.26 (3H, s), 2.09 (1H, dddd, J = 14.2, 7.3, 3.6, 1.9 Hz), 1.96-1.79 (3H, m), 
1.72-1.61 (1H, m); 13C NMR (126 MHz, CDCl3) δ = 205.8, 170.2, 86.4, 71.1, 52.7, 40.2, 36.0, 27.1, 21.0, 
14.8; νmax (film) 2950, 2867, 1746, 1721, 1435, 1247, 1097, 1032, 998 cm-1; HRMS (ESI+) m/z calculated 
for (C10H15O4SNa)+ 255.0662; found 255.0676.
Methyl (1S,6R)-1,6-dihydroxycyclohexa-2,4-diene-1-carboxylate II-27
To a solution of diol acid II-06 (0.546 g, 3.50 mmol) in MeOH (10 mL) and benzene (10 mL) was added 
TMS-diazomethane (~3.5 mL, “2M” in hexanes) slowly until a yellow colour persisted in solution and 
effervescence ceased. The yellow solution was stirred for 20 minutes before the solvent was removed 
under vacuum and the crude product purified by column chromatography (30% EtOAc, 70% petroleum 
ether → 50% EtOAc, 50% petroleum ether) to give methyl ester II-27 as a white solid (0.492 g, 2.89 
mmol, 83%).
1H NMR (500 MHz, CDCl3) δ = 6.11 (1H, ddt, J = 9.5, 5.3, 0.8 Hz), 5.92 (1H, dddd, J = 9.8, 5.4, 2.8, 1.1 
Hz), 5.79 (1H, ddt, J = 9.7, 2.3, 1.0 Hz), 5.74 (1H, dq, J = 9.6, 1.1 Hz), 4.81 (1H, dt, J = 9.0, 2.9 Hz), 3.84 
(3H, s), 3.71 (1H, s, OH), 3.00 (1H, d, J = 10.2 Hz). HRMS (ESI+) m/z calculated for (C8H10O4Na)+ 
193.0471; found 195.0499. Data are in agreement with those previously reported.14
Methyl (S)-1-hydroxy-2-oxocyclohex-3-ene-1-carboxylate II-28
Diene II-27 (0.692 g, 4.07 mmol, 1.0 equiv.), Grubbs’ 1st generation catalyst (0.165 g, 0.200 mmol, 5 
mol%) and toluene (15 mL) were heated to reflux and stirred for 18 hours. The solvent was removed 
under reduced pressure to give a black oil. This was then purified by flash column chromatography 
(25% EtOAc, 75% petroleum ether) to give II-28 as a light brown oil (70 mg, 0.412 mmol, 10%). 
1H NMR (250 MHz, CDCl3) δ = 7.09-6.98 (1H, m), 6.10 (1H, d, J = 10.1 Hz), 4.29 (1H, s, OH), 3.73 (3H, s), 




To enone II-28 (52.0 mg, 0.301 mmol, 1.0 equiv.) and ethanethiol (24.0 μL, 0.331 mmol, 1.1 equiv.) in 
CHCl3 (3.0 mL) was added trimethylamine (0.50 mL).  The solution was heated to 30oC and stirred for 
22 hours. After this time, Et2O (10 mL) was added and the solution washed with aqueous HCl (3 wt%, 
3 x 10 mL) and water (10 mL). The organic layer was dried over MgSO4 and the solvent removed under 
vacuum to give an orange oil. This oil was purified by flash column chromatography (20% EtOAc, 80% 
petroleum ether) to give an orange, waxy oil (0.032 g, 0.136 mmol, 45%). The product was determined 
to be a mixture of 2 diastereomers in a ratio of 64:34, which were characterised from analysis of the 
crude mixture.
Rf = 0.48 (25% EtOAc, 75% petroleum ether); vmax (film) 3444, 2956, 2930, 2878, 1718, 1437, 1253, 
1170, 1110, 1075, 979 cm-1; HRMS (ESI+) m/z calculated (C10H16O4SNa)+ 255.0662, found 255.0664.
NMR data for major product: 1H NMR (500 MHz, CDCl3) δ = 3.80 (3H, s), 3.36 (1H, apparent p, 
J = 5.7 Hz), 2.92 (1H, dd, J = 14.2, 4.9 Hz), 2.82 (1H, dd, J = 14.3, 6.3 Hz), 2.62-2.49 (2H, m), 2.42 
(1H, ddd, J = 13.7, 6.9, 3.5 Hz), 2.26-2.11 (2H, m), 2.04-1.95 (1H, m), 1.30-1.20 (3H, m); 13C 
NMR (126 MHz, CDCl3) δ = 204.5, 171.2, 80.1, 53.3, 44.1, 42.3, 33.6, 27.2, 24.8, 14.7.
NMR data for minor product: 1H NMR (500 MHz, CDCl3) δ = 3.79 (3H, s), 3.04-2.94 (2H, m), 
2.73 (1H, dt, J = 13.9, 4.1 Hz), 2.66 (1H, dd, J = 14.1, 12.2 Hz), 2.62-2.49 (2H, m), 2.26-2.11 (1H, 
m), 1.90 (1H, dddd, J = 14.9, 13.1, 11.2, 3.8 Hz), 1.65 (1H, td, J = 13.3, 4.1 Hz), 1.30-1.20 (1H, 
m); 13C NMR (126 MHz, CDCl3) δ = 204.5, 170.1, 80.2, 53.3, 45.5, 42.6, 35.8, 29.3, 24.8, 14.9.
Methyl E-(S)-1-hydroxy-2-(hydroxyimino)cyclohexane-1-carboxylate II-30
To ketone II-25 (0.130 g, 0.756 mmol, 1.0 equiv.), hydroxylamine hydrochloride (0.158 g, 2.27 mmol, 
3.0 equiv.) and NaOAc (1.04 g, 7.56 mmol, 10 equiv.) was added MeOH (5.0 mL).  The suspension was 
stirred for 16 hours at RT.  The solvent was then removed under vacuum and the resulting solid re-
dissolved in water (20 mL).  The product was extracted with EtOAc (3 x 20 mL).  Organic extracts were 
combined, dried over MgSO4 and the solvent removed under vacuum. The resulting solid was purified 




Rf = 0.42 (50% EtOAc, 50% petroleum ether); [α]D25 = +47 (CH2Cl2, c. 0.77 g/100 mL); melting point =
103-106oC; 1H NMR (500 MHz, CDCl3) δ = 3.80 (3H, s), 2.89 (1H, dt, J = 14.8, 4.9 Hz), 2.43 (1H, ddd, J = 
15.5, 10.8, 5.2 Hz), 2.19 (1H, ddd, J = 13.6, 10.7, 4.1 Hz), 1.93-1.62 (4H, m), 1.60-1.48 (1H, m); 13C NMR 
(126 MHz, CDCl3) δ = 174.0, 160.0, 76.2, 53.1, 36.0, 24.6, 21.6, 20.8; νmax (film) 3353, 2974, 2952, 2925, 
2867, 1717, 1442, 1281, 1160, 1017, 937 cm-1; HRMS (ESI+) m/z calculated (C8H13O4NH)+ 188.0917, 
found 188.0927.
Crystal structure data for II-30 to be found in the appendix.
Methyl 6-cyano-2-oxohexanoate II-32
A solution of SOCl2 (0.8 mL, 1.10 mmol, 10 equiv.) in anhydrous THF (1.5 mL) was cooled to 0oC.  Oxime 
II-30 (20 mg, 0.107 mmol, 1.0 equiv.) in THF (0.5 mL) was added dropwise and the solution was stirred 
at 0oC for 3 hours.  After this time, the reaction was quenched through addition of water (10 mL) and 
extracted with EtOAc (3 x 10 mL).  Organic layers were combined, washed with brine (20 mL) and dried 
over MgSO4.  The solvent was removed under vacuum to give II-32 as a yellow oil (19 mg, 1.10 mmol, 
quantitative) which was characterised by NMR. 
1H NMR (500 MHz, CDCl3) δ = 3.87 (3H, s), 2.91 (2H, t, J = 6.9 Hz), 2.38 (2H, t, J = 7.0 Hz), 1.87-1.66 (4H, 
m); 13C NMR (126 MHz, CDCl3) δ = 193.2, 161.3, 119.3, 53.2, 38.4, 24.7, 22.1, 17.2.
Methyl (3aS,7aR)-2,2-dimethylbenzo[d][1,3]dioxole-3a(7aH)-carboxylate II-13
Acid diene II-07 (1.20 g, 6.10 mmol) was dissolved in MeOH (20 mL) and benzene (20 mL) and TMS-
diazomethane (~6 mL, “2M” in hexanes) added slowly until a yellow colour persisted in solution and 
effervescence ceased.  The solution was stirred for 20 minutes, the solvent removed under vacuum 
and the product purified by column chromatography (15% EtOAc, 85% petroleum ether) to give II-13
as a colourless oil (0.843 g, 4.01 mmol, 66%).
1H NMR (500 MHz, CDCl3) δ = 6.11-6.02 (2H, m), 6.02-5.93 (1H, m), 5.82-5.74 (1H, m), 4.93 (1H, dd, J = 
4.2, 0.7 Hz), 3.75 (3H, s), 1.40 (3H, s), 1.38 (3H, s); HRMS (ESI+) m/z calculated (C11H14O4Na)+ 233.0784, 




Methyl ester II-13 (1.41 g, 6.71 mmol, 1.0 equiv.) was dissolved in anhydrous THF (15 mL) and cooled 
to 0oC.  LiBH4 (4.0 M, 3.4 mL, 13.4 mmol, 2.0 equiv.) was added dropwise and the solution allowed to 
warm to RT over 16 h.  The reaction was quenched through addition of EtOAc (20 mL) followed by 
water (20 mL).  The organic phase was collected and the product further extracted from the aqueous 
phase using EtOAc (2 x 20 mL).  Organic phases were combined and dried over MgSO4.  The solvent 
was removed under vacuum to give II-49 a colourless oil (1.03 g, 0.566 mmol, 84%). The product 
obtained was of good purity, so no further purification was necessary.
1H NMR (500 MHz, CDCl3) δ = 6.06 (1H, dd, J = 9.7, 5.2 Hz), 6.02-5.95 (2H, m), 5.67 (1H, d, J = 9.9 Hz), 
4.46 (1H, d, J = 4.7 Hz), 3.56 (1H, dd, J = 12.0, 2.9 Hz), 3.34 (1H, dd, J = 11.9, 7.1 Hz), 2.22-2.15 (1H, m), 
1.42 (3H, s), 1.34 (3H, s); HRMS (ESI+) m/z calculated (C10H14O3Na)+ 205.0835, found 205.0841. Data 
are in agreement with those previously reported.10
tert-Butyl(((3aR,7aR)-2,2-dimethylbenzo[d][1,3]dioxol-3a(7aH)-yl)methoxy)dimethylsilane II-33
Alcohol II-49 (0.285 g, 1.57 mmol, 1.0 equiv.) was dissolved in anhydrous CH2Cl2 (8.0 mL) and cooled 
to -78oC.  Triethylamine (0.26 mL, 1.88 mmol, 1.2 equiv.) was added dropwise, followed by TBDMSOTf
(0.38 mL, 1.64 mmol, 1.05 equiv.) and the solution allowed to warm to RT over 16 hours.  Water (20 
mL) was then added and the product extracted with CH2Cl2 (2 x 20 mL).  Organic phases were combined 
and dried over MgSO4 and the solvent removed under vacuum.  The crude product was purified by 
column chromatography (5% EtOAc, 95% petroleum ether) to give II-33 as a colourless oil (0.395 g, 
1.33 mmol, 85%).
1H NMR (500 MHz, CDCl3) δ = 6.07 (1H, ddt, J = 9.6, 5.3, 0.6 Hz), 6.00 (1H, tt, J = 5.0, 1.0 Hz), 5.97 (1H, 
ddd, J = 9.7, 5.3, 1.1 Hz), 5.67 (1H, dq, J = 9.7, 0.8 Hz), 4.52 (1H, d, J = 4.6 Hz), 3.61 (1H, d, J = 10.5 Hz), 
3.44 (1H, d, J = 10.5 Hz), 1.43 (3H, s), 1.36 (3H, s), 0.88 (9H, s), 0.05 (3H, s), 0.04 (3H, s). Data are in 





Diene II-33 (0.184 g, 0.621 mmol, 1.0 equiv.) was dissolved in CH2Cl2 (5.0 mL) and cooled to 0oC.  mCPBA 
(0.139 g, 0.808 mmol, 1.3 equiv.) was added and the solution allowed to warm to RT over 14 hours.  
Following this, a further quantity of mCPBA (10 mg, 57.9 μmol, 0.1 equiv.) was added and the solution 
stirred for a further 5 hours.  The reaction was quenched through the addition of aqueous sodium 
thiosulfate (1.0 M, 20 mL) and the product extracted with CH2Cl2 (3 x 20 mL).  Organic phases were 
combined, dried over MgSO4 and the solvent removed under vacuum.  The crude product was purified 
by column chromatography (5% EtOAc, 95% petroleum ether) to give II-34 as a colourless oil (0.145 g, 
0.464 mmol, 75%).  
Rf = 0.25 (5% EtOAc, 95% petroleum ether); [α]D25 = -31 (CH2Cl2, c. 1 g/100 mL); 1H NMR (500 MHz, 
CDCl3) δ = 6.03 (1H, dd, J = 10.2, 4.0 Hz), 5.66 (1H, dt, J = 10.2, 1.3 Hz), 4.73 (1H, dt, J = 2.0, 0.9 Hz), 3.68 
(1H, d, J = 10.9 Hz), 3.63 (1H, dd, J = 3.7, 2.2 Hz), 3.43 (1H, d, J = 10.9 Hz), 3.37-3.34 (1H, m), 1.42 (3H, 
s), 1.37 (3H, s), 0.91 (9H, s), 0.07 (3H, s), 0.07 (3H, s); 13C NMR (126 MHz, CDCl3) δ = 134.2, 123.4, 110.0, 
81.5, 69.9, 66.4, 50.9, 46.9, 28.2, 27.0, 26.1, 18.6, -5.1, -5.3; vmax (film) 2989, 2955, 2930, 2858, 1463, 




Diene II-13 (0.232 g, 1.10 mmol) was dissolved in CH2Cl2 (5.0 mL) and TPP (0.1 mL, 30 mg/mL solution) 
added.  The solution was cooled to ~0oC.  Four needles attached to an oxygen cylinder delivered oxygen 
to the solution for 8 h, whilst the solution was irradiated by five L.E.D. lights (12 V).  The solvent was 
removed and analysis of the crude 1H NMR showed 90% conversion of the starting material.  The crude 
product was purified by column chromatography (20% EtOAc, 80% petroleum ether) to give II-35 as
an off-white solid (0.152 g, 0.628 mmol, 57%).
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1H NMR (500 MHz, CDCl3) δ = 6.59-6.55 (2H, m), 5.14 (1H, d, J = 4.9 Hz), 5.11-5.08 (1H, m), 4.97-4.93 
(1H, m), 3.85 (3H, s), 1.30 (3H, s), 1.28 (3H, s); HRMS (ESI+) m/z calculated (C11H14O6Na)+ 265.0683, 
found 223.0704. Data are in agreement with those previously reported.10
(3aR,4S,7aR)-7a-(Hydroxymethyl)-2,2-dimethyl-3a,4,5,7a-tetrahydrobenzo[d][1,3]dioxol-4-ol II-36
Epoxide II-34 (91 mg, 0.291 mmol, 1.0 equiv.) was dissolved in anhydrous THF (5.0 mL) and cooled to 
0oC.  LiAlH4 (2.4 M in THF, 0.24 mL, 0.582 mmol, 2.0 equiv.) was added dropwise and the reaction 
allowed to warm to RT over 16 hours.  The reaction was cooled to 0oC and quenched through slow 
addition of water (10 mL).  The resulting suspension was filtered and the product extracted with EtOAc 
(2 x 10 mL).  The solvent was removed under vacuum and the crude product purified by column 
chromatography (50% EtOAc, 50% petroleum ether) to give II-36 as a white solid (32 mg, 0.160 mmol, 
55%).
Rf = 0.25 (50% EtOAc, 50% petroleum ether); [α]D25 = -34 (CH2Cl2, c. 1 g/100 mL); melting point = 103-
105oC; 1H NMR (500 MHz, CDCl3) δ = 5.81 (1H, dddd, J = 10.3, 5.2, 2.4, 1.1 Hz), 5.52 (1H, ddt, J = 10.3, 
2.8, 1.3 Hz), 4.25-4.21 (1H, m), 4.12 (1H, d, J = 4.0 Hz), 3.66 (1H, d, J = 10.8 Hz), 3.59 (1H, d, J = 10.9 Hz), 
3.48 (2H, s, OH), 2.46 (1H, ddt, J = 18.1, 4.2 2.7 Hz), 2.17-2.10 (1H, m), 1.38 (3H, s), 1.36 (3H, s); 13C 
NMR (126 MHz, CDCl3) δ = 127.4, 127.2, 108.9, 79.4, 78.4, 66.2, 66.0, 28.8, 28.0, 27.5; vmax (film) 3325, 






Methyl ester II-13 (0.476 g, 2.27 mmol, 1.0 equiv.) was dissolved in acetone (10 mL) and NMO (0.319 
g, 2.72 mmol, 1.2 equiv.) was added.  Water (~1 mL) was added until full dissolution of NMO was 
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observed, then OsO4 (2.5 wt% in tBuOH, 0.58 mL, 56.8 μmol, 2.5 mol%) added.  The solution was stirred 
at RT for 16 h.  Aqueous sodium thiosulfate (20 mL, 0.5 M) was added to quench the reaction and the 
product extracted with EtOAc (3 x 20 mL).  Organic phases were combined, dried over MgSO4 and the 
solvent removed under vacuum to give a dark brown oil.  This oil was purified by flash column 
chromatography (0% MeOH, 100% CH2Cl2 → 3% MeOH, 97% CH2Cl2) using a Reveleris™ column 
cartridge (40 μm, 12 g silica, 30 mL/min) to give a pure faction of major diol II-40 (0.229 g, 0.938 mmol, 
41%) and a mixed faction of both II-40 and II-42.  The mixed faction was again subjected to purification 
by flash column chromatography (30% EtOAc, 70% petroleum ether → 50% EtOAc, 50% petroleum 
ether) using a GraceResolv™ column cartridge (12 g silica, 28 mL/min) to give a mixed faction of II-40
and II-42 (52 mg) and a pure faction of minor diol II-42 (34 mg, 0.139 mmol, 6%).
Data for II-40. 1H NMR (500 MHz, CDCl3) δ = 5.87 (1H, ddd, J = 10.4, 2.3, 1.3 Hz), 5.70 (1H, dt, J = 10.3, 
1.9 Hz), 4.59 (1H, dd, J = 4.1, 1.6 Hz), 4.32-4.19 (2H, m), 3.83 (3H, s), 3.59 (1H, d, J = 7.5 Hz, OH), 3.02 
(1H, d, J = 9.5 Hz, OH), 1.42 (3H, s), 1.38 (3H, s); 13C NMR (126 MHz, CDCl3) δ = 173.3, 132.3, 125.3, 
111.3, 77.5, 68.7, 65.2, 53.8, 27.7, 26.2. Data are in agreement with those previously reported.17
Data for II-42. 1H NMR (500 MHz, CDCl3) δ = 5.93 (1H, dd, J = 10.3, 2.7 Hz), 5.90 (1H, ddd, J = 10.3, 3.4, 
1.2 Hz), 4.97 (1H, dd, J = 3.3, 1.1 Hz), 4.39-4.31 (1H, m), 4.21 (1H, t, J = 4.9 Hz), 3.84 (3H, s), 3.17 (1H, 
d, J = 9.5 Hz, OH), 3.09 (1H, d, J = 5.5 Hz, OH), 1.44 (3H, s), 1.37 (3H, s); 13C NMR (500 MHz, CDCl3) δ = 




Diene II-33 (0.325 g, 1.10 mmol, 1.0 equiv.) was dissolved in acetone (15 mL) and NMO (0.155 g, 1.32 
mmol, 1.2 equiv.) was added.  Water (~0.5 mL) was added until full dissolution of NMO was observed. 
OsO4 (2.5 wt% in tBuOH, 0.28 mL, 27.5 μmol, 2.5 mol%) was then added.  The solution was stirred at 
RT for 16 h.  Aqueous sodium thiosulfate (1.0 M, 20 mL) was added to quench the reaction and the 
product extracted with EtOAc (3 x 20 mL).  Organic phases were combined, dried over MgSO4 and the 
solvent removed under vacuum.  The product was purified by column chromatography (20% EtOAc, 
80% petroleum ether) to give II-43 as a colourless oil (0.331 g, 1.00 mmol, 91%).
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Rf = 0.33 (20% EtOAc, 80% petroleum ether); [α]D25 = -14.5 (CH2Cl2, c. 2 g/100 mL); 1H NMR (500 MHz, 
CDCl3) δ = 5.81 (1H, dt, J = 10.4, 1.7 Hz), 5.43 (1H, dt, J = 10.5, 2.1 Hz), 4.30 (1H, dd, J = 3.6, 1.8 Hz), 
4.28-4.22 (1H, m), 4.20-4.13 (1H, m), 4.13 (1H, d, J = 10.5 Hz, OH), 3.74 (1H, d, J = 9.4 Hz), 3.62 (1H, d,
J = 9.4 Hz), 2.79 (1H, d, J = 10.1 Hz, OH), 1.36 (3H, s), 1.36 (3H, s), 0.89 (9H, s), 0.11 (3H, s), 0.10 (3H, s); 
13C NMR (126 MHz, CDCl3) δ = 132.6, 128.3, 109.4, 80.7, 78.7, 68.3, 67.9, 65.4, 27.8, 27.2, 25.9, 18.4, -
5.5, -5.5; vmax (film) 3408, 2955, 2930, 2858, 1472, 1370, 1251, 1070, 833 cm-1; HRMS (ESI+) m/z 
calculated (C16H30O5SiNa)+ 353.1755, found 353.1778.
Methyl (3aS,6aS)-6-hydroxy-2,2-dimethyl-4-(2-oxoethyl)dihydrofuro[3,4-d][1,3]dioxole-3a(4H)-
carboxylate II-39
Diol II-40 (0.368 g, 1.51 mmol, 1.0 equiv.) was dissolved in THF (10 mL) and water (2.0 mL).  NaIO4
(0.645 g, 3.02 mmol, 2.0 equiv.) was added and the solution stirred for 16 hours.  Aqueous sodium 
thiosulfate (1.0 M, 20 mL) was added and the product extracted with EtOAc (3 x 20 mL).  Organic phases 
were combined and dried over MgSO4.  The solvent was removed under vacuum to give II-39 as a 
colourless oil (0.240 g, 0.923 mmol, 61%).  Obtained product was of good purity and was found to be 
unstable on silica.
[α]D25 = +16 (CH2Cl2, c. 1.0 g/100 mL); 1H NMR (500 MHz, CDCl3) δ = 9.77 (1H, t, J = 1.1 Hz), 5.38 (1H, d, 
J = 5.5 Hz), 4.89 (1H, t, J = 6.4 Hz), 4.76 (1H, s), 3.89 (3H, s), 3.17 (1H, d, J = 5.5 Hz, OH), 2.94-2.86 (2H, 
m), 1.51 (3H, s), 1.37 (3H, s); 13C NMR (126 MHz, CDCl3) δ = 199.2, 172.2, 115.4, 100.7, 90.3, 90.1, 78.1, 
53.4, 43.4, 26.6, 25.4; vmax (film) 3452, 2991, 2955, 1725, 1438, 1378, 1261, 1077 cm-1; HRMS (ESI+) 
m/z calculated (C11H16O7Na)+ 283.0792, found 283.0788.
2-((3aS,6aS)-3a-(((tert-Butyldimethylsilyl)oxy)methyl)-6-hydroxy-2,2-dimethyltetrahydrofuro[3,4-
d][1,3]dioxol-4-yl)acetaldehyde II-44
Diol II-43 (0.252 g, 0.763 mmol, 1.0 equiv.) was dissolved in THF (8.0 mL) and water (2.0 mL).  NaIO4
(0.326 g, 1.53 mmol, 2.0 equiv.) was added and the solution stirred for 16 hours.  Aqueous sodium 
thiosulfate (1.0 M, 10 mL) was added and the product extracted with EtOAc (3 x 10 mL).  Organic phases 
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were combined and dried over MgSO4.  The solvent was removed under vacuum to give II-44 as a 
colourless oil (0.228 g, 0.659 mmol, 86%).  Obtained product was of good purity and was found to be 
unstable on silica.
[α]D24 = +25 (CH2Cl2, c. 0.44 g/100 mL); 1H NMR (500 MHz, CDCl3) δ = 9.80 (1H, t, J = 1.5 Hz), 5.27 (1H, 
d, J = 6.8 Hz), 4.55 (1H, t, J = 6.4 Hz), 4.39 (1H, s), 3.91 (1H, d, J = 10.0 Hz), 3.82 (1H, d, J = 6.8 Hz, OH),
3.73 (1H, d, J = 9.9 Hz), 2.81 (1H, t, J = 1.4 Hz), 2.80 (1H, t, J = 1.3 Hz), 1.47 (3H, s), 1.36 (3H, s), 0.92 (9H,
s), 0.13 (3H, s), 0.13 (3H, s); 13C NMR (126 MHz, CDCl3) δ = 200.3, 113.6, 99.4, 90.3, 88.3, 75.4, 65.2, 
44.7, 26.9, 26.6, 26.0, 18.5, -5.4, -5.4; vmax (film) 3443, 2959, 2932, 2858, 1727, 1464, 1372, 1253, 1098, 
779 cm-1; HRMS (ESI+) m/z calculated (C16H30O6SiNa)+ 369.1704, found 369.1740.
(R)-7a-(((tert-Butyldimethylsilyl)oxy)methyl)-4-hydroxy-2,2-dimethylbenzo[d][1,3]dioxol-5(7aH)-
one II-45
Diol II-43 (80 mg, 0.242 mmol, 1.0 equiv.) and NMO (28 mg, 0.239 mmol, 0.99 equiv.) were dissolved 
in anhydrous CH2Cl2 (4.0 mL) and TPAP (5 mg, 14.2 μmol, 6 mol%) was added.  The solution was stirred 
for 3 hours and then filtered through a pad of Celite.  The solvent was removed and the product 
purified by column chromatography (20% EtOAc, 80% petroleum ether) to give II-45 as a yellow oil (22 
mg, 67.5 μmol, 28%).
Rf = 0.50 (20% EtOAc, 80% petroleum ether); [α]D25 = +107 (CH2Cl2, c. 0.67 g/100 mL); 1H NMR (500 
MHz, CDCl3) δ = 6.88 (1H, d, J = 9.8 Hz), 6.22 (1H, d, J = 9.8 Hz), 5.67 (1H, s, OH), 3.66 (1H, d, J = 9.3 Hz), 
3.63 (1H, d, J = 9.3 Hz), 1.72 (3H, s), 1.49 (3H, s), 0.82 (9H, s), 0.00 (3H, s), -0.01 (3H, s); 13C NMR (126 
MHz, CDCl3) δ = 183.4, 147.8, 142.8, 128.7, 128.2, 118.9, 84.3, 68.9, 29.2, 27.6, 25.8, 18.3, -5.4, -5.5; 
vmax (film) 3369, 2958, 2930, 2858, 1647, 1599, 1461, 1375, 1147, 1115 cm-1; HRMS (ESI+) m/z 





Diol II-43 (0.129 g, 0.391 mmol, 1.00 equiv.) and Pb(OAc)4 (0.182 g, 0.410 mmol, 1.05 equiv.) were 
dissolved in anhydrous MeCN (5.0 mL) and stirred for 50 minutes.  The suspension was then filtered 
and the solvent was removed under vacuum.  Pentane (10 mL) was added, the suspension filtered 
once more and the solvent again removed.  The resulting material (0.023 g, 70.1 μmol, 1.00 equiv.) 
was immediately dissolved in MeOH (2.0 mL) and NaBH4 (76 mg, 70.1 μmol, 10.0 equiv.) added. The 
solution was stirred for 5 hours.  Saturated aqueous NH4Cl (5.0 mL) was added and the product 
extracted with EtOAc (3 x 5.0 mL).  Organic phases were combined, dried over MgSO4 and the solvent 
removed under vacuum. The crude product was purified by column chromatography (50% EtOAc, 50% 
petroleum ether) to give II-47 as a white solid (13 mg, 48.2 μmol, 12%).
Rf = 0.36 (50% EtOAc, 50% petroleum ether); [α]D25 = +16 (CH2Cl2, c. 0.5 g/100 mL); melting point = 49-
51oC; 1H NMR (500 MHz, CDCl3) δ = 5.80 (1H, dt, J = 12.5, 5.7 Hz), 5.53 (1H, dt, J = 12.5, 1.7 Hz), 4.41 
(1H, ddd, J = 14.6, 5.5, 1.9 Hz), 4.30-4.23 (2H, m), 3.80-3.76 (2H, m), 3.69 (1H, d, J = 9.9 Hz), 3.66 (1H, 
d, J = 9.9 Hz), 2.75 (1H, s, OH), 2.33 (1H, s, OH), 1.48 (3H, s), 1.42 (3H, s), 0.89 (9H, s), 0.07 (3H, s), 0.07 
(3H, s); 13C NMR (126 MHz, CDCl3) δ = 133.6, 128.0, 109.4, 84.5, 81.8, 68.6, 62.2, 59.8, 27.8, 27.2, 26.0, 
18.5, -5.3, -5.4; ; vmax (film) 3382, 2958, 2930, 2858, 1464, 1380, 1252, 1081 cm-1; HRMS (ESI+) m/z 
calculated (C16H32O5SiNa)+ 355.1911, found 355.1942.
tert-Butyl(((3aS,4S,8S,8aS)-2,2-dimethyl-3a,4-dihydro-4,8-epoxy[1,3]dioxolo[4,5-c]oxepin-8a(8H)-
yl)methoxy)dimethylsilane II-48
To diol II-43 (62 mg g, 0.188 mmol, 1.0 equiv.) and Pb(OAc)4 (83 mg, 0.188 mmol, 1.0 equiv.) was added 
anhydrous MeCN (4.0 mL).  The suspension was stirred for 16 hours.  Following this period, the 
suspension was filtered and the solvent removed under vacuum.  1H NMR of the crude product showed 
a majority of II-48 as the product, with a small quantity of a dialdehyde.  The crude product was purified 
by column chromatography (5% EtOAc, 95% petroleum ether) to give II-48 as a white solid (32 mg, 
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97.5 μmol, 52%). Crystals of the product were grown and X-ray crystallography was used to determine 
its absolute stereochemistry.
Rf = 0.25 (5% EtOAc, 95% petroleum ether); [α]D25 = +17 (CH2Cl2, c. 1 g/100 mL); melting point = 43-
45oC; 1H NMR (500 MHz, CDCl3) δ = 6.19 (1H, d, J = 6.0 Hz), 5.40 (1H, d, J = 1.2 Hz), 5.10 (1H, ddd, J = 
5.8, 5.1, 0.6 Hz), 4.49 (1H, d, J = 0.5 Hz), 4.39 (1H, ddd, J = 5.1, 1.2, 0.6 Hz), 4.06 (1H, d, J = 10.8 Hz), 
3.98 (1H, d, J = 10.8 Hz), 1.48 (3H, s), 1.41 (3H, s), 0.90 (9H, s), 0.08 (3H, s), 0.07 (3H, s); 13C NMR (126 
MHz, CDCl3) δ = 141.2, 114.8, 103.9, 103.7, 100.6, 88.6, 79.0, 65.3, 28.7, 28.2, 26.0, 18.5, -5.2, -5.3; vmax
(film) 2955, 2930, 2858, 1636, 1463, 1380, 1239, 1211, 1112, 1061 cm-1; HRMS (ESI+) m/z calculated 
(C16H28O5SiNa)+ 351.1598, found 355.1622.
Crystal structure data for II-48 to be found in the appendix.
((3aR,7aR)-2,2-Dimethylbenzo[d][1,3]dioxol-3a(7aH)-yl)methyl 4-nitrobenzoate II-50
A solution of alcohol II-49 (0.131 g, 0.719 mmol, 1.0 equiv.) in anhydrous CH2Cl2 (3 mL) was cooled to 
0oC.  NEt3 (0.12 mL, 0.863 mmol, 1.2 equiv.) was then added, followed by a solution of 4-nitrobenzoyl 
chloride (0.147 g, 0.791 mmol, 1.1 equiv.) in CH2Cl2 (1 mL).  The solution was allowed to warm to room 
temperature over 16 hours before brine (10 mL) was added to quench the reaction.  The product was 
extracted with CH2Cl2 (2 x 10 mL).  Organic layers were combined, washed with saturated aqueous 
NaHCO3 (15 mL), dried over MgSO4 and the solvent removed under vacuum.  The resulting 
orange/yellow solid was purified by flash column chromatography (100% petroleum ether → 10% 
EtOAc, 90% petroleum ether) using a Reveleris™ column cartridge (4 g silica, 15 mL/minute) to give II-
50 as a white solid (0.148 g, 0.447 mmol, 62%).
Rf = 0.30 (10% EtOAc, 90% petroleum ether); [α]D25 = -168 (CH2Cl2, c. 1 g/100 mL); melting point = 99-
100oC; 1H NMR (500 MHz, CDCl3) δ = 8.32-8.27 (2H, m), 8.21-8.17 (2H, m), 6.18-6.13 (1H, m), 6.11-6.04 
(2H, m), 5.80 (1H, d, J = 9.9 Hz), 4.55 (1H, d, J = 4.5 Hz), 4.42 (1H, d, J = 11.4 Hz), 4.30 (1H, d, J = 11.4 
Hz), 1.43 (3H, s), 1.39 (3H, s); 13C NMR (126 MHz, CDCl3) δ = 164.4, 150.8, 135.3, 131.0, 128.1, 125.5, 
124.7, 123.9, 123.8, 107.1, 78.4, 72.5, 67.7, 27.2, 26.7; νmax (film) 3053, 2987, 2940, 1727, 1527, 





To a solution of diene II-50 (0.146 g, 0.441 mmol, 1.0 equiv.) in acetone (3 mL) was added NMO (67 
mg, 0.573 mmol, 1.3 equiv.).  Water (~0.7 mL) was added slowly until full dissolution of NMO was 
observed.  OsO4 (2.5 wt% in tBuOH, 0.15 mL, 14.7 μmol, 3 mol%) was subsequently added dropwise.  
After stirring at room temperature for 16 hours, the reaction was quenched through the addition of 
sodium thiosulfate (1 M, 10 mL).  The aqueous phase was extracted with EtOAc (3 x 10 mL).  Organic 
layers were combined, washed with brine (20 mL) and dried over MgSO4.  The solvent was removed 
under vacuum and the crude product purified by flash column chromatography (100% petroleum ether 
→ 50% EtOAc, 50% petroleum ether) using a Reveleris™ column cartridge (4 g silica, 15 mL/min) to 
give II-51 as a white solid (0.106 g, 0.290 mmol, 66%).
Rf = 0.26 (50% EtOAc, 50% petroleum ether; [α]D25 = +2 (CH2Cl2, c. 0.5 g/100 mL); melting point = 119-
121oC; 1H NMR (500 MHz, CDCl3) δ = 8.31-8.27 (2H, m), 8.26-8.21 (2H, m), 5.76 (1H, dt, J = 10.4, 1.8 
Hz), 5.69 (1H, dt, J = 10.4, 1.9 Hz), 4.63 (1H, d, J = 11.6 Hz), 4.50-4.43 (1H, m), 4.42 (1H, dd, J = 4.4, 1.6 
Hz), 4.40-4.35 (2H, m), 2.86 (1H, d, J = 3.2 Hz, OH), 2.60 (1H, d, J = 7.2 Hz, OH), 1.35 (3H, s), 1.34 (3H, 
s); 13C NMR (126 MHz, CDCl3) δ = 164.6, 150.8, 135.4, 130.9, 130.0, 127.2, 123.8, 109.6, 78.1, 76.1, 
69.0, 67.3, 65.7, 27.9, 27.4; νmax (film) 3443, 2983, 1726, 1608, 1528, 1273, 1065, 839 cm-1; HRMS (ESI+) 
m/z calculated (C17H19O8NH)+ 388.1003, found 388.1025.
Methyl (1S,2R)-2-((tert-butyldimethylsilyl)oxy)-1-hydroxycyclohexane-1-carboxylate II-52
Diol II-23 (0.368 g, 2.11 mmol, 1.0 equiv.) was dissolved in CH2Cl2 (20 mL) and cooled to -78oC.  
Triethylamine (0.59 mL, 4.23 mmol, 2.0 equiv.) was added dropwise followed by addition of TBDMSOTf 
(0.58 mL, 2.54 mmol, 1.2 equiv.).  The reaction was stirred for 90 minutes and then quenched by 
addition of water (20 mL).  The organic phase was collected and washed with brine (20 mL) and water 
(20 mL).  The organic phase was dried over MgSO4 and the solvent removed under vacuum.  The crude 
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product was purified by column chromatography to give II-52 as a colourless oil (0.535 g, 1.86 mmol, 
87%).
1H NMR (300 MHz, CDCl3) δ = 3.89 (1H, dd, J = 10.3, 5.3 Hz), 3.68 (3H, s), 3.00 (1H, d, J = 2.1 Hz), 1.95-
1.15 (8H, m), 0.79 (9H, s), 0.00 (3H, s), -0.07 (3H, s). Data are in agreement with those previously 
reported.12
(1R,2R)-2-((tert-Butyldimethylsilyl)oxy)-1-(hydroxymethyl)cyclohexan-1-ol II-53
Methyl ester II-52 (0.535 g, 1.86 mmol, 1.0 equiv.) was dissolved in anhydrous THF (20 mL) and the 
solution cooled to -78oC.  LiBH4 (4.0 M, 1.0 mL, 4 mmol, 2.2 equiv.) was added dropwise.  The solution 
was allowed to warm to RT over 16 hours.  The reaction was then quenched through slow addition of 
EtOAc (20 mL) and water (20 mL).  The organic phase was collected and the product further extracted 
with EtOAc (2 x 20 mL).  Organic phases were combined, dried over MgSO4 and the solvent removed.  
The product was purified by column chromatography (20% EtOAc, 80% petroleum ether) to give II-53 
as a colourless oil (0.374 g, 1.44 mmol, 77%).
1H NMR (300 MHz, CDCl3) δ =3.73-3.50 (2H, m), 3.37 (1H, dd, J = 11.2, 5.4 Hz), 2.44 (1H, d, J = 1.6 Hz, 
OH), 2.12 (1H, s, OH), 1.91-1.06 (8H, m), 0.89 (9H, s), 0.08 (6H, s). Data are in agreement with those 
previously reported.12
(((3R,4R)-1-Oxaspiro[2.5]octan-4-yl)oxy)(tert-butyl)dimethylsilane II-54
To a 0oC stirred solution of diol II-53 (0.374 g, 1.44 mmol, 1.0 equiv.), DMAP (0.018 g, 0.144 mmol, 10 
mol%) and triethylamine (1.0 mL, 7.19 mmol, 5.0 equiv.) in CH2Cl2 (3 mL) was added pTsCl (0.380 g in 
CH2Cl2, 2.01 mmol, 1.4 equiv.) dropwise.  The solution was allowed to warm to RT over 20 hours.  Ice 
water (10 mL) was added to the solution, and the resulting biphasic solution was stirred vigorously for 
1 hour. The biphasic solution was extracted with EtOAc (3 x 15 mL).  Organic phases were combined 
and washed with water (20 mL), cold aqueous HCl (1.0 M, 20 mL), water (20 mL), aqueous saturated 
NaHCO3 (20 mL), water (20 mL) and brine (20 mL).  Organic phases were dried over MgSO4 and the 
solvent removed under vacuum.  The product was re-dissolved in MeOH (4.0 mL), cooled to 0oC and 
K2CO3 (0.199 g, 1.44 mmol, 1.0 equiv.) was added.  The solution was stirred at 0oC for 1 hour and then 
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allowed to warm to RT over 1 hour.  The solvent was removed under vacuum.  CH2Cl2 (5 mL) was added 
to the resulting product, the suspension filtered and the solvent again removed under vacuum.  The 
crude product was purified by column chromatography (10% EtOAc, 90% petroleum ether) to give II-
54 as a colourless oil (0.144 g, 0.594 mmol, 41%).
Rf = 0.28 (20% EtOAc, 80% petroleum ether); [α]D25 = -23 (CHCl3, c. 1 g/100 mL); 1H NMR (500 MHz, 
CDCl3) δ = 3.50 (1H, dd, J = 6.1, 3.0 Hz), 2.71 (1H, dd, J = 5.1, 1.2 Hz), 2.55 (1H, d, J = 5.1 Hz), 1.98 (1H, 
ddd, J = 13.1, 9.9, 4.3 Hz), 1.82-1.68 (3H, m), 1.67-1.57 (1H, m), 1.52-1.36 (2H, m), 1.33-1.23 (1H, m), 
0.90 (9H, s), 0.08 (3H, s), 0.04 (3H, s); 13C NMR (126 MHz, CDCl3) δ = 72.1, 61.4, 51.9, 34.1, 30.1, 26.0, 
24.9, 21.1, 18.3, -4.5, -4.8; νmax (neat) 2934, 2857, 1462, 1446, 1250, 1052, 835 cm-1; HRMS (ESI+) m/z 
calculated (C13H26O2SiNa)+ 265.1594, found 265.1582.
(1S,6R)-N-benzyl-1,6-dihydroxycyclohexa-2,4-diene-1-carboxamide II-55
A solution of diol acid II-06 (0.237 g, 1.52 mmol, 1.0 equiv.) in EtOAc (20 mL) was cooled to 0oC.  T3P®
(50% in EtOAc, 0.99 mL, 1.67 mmol, 1.1 equiv.) and freshly distilled benzylamine (0.28 mL, 2.58 mmol, 
1.7 equiv.) were added slowly.  After stirred for 5 minutes at 0oC, NMM (0.50 mL, 4.56 mmol, 3.0 equiv.) 
was added slowly.  At this point, bubbling was observed in the solution. The solution was warmed to 
RT over 72 hours, during which a white precipitate formed in solution.  Water (30 mL) was added and 
the product extracted with EtOAc (3 x 25 mL).  Organic phases were combined, washed with brine (50 
mL), dried over MgSO4 and the solvent removed under vacuum to give an oil.  1H NMR of the crude 
product indicated phenol, NMM and unreacted benzylamine as the predominant components of the 
mixture.  Purification by column chromatography (50% EtOAc, 50% petroleum ether → 75% EtOAc, 
25% petroleum ether) gave II-55 as a white solid (12 mg, 49.0 μmol, 3%).
Rf = 0.13 (50% EtOAc, 50% petroleum ether; [α]D25 = -141 (CH2Cl2, c. 0.44 g/100 mL); melting point =
133-136oC; 1H NMR (500 MHz, CDCl3) δ = 7.38-7.31 (2H, m), 7.31-7.25 (3H, m), 7.13 (1H, m, NH), 6.14 
(1H, dd, J = 9.5, 5.2 Hz), 6.00-5.94 (1H, m), 5.87 (1H, dd, J = 9.7, 2.5 Hz), 5.79 (1H, d, J = 9.5 Hz), 4.99 (t, 
J = 2.5 Hz), 4.52 (1H, dd, J = 14.9, 6.0 Hz), 4.46 (1H, dd, J = 14.9, 5.8 Hz); 13C NMR (126 MHz, CDCl3) δ = 
173.7, 137.8, 131.8, 128.9, 127.8, 127.7, 127.3, 127.0, 123.1, 75.2, 70.6, 43.9; vmax (film) 3384, 3312, 





Acid II-07 (0.440 g, 2.24 mmol, 1.00 equiv.) was dissolved in CH2Cl2 (20 mL).  DCC (0.485 g, 2.35 mmol, 
1.05 equiv.), DMAP (27 mg, 0.224 mmol, 10 mol%) and freshly distilled benzylamine (0.26 mL, 2.35 
mmol, 1.05 equiv.) were then added.  The solution was stirred for 16 hours.  The suspension was 
filtered and the solvent removed under vacuum.  The resulting heterogeneous oil/solid was purified 
by column chromatography (25% EtOAc, 75% petroleum ether) to give II-57 as an off white solid (0.352 
g, 1.23 mmol, 55%).
Rf = 0.28 (20% EtOAc, 80% petroleum ether); [α]D25 = -278 (CH2Cl2, c. 1 g/100 mL); MP 73-76oC; 1H NMR 
(500 MHz, CDCl3) δ = 7.35 (2H, tt, J = 7.0, 1.2 Hz), 7.31-7.26 (3H, m), 7.02 (1H, t, J = 6.9 Hz, NH), 6.17-
6.10 (2H, m), 6.04-5.99 (1H, m), 5.72-5.66 (1H, m), 4.93 (1H, d, J = 4.2 Hz), 4.48 (1H, dd, J = 14.0, 5.9 
Hz), 4.45 (1H, dd, J = 14.0, 5.9 Hz), 1.40 (6H, s); 13C NMR (126 MHz, CDCl3) δ = 172.5, 138.0, 128.9, 
127.8, 127.8, 125.5, 125.1, 124.6, 124.1, 107.2, 80.5, 73.9, 43.5, 27.1, 25.8; vmax (film) 3366, 2987, 2931, 




Diol II-43 (55 mg, 0.167 mmol, 1.0 equiv.) was dissolved in CH2Cl2 (3.0 mL) and mCPBA (34 mg, 0.200 
mmol, 1.2 equiv.) was added.  The solution was stirred for 1 day and a further quantity of mCPBA 
added (34 mg, 0.200 mmol, 1.2 equiv.).  After stirring for another 2 days, the reaction was quenched 
with aqueous sodium thiosulfate (1.0 M, 10 mL).  The product was extracted with CH2Cl2 (3 x 10 mL).  
Organic phases were combined and washed with aqueous saturated NaHCO3 (20 mL).  The organic 
phase was dried over MgSO4 and the solvent removed to give II-59 as a white solid (51 mg, 0.147 mmol, 
88%).  The crude product was found to be of good purity.
Rf = 0.34 (30% EtOAc, 70% petroleum ether); [α]D25 = -11 (CH2Cl2, c. 2 g/100 mL); 1H NMR (500 MHz, 
CDCl3) δ = 4.34 (1H, dd, J = 3.8, 2.0 Hz), 4.23-4.19 (1H, m), 4.03 (1H, dtd, J = 11.5, 4.0, 1.5 Hz), 3.87 (1H, 
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d, J = 10.7 Hz), 3.81 (1H, d, J = 10.7 Hz), 3.44 (1H, dt, J = 4.1, 1.5 Hz), 3.28 (1H, dd, J = 4.1, 2.0 Hz), 3.03 
(1H, d, J = 11.7 Hz), 2.93 (1H, s), 1.40 (3H, s), 1.37 (3H, s), 0.92 (3H, s), 0.11 (3H, s), 0.11 (3H, s); 13C NMR 
(126 MHz, CDCl3) δ = 109.6, 78.6, 78.6, 68.0, 67.4, 64.7, 57.4, 55.9, 28.0, 26.3, 26.0, 18.6, -5.4, -5.4; vmax
(film) 3466, 2988, 2954, 2930, 2857, 1381, 1372, 1078, 835 cm-1; HRMS (ESI+) m/z calculated 
(C16H30O6SiNa)+ 369.1704, found 369.1725.
Methyl (3aS,4S,9R,9aR)-2,2-dimethyl-9,9a-dihydro-4,9-ethenonaphtho[2,3-d][1,3]dioxole-3a(4H)-
carboxylate II-61
To a solution of diene II-13 (0.166 g, 0.790 mmol, 1.0 equiv.) in MeCN (4.0 mL) was added 2-
(trimethylsilyl)phenyl trifluoromethanesulfonate (0.38 mL, 1.58 mmol, 2.0 equiv.).  CsF (0.480 g, 3.16 
mmol, 4.0 equiv.) was then added and the suspension stirred for 16 hours.  After this time, water (20 
mL) was added and the product extracted with Et2O (3 x 15 mL).  Organic phases were combined, dried 
over MgSO4 and the solvent removed under vacuum to give an orange oil.  This crude product was 
purified by column chromatography (5% EtOAc, 95% petroleum ether → 10% EtOAc, 90% petroleum 
ether) to give II-61 as a colourless oil (0.205 g, 0.716 mmol, 91%).
Rf = 0.41 (10% EtOAc, 90% petroleum ether); [α]D25 = -12 (CH2Cl2, c. 0.5 g/100 mL); 1H NMR (500 MHz, 
CDCl3) δ = 7.25 (1H, d, J = 7.3 Hz), 7.15-7.07 (3H, m), 6.58 (1H, t, J = 6.5 Hz), 6.52 (1H, ddd, J = 7.6, 6.1, 
1.6 Hz), 4.87 (1H, d, J = 3.7 Hz), 4.32 (1H, dd, J = 6.0, 1.4 Hz), 4.20 (1H, ddd, J = 5.5, 3.7, 1.6 Hz), 3.61 
(3H, s), 1.42 (3H, s), 1.26 (3H, s); 13C NMR (126 MHz, CDCl3) δ = 172.0, 139.9, 138.8, 134.4, 132.1, 126.8, 
126.6, 125.1, 125.0, 113.9, 89.2, 82.0, 52.6, 48.2, 46.0, 26.3, 26.3; vmax (film) 2988, 2952, 1737, 1373, 
1250, 1206, 1064, 709 cm-1; HRMS (ESI+) m/z calculated (C17H18O4Na)+ 309.1097, found 309.1104.
((3aR,4S,9R,9aR)-2,2-Dimethyl-9,9a-dihydro-4,9-ethenonaphtho[2,3-d][1,3]dioxol-3a(4H)-
yl)methanol II-62
Methyl ester II-61 (0.195 g, 0.682 mmol, 1.0 equiv.) was dissolved in anhydrous THF (5.0 mL).  The
solution was cooled to 0oC and LiAlH4 (2.4 M solution in THF, 0.52 mL, 1.25 mmol, 1.8 equiv.) added 
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dropwise.  After allowing to warm to RT over 6 hours, the reaction was cooled to 0oC and quenched 
through slow addition of water (15 mL).  The suspension was filtered and the product extracted from 
the filtrate using EtOAc (3 x 15 mL).  Organic phases were combined, dried over MgSO4 and the solvent 
removed under vacuum.  The crude product was purified by column chromatography (50% EtOAc, 
petroleum ether) to give II-62 as a colourless oil (0.100 g, 0.390 mmol, 57%).
Rf = 0.53 (50% EtOAc, 50% petroleum ether); [α]D25 = +15 (CH2Cl2, c. 1 g/100 mL); 1H NMR (500 MHz, 
CDCl3) δ = 7.28-7.24 (1H, m), 7.22-7.19 (1H, m), 7.13-7.10 (1H, m), 6.58-6.54 (2H, m), 4.32 (1H, dd, J = 
4.4, 3.2 Hz), 4.14 (1H, q, J = 3.7 Hz), 3.95 (1H, d, J = 3.6 Hz), 3.53 (1H, d, J = 11.6 Hz), 2.98 (1H, d, J = 11.6 
Hz), 1.90 (1H, s, OH), 1.43 (3H, s), 1.38 (3H, s); 13C NMR (126 MHz, CDCl3) δ = 141.6, 139.2, 134.1, 133.9, 
126.7, 126.4, 125.3, 125.0, 113.4, 90.5, 83.1, 67.6, 46.7, 46.6, 28.8, 27.2; vmax (film) 3461, 3062, 2984, 




Alcohol II-62 (87 mg, 0.337 mmol, 1.0 equiv.) was dissolved in anhydrous CH2Cl2 (4.0 mL) and the 
solution cooled to -78oC.  Triethylamine (70 μL, 0.506 mmol, 1.5 equiv.) and TBDMSOTf (90 μL, 0.388 
mmol, 1.2 equiv.) were added dropwise.  The solution was allowed to warm to RT over 24 hours, at 
which point water (5.0 mL) was added.  The organic phase was collected, and the aqueous phase 
further extracted with CH2Cl2 (2 x 5.0 mL).  Organic phases were combined, dried over MgSO4 and the 
solvent removed under vacuum.  The crude product was purified by column chromatography (5% 
EtOAc, 95% petroleum ether) to give II-63 as a colourless oil (0.112 g, 0.301 mmol, 89%).
Rf = 0.58 (5% EtOAc, 95% petroleum ether); [α]D25 = -1.0 (CH2Cl2, c. 2 g/100 mL); 1H NMR (500 MHz, 
CDCl3) δ = 7.20-7.17 (2H, m), 7.12-7.07 (2H, m), 6.58-6.51 (2H, m), 4.29 (1H, dd, J = 5.7, 1.9 Hz), 4.13 
(1H, ddd, J = 5.5, 3.6, 2.0 Hz), 3.96 (1H, d, J = 3.6 Hz), 3.50 (1H, d, J = 10.8 Hz), 3.01 (1H, d, J = 10.8 Hz), 
1.41 (3H, s), 1.37 (3H, s), 0.87 (9H, s), -0.04 (3H, s), -0.04 (3H, s); 13C NMR (126 MHz, CDCl3) δ = 142.3, 
139.4, 134.2, 134.0, 126.3, 126.1, 125.1, 124.9, 113.3, 91.2, 82.3, 68.6, 46.9, 46.9, 28.5, 27.4, 26.1, 
18.6, -5.3, -5.4; vmax (film) 2955, 2930, 2857, 1472, 1461, 1250, 1094, 777 cm-1; HRMS (ESI+) m/z 





Alkene II-63 (0.175 g, 0.470 mmol, 1.0 equiv.) was dissolved in acetone (5.0 mL) and NMO added (83 
mg, 0.705 mmol, 1.5 equiv.).  Water (~0.2 mL) was then added until full dissolution of NMO was 
observed.  OsO4 (2.5 wt% in BuOH, 0.24 mL, 23.5 μmol, 5 mol%) was added and the solution heated to 
45oC for 16 hours.  After allowing to cool to RT, aqueous sodium thiosulfate (1.0 M, 15 mL) was added 
and the product extracted with EtOAc (3 x 15 mL).  Organic phases were combined, dried over MgSO4
and the solvent removed under vacuum.  The crude product was purified by column chromatography 
(5% EtOAc, 95% petroleum ether → 50% EtOAc, 50% petroleum ether) to give II-64 as a colourless oil 
(0.128 g, 0.315 mmol, 67%).
Rf = 0.47 (50% EtOAc, 50% petroleum ether); [α]D25 = -14 (CH2Cl2, c. 1 g/100 mL); 1H NMR (500 MHz, 
CD2Cl2) δ =  7.28-7.22 (4H, m), 4.64-4.59 (1H, m), 4.54-4.50 (1H, m), 3.83 (1H, d, J = 4.4 Hz), 3.55 (1H, 
d, J = 2.8 Hz), 3.54 (1H, dd, J = 4.4, 3.3 Hz), 3.38 (1H, d, J = 10.9 Hz), 2.88 (1H, d, J = 10.9 Hz), 2.08-2.03 
(1H, m, OH), 1.94-1.88 (1H, m, OH), 1.51 (3H, s), 1.39 (3H, s), 0.87 (9H, s), -0.05 (3H, s), -0.06 (3H, s); 
13C NMR (126 MHz, CD2Cl2) δ = 138.1, 135.6, 128.8, 128.5, 128.2, 127.9, 112.3, 87.0, 78.1, 68.4, 66.0, 
49.0, 48.2, 27.5, 27.5, 26.2, 18.8, -5.3, -5.3; vmax (film) 3389, 2957, 2930, 2857, 1463, 1371, 1254, 1061 
cm-1; HRMS (ESI+) m/z calculated (C22H34O5SiNa)+ 429.2068, found 429.2084.
(3aR,4R)-11-Benzyl-3a-(((tert-butyldimethylsilyl)oxy)methyl)-2,2-dimethyl-3a,4,9,9a-tetrahydro-
4,9-(methanoiminomethano)naphtho[2,3-d][1,3]dioxole II-65
Diol II-64 (59 mg, 0.145 mmol, 1.0 equiv.) and NaIO4 (62 mg, 0.290 mmol, 2.0 equiv.) were dissolved in 
THF (4.0 mL) and water (0.4 mL) and stirred for 3 h. The reaction was quenched with aqueous sodium 
thiosulfate (1.0 M, 15 mL) and the product extracted with EtOAc (3 x 15 mL).  Organic phases were 
combined, dried of MgSO4 and the solvent removed under vacuum.  The product was immediately re-
dissolved in anhydrous CH2Cl2 (4.0 mL) and freshly distilled benzylamine (16 μL, 0.152 mmol, 1.05 
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equiv.) added.  The solution was stirred for 1 hour, after which sodium triacetoxyborohydride (0.154 
g, 0.725 mmol, 5.0 equiv.) was added.  After stirred for 16 hours, the reaction was quenched through 
slow addition of water (8.0 mL).  The product was extracted with CH2Cl2 (3 x 8.0 mL).  Organic phases 
were combined, dried over MgSO4 and the solvent removed under vacuum.  The crude product was 
purified by column chromatography (2.5% EtOAc, 97.5% petroleum ether) to give II-65 as a pale yellow 
oil (33 mg, 68.9 μmol, 48%).
Rf = 0.54 (2.5% EtOAc, 97.5% petroleum ether); [α]D25 = +4.0 (CH2Cl2, c. 0.5 g/100 mL); 1H NMR (500 
MHz, CDCl3) δ = 7.25-7.08 (7H, m), 6.98-6.94 (2H, m), 3.98 (1H, d, J = 6.5 Hz), 3.58 (1H, d, J = 14.3 Hz), 
3.55 (1H, d, J = 14.4 Hz), 3.39 (1H, d, J = 10.8 Hz), 3.35 (1H, d, J = 8.4 Hz), 3.30 (1H, t, J = 6.9 Hz), 3.12 
(1H, d, J = 11.5 Hz), 3.02 (1H, d, J = 10.8 Hz), 2.96 (1H, d, J = 12.1 Hz), 2.70 (1H, t, J = 10.3 Hz), 2.59 (1H, 
dd, J = 11.5, 7.5 Hz), 1.46 (3H, s), 1.45 (3H, s), 0.83 (9H, s), -0.07 (3H, s), -0.10 (3H, s); 13C NMR (126 
MHz, CDCl3) δ = 140.3, 138.8, 137.4, 128.8, 128.1, 127.4, 127.1, 127.0, 126.8, 126.7, 111.5, 87.6, 78.7, 
69.1, 61.8, 50.0, 49.5, 44.2, 43.8, 30.5, 28.0, 26.9, 26.1, 18.6, -5.3, -5.4; vmax (film) 2927, 2856, 1459, 
1378, 1256, 1109, 1083, 750 cm-1; HRMS (ESI+) m/z calculated (C29H41O3NSiH)+ 480.2928, found 
480.2939.
(3aR,7aR)-3a-((Methoxymethoxy)methyl)-2,2-dimethyl-3a,7a-dihydrobenzo[d][1,3]dioxole II-66
Alcohol II-49 (1.77 g, 9.7 mmol, 1.0 equiv.) was dissolved in anhydrous CH2Cl2 (20 mL) and cooled to 
0oC.  Following addition of DIPEA (3.3 mL, 19.4 mmol, 2.0 equiv.) and MOMCl (2.2 mL, 29.1 mmol, 3.0 
equiv.), the reaction was stirred at 0oC for 1 hour and then allowed to warm to room temperature of 
5 hours.  Water (20 mL) was added and the organic phase collected.  The aqueous phase was further 
extracted with CH2Cl2 (20 mL).  Combined organic phases were washed with aqueous saturated 
NaHCO3 (30 mL) and brine (30 mL) before being dried over MgSO4 and the solvent removed under 
vacuum.  The crude product was purified by column chromatography (10% EtOAc, 90% petroleum 
ether) to give II-66 as a colourless oil (1.62 g, 7.16 mmol, 74%).
Rf = 0.76 (23% EtOAc, 77% petroleum ether); [α]D25 = -184 (CH2Cl2, c. 1.0 g/100 mL); 1H NMR (500 MHz, 
CDCl3) δ = 6.09 (1H, dd, J = 9.6, 5.3 Hz), 6.04-5.95 (2H, m), 5.79 (1H, d, J = 9.8 Hz), 4.66 (1H, d, J = 6.5 
Hz), 4.64 (1H, d, J = 6.5 Hz), 4.47 (1H, d, J = 4.5 Hz), 3.56 (1H, d, J = 10.3 Hz), 3.44 (1H, d, J = 10.4 Hz), 
3.35 (3H, s), 1.44 (3H, s), 1.37 (3H, s); 13C NMR (126 MHz, CDCl3) δ = 129.3, 125.3, 124.8, 122.7, 106.5, 
96.9, 79.4, 72.3, 71.1, 55.5, 27.3, 26.8; vmax (film) 2985, 2935, 2883, 1459, 1376, 1106, 919 cm-1; HRMS 





To a solution of diene II-66 (0.100 g, 0.442 mmol, 1.0 equiv.) in MeCN (10 mL) was added CsF (0.402 g, 
2.65 mmol, 6.0 equiv.) and 2-(trimethylsilyl)phenyl trifluoromethanesulfonate (0.32 mL, 1.33 mmol, 
3.0 equiv.).  The reaction was stirred at room temperature for 16 hours.  Water (10 mL) was added to 
the reaction and the aqueous phase extracted with Et2O (2 x 20 mL).  Combined organic phases were 
washed with brine (30 mL) and dried over MgSO4.  The solvent was then removed under vacuum and 
the crude product purified by column chromatography (10% EtOAc, 90% pentane) to give II-67 as a 
yellow oil (75 mg, 0.248 mmol, 56%).
Rf = 0.64 (25% EtOAc, 75% hexane); [α]D26 = +16 (CH2Cl2, c. 1.0 g/100 mL); 1H NMR (500 MHz, CDCl3) δ 
= 7.23-7.18 (2H, m), 7.14-7.08 (2H, m), 6.60-6.50 (2H, m), 4.64 (1H, d, J = 6.5 Hz), 4.57 (1H, d, J = 6.5 
Hz), 4.35 (1H, dd, J = 5.6, 2.0 Hz), 4.14 (1H, ddd, J = 5.5, 3.6, 2.1 Hz), 3.97 (1H, d, J = 3.6 Hz), 3.50 (1H, 
d, J = 10.5 Hz), 3.34 (3H, s), 2.87 (1H, d, J = 10.5 Hz), 1.43 (3H, s), 1.40 (3H, s); 13C NMR (126 MHz, CDCl3) 
δ = 141.9, 139.2, 134.0 , 126.5, 126.3, 125.1, 125.1, 113.6, 96.8, 89.7, 83.0, 72.3, 55.4, 47.0, 46.7, 28.5, 
27.2; vmax (film) 2985, 2935, 2883, 1709, 1459, 1376, 1209, 1039 cm-1; HRMS (ESI+) m/z calculated 
(C18H22O4Na)+ 325.1410, found 325.1431.
(3aR,4S,9R,9aR,10S,11R)-9a-((Methoxymethoxy)methyl)-2,2-dimethyl-3a,4,9,9a-tetrahydro-4,9-
ethanonaphtho[2,3-d][1,3]dioxole-10,11-diol II-68
To a solution of alkene II-67 (70 mg, 0.232 mmol, 1.0 equiv.) in acetone (3 mL) and water (3 mL) was 
added NMO (27 mg, 0.232 mmol, 1.0 equiv.).  OsO4 (2.5 wt% in tBuOH, 0.12 mL, 12 μmol, 5 mol%) was 
then added.  The reaction was stirred at room temperature for 72 hours.  Aqueous sodium thiosulfate 
(1.0 M, 10 mL) was added to quench the reaction and the product was extracted with EtOAc (3 x 10 
mL).  Organic layers were combined, washed with brine (20 mL) and dried over MgSO4.  The solvent 
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was removed and the crude product purified by column chromatography (75% EtOAc, 25% hexane) to 
give II-68 as a white solid (32 mg, 95 μmol, 41%).
Rf = 0.53 (75% EtOAc, 25% petroleum ether); [α]D26 = -10 (CH2Cl2, c. 1.5 g/100 mL); 1H NMR (500 MHz, 
CDCl3) δ = 7.29-7.24 (4H, m), 4.64 (1H, dd, J = 7.6, 3.2 Hz), 4.60 (1H, d, J = 6.5 Hz), 4.64 (1H, dd, J = 7.7,
2.8 Hz), 4.52 (1H, d, J = 6.5 Hz), 3.86 (1H, d, J = 4.4 Hz), 3.66 (1H, d, J = 2.8 Hz), 3.58 (1H, ddd, J = 4.4, 
3.2, 1.1 Hz), 3.34 (1H, d, J = 10.6 Hz), 3.31 (3H, s), 2.80 (1H, d, J = 10.6 Hz), 1.54 (3H, s), 1.43 (3H, s); 13C 
NMR (126 MHz, CDCl3) δ = 137.0, 134.7, 128.3, 128.3, 128.2, 127.9, 112.3, 96.8, 85.3, 78.4, 71.9, 65.5, 
65.4, 55.5, 48.7, 47.5, 27.2, 27.2; vmax (film) 3427, 3399, 2989, 2936, 2884, 1402, 1252, 1059, 754 cm-
1; HRMS (ESI+) m/z calculated (C18H24O6Na)+ 359.1465, found 359.1592.
(1S,2R,3R,4R,9S,10R)-3-(Hydroxymethyl)-1,2,3,4-tetrahydro-1,4-ethanonaphthalene-2,3,9,10-
tetraol II-69
Diol II-68 (30 mg, 89 μmol, 1.0 equiv.) was dissolved in MeOH (5 mL) and acidic ion exchange resin 
(DOWEX 50W-X8, 20-50 mesh) added.  After stirring for 48 hours, the suspension was filtered and the 
solvent was removed under vacuum.  The crude product was purified by recrystallisation with CHCl3
to give II-68 as a white solid (22 mg, 87 μmol, 98%). 
[α]D26 = +4 (MeOH, c. 0.5 g/100 mL); 1H NMR (500 MHz, CD3OD) δ = 7.23-7.17 (4H, m), 4.59 (1H, dd, J = 
7.8, 3.4 Hz), 4.49 (1H, dd, J = 7.8, 2.2 Hz), 3.34 (1H, d, J = 3.4 Hz), 3.22 (1H, d, J = 3.2 Hz), 3.18 (1H, t, J = 
2.9 Hz), 3.00 (1H, d, J = 11.3 Hz), 2.90 (1H, d, J = 11.2 Hz); 13C NMR (126 MHz, CD3OD) δ = 138.5, 138.1, 
128.8, 128.1, 128.0, 127.8, 73.0, 70.4, 69.7, 66.3, 65.4, 51.9, 50.9; vmax (film) 3454, 3233, 2960, 2889, 
1484, 1360, 1127, 821 cm-1; HRMS (ESI+) m/z calculated (C13H16O5Na)+ 275.0890, found 275.0949.





To a solution of diol II-68 (41 mg, 0.123 mmol, 1.0 equiv.) in MeOH (10 mL) and water (2 mL) was added 
NaIO4 (1.09 g, 5.10 mmol, 24 equiv.).  The solution was stirred at room temperature for 6 hours before 
addition of aqueous sodium thiosulfate (1.0 M, 20 mL).  The aqueous phase was extracted with EtOAc 
(3 x 20 mL) and combined organic phases were dried over MgSO4.  After the solvent was removed 
under vacuum, the crude product was immediately re-dissolved in MeOH (10 mL).  The solution was 
cooled to 0oC and NaBH4 (45 mg, 1.20 mmol, 9.8 equiv.) added.  The solution was allowed to warm to 
room temperature over 24 hours, at which point water (20 mL) was added and the aqueous phase 
extracted with EtOAc (3 x 20 mL).  Organic phases were combined and washed with brine (30 mL).  
After drying over MgSO4, the solvent was removed under vacuum.  The crude product was purified by 
column chromatography (75% EtOAc, 25% hexane) to give II-70 as a white solid (16 mg, 47 μmol, 38%).
Rf = 0.60 (75% EtOAc, 25% hexane); [α]D25 = +20 (CHCl3, c. 0.5 g/100 mL); melting point = 121-124oC; 1H 
NMR (500 MHz, CD3OD) δ = 7.71-7.65 (1H, m), 7.41-7.35 (1H, m), 7.33-7.26 (2H, m), 4.83 (1H, d, J = 2.4 
Hz), 4.71 (1H, d, J = 6.5 Hz), 4.69 (1H, d, J = 6.5 Hz), 4.48-4.27 (4H, m), 4.04 (1H, d, J = 9.7 Hz), 3.78 (1H, 
d, J = 9.7 Hz), 3.41 (3H, s), 3.11 (1H, dd, J = 8.1, 2.4 Hz, OH), 2.84-2.79 (2H, m), 2.29 (1H, dd, J = 6.9, 3.6 
Hz, OH), 1.31 (3H, s), 0.67 (3H, s); 13C NMR (126 MHz, CDCl3) δ = 135.9, 135.8, 127.1, 126.7, 126.6, 
125.7, 110.9, 97.0, 86.5, 82.9, 71.3, 62.5, 60.0, 55.9, 42.5, 41.4, 27.8, 26.8; vmax (film) 3317, 2985, 2930, 




Alkene II-61 (0.178 g, 0.622 mmol, 1.0 equiv.) was dissolved in acetone (8.0 mL) and NMO (0.109 g, 
0.933 mmol, 1.5 equiv.) was added.  Water (~0.5 mL) was added until full dissolution of NMO was 
Chapter 2
89
observed.  To the resulting solution was added OsO4 (2.5 wt% in tBuOH, 0.16 mL, 15.5 μmol, 2.5 mol%). 
The solution was heated to 65oC and stirred for 24 hours.  After this time, the reaction was allowed to 
cool to RT and quenched through addition of aqueous sodium thiosulfate (20 mL).  The product was 
extracted with EtOAc (3 x 20 mL).  Combined aqueous phases were dried over MgSO4 and the solvent 
removed under vacuum.  The crude product was purified by column chromatography (50% EtOAc, 50% 
petroleum ether) to give II-71 as a colourless oil (0.158 g, 0.494 mmol, 79%).
Rf = 0.29 (50% EtOAc, 50% petroleum ether); [α]D25 = -23 (CH2Cl2, c. 1 g/100 mL); 1H NMR (500 MHz, 
CDCl3) δ = 7.32-7.22 (3H, m), 7.18-7.15 (1H, m), 4.82 (1H, d, J = 4.4 Hz), 4.67-4.55 (2H, m), 3.66 (1H, dd, 
J = 4.4, 3.1 Hz), 3.64 (1H, d, J = 2.6 Hz), 3.60 (3H, s), 2.10 (1H, d, J = 6.5 Hz, OH), 1.81 (1H, d, J = 6.8 Hz, 
OH), 1.55 (3H, s), 1.29 (3H, s); 13C NMR (126 MHz, CDCl3) δ = 171.6, 135.2, 134.3, 128.5, 128.3, 128.2, 
113.0, 85.0, 77.6, 64.9, 64.7, 52.8, 49.6, 47.0, 26.3, 24.9; vmax (film) 3446, 2993, 2952, 1739, 1463, 1378, 
1212, 1055, 1033 cm-1; HRMS (ESI+) m/z calculated (C17H20O6Na)+ 343.1152, found 343.1172.
(3aR,4S,9R,9aR,10S,11R)-9a-(Hydroxymethyl)-2,2-dimethyl-3a,4,9,9a-tetrahydro-4,9-
ethanonaphtho[2,3-d][1,3]dioxole-10,11-diol II-72
Diol II-71 (43 mg, 0.134 mmol, 1.0 equiv.) was dissolved in anhydrous THF (4.0 mL) and cooled to 0oC.  
LiAlH4 (2.4 M, 0.11 mL, 0.264 mmol, 2.0 equiv.) was added dropwise and the solution allowed to warm 
to RT over 4 hours.  The reaction was cooled to 0oC, quenched through slow addition of water (10 mL) 
and filtered.  The product was extracted from the filtrate with EtOAc (3 x 10 mL) and the solvent 
removed to give II-72 as a white solid (13 mg, 44.5 μmol, 33%), which was of suitable purity for full 
characterisation.
Rf = 0.43 (90% EtOAc, 10% petroleum ether); [α]D25 = -13 (CH2Cl2, c. 0.5 g/100 mL); 1H NMR (500 MHz, 
CD3OD) δ = 7.29-7.19 (4H, m), 4.59 (1H, dd, J = 7.9, 3.2 Hz), 4.51 (1H, dd, J = 2.9, 2.8 Hz), 3.80 (1H, d, J 
= 4.4 Hz), 3.53 (1H, d, J = 2.8 Hz), 3.46 (1H, dd, J = 4.4, 3.2 Hz), 3.34 (1H, d, J = 11.9 Hz), 2.79 (1H, d, J = 
11.9 Hz), 1.52 (3H, s), 1.42 (3H, s); 13C NMR (126 MHz, CD3OD) δ = 138.7, 136.6, 129.1, 128.9, 128.5, 
128.2, 112.9, 87.6, 79.5, 67.4, 66.1, 65.9, 49.6, 27.6, 27.4; vmax (film) 3355, 3260, 2962, 2933, 1405, 
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Synthesis and testing of a novel epoxidation catalyst
Introducing epoxidation catalysis
Over previous decades, numerous small organic molecules have been shown to be highly selective and 
efficient catalysts for a number of transformations.1-3 In contrast to the majority of metal-based 
catalysts, organocatalysts also tend to be non-toxic, inexpensive and environmentally benign.  These 
valuable features have led to significant interest in the synthesis of asymmetric organocatalysts.  Some 
of the most well-known organocatalysts currently in use are so-called MacMillan catalysts, which are 
based on the imidazolidinone motif. MacMillan catalysts can be employed to catalyse a range of 
enantioselective transformations, including the fluorination of aldehydes,4 intermolecular Michael 
additions5 (scheme III-01) and Diels–Alder reactions.6
Scheme III-01: MacMillan catalyst III-01 employed in a conjugate addition reaction.5 a) III-01, CHCl3, RT.
Asymmetric epoxidation catalysts enable the synthesis of enantiomerically pure epoxides from alkenes 
in one step.7 The resulting epoxides may be further functionalised in a number of ways to furnish a 
variety of enantiopure compounds.  As a result, epoxides can be used as key intermediates in the 
synthesis of biologically active compounds, for example (–)-Mesembrine8 (scheme III-02), or as 
biologically active compounds themselves.9, 10
Scheme III-02: Epoxidation used in the total synthesis of (–)-Mesembrine.8 a) Shi’s epoxidation catalyst, 
Oxone®, DME, MeCN, water, 0oC.  b) allylmagnesium chloride, THF, 0oC to RT.
The value of epoxides has seen many asymmetric epoxidation catalysts developed over the previous 
decades.  Two of the most popular metal-based methodologies for epoxide synthesis are the Sharpless 
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epoxidation11 and epoxidation using Jacobsen’s catalyst.12, 13 The Sharpless epoxidation requires 
Ti(OiPr)4, TBHP and DET to enantioselectively epoxidize allylic alcohols (scheme III-03).  Whilst this 
procedure does tend to provide epoxides with a high e.e., the necessity of the substrate to be an allylic 
alcohol significantly reduces its utility.
Scheme III-03: Example of an enantioselective Sharpless epoxidation.11 a) L–(+)-DET, Ti(OiPr)4, butanoic acid, 
CH2Cl2, -20oC.
The Jacobsen (Katsuki) catalyst, independently developed in 1990 and 1991 by both Jacobsen and 
Katsuki,12-14 utilises a manganese-salen complex to achieve the asymmetric epoxidation of olefins.
Reported e.e.s using Jacobsen’s catalyst tend to be high (90-95%), which has contributed, along with 
its ease of synthesis, to its wide-spread use.  The utility of Jacobsen’s catalyst is well illustrated by its 
use in Hashimoto’s synthesis of the tetra-substituted dihydroquinoline fragment of Siomycin D1
(scheme III-04) – a member of the thiostrepton family of peptide antibiotics.15, 16
Scheme III-04: Epoxidation reaction used in the synthesis of a fragment of Siomycin D1.15 a) Jacobsen’s catalyst,
4-phenylpyridine N-oxide, NaOCl, CH2Cl2, RT.
Due to the diminishing supply of transition metals and the toxicity generally associated with transition 
metal based complexes, the development of asymmetric epoxidation organocatalysts is highly 
desirable and has consequentially been pursued by several research groups.2 In 1980, Curci reported 
the epoxidation of olefins using acetone and potassium peroxymonosulfate.17 Upon reaction of 
acetone with potassium peroxymonosulfate, a reactive dioxirane is formed.  Subsequent epoxidation 
of an olefin results in the dioxirane being converted back to its parent ketone (scheme III-05). 
Chapter 3
97
Scheme III-05: Conditions employed in the epoxidation of cinnamic acid using acetone and potassium 
peroxymonosulfate (left) and the catalytic cycle when epoxidizing cinnamic acid with acetone and  potassium 
peroxymonosulfate (right).17 a) potassium peroxymonosulfate, acetone, water, 2oC.
Curci later reported the first example of an enantiopure ketone being using in an epoxidation reaction 
in 1984.18 Curci selected (+)-isopinocamphone III-02 as the ketone in the epoxidation of trans-β-
methylstyrene, which provided the corresponding epoxide with an e.e. of 11-12%. Subsequently,
several other ketones have been tested as enantioselective epoxidation organocatalysts,2 including 
binaphthyl based α-fluoroketones19 and ammonium α-fluoroketones20 (figure III-01).
Figure III-01: Examples of ketones tested as asymmetric epoxidation catalysts.18, 19
Research into the use of carbohydrate-derived ketones as asymmetric epoxidation catalysts has been 
pioneered by Shi.  Shi first reported the use of D-fructose derived ketone III-03 in asymmetric 
epoxidation reactions in 1996.21 Three key principles governed Shi’s catalyst design: close proximity 
between the stereogenic centres and the reactive centre (ketone); a spiro-acetonide group to minimise 




Scheme III-06: Synthesis of Shi’s catalyst from D-fructose.21 a) HClO4, acetone, 0oC.  b) PCC, CH2Cl2, RT.
Shi catalyst III-03 can be easily synthesised in 2 steps from fructose (scheme III-06).21 Its ease of 
synthesis has been essential in ensuring its success as an epoxidation catalyst, with applications in the 
total syntheses of Cryptophycin 52 and (+)-Murisolin.22, 23 Its popularity is further enhanced by a vast 
substrate scope (figure III-02). One of the major limitations of Shi’s catalyst, however, is the high 
catalyst loadings required as a result of catalyst de-activation through Baeyer–Villiger rearrangement, 
which occurs at low pH.24 Catalyst de-activation can be somewhat mitigated by careful control of the 
reaction pH, however catalyst loadings of 20-30 mol% are generally still required.
Figure III-02: A selection of epoxides synthesised using Shi’s catalyst.24
Shi has investigated a wide range of carbohydrate-based ketones for asymmetric epoxidation reactions 
since the discovery of Shi’s original catalyst III-03.2 Some of these ketones have proved less prone to 
de-activation at low pH.  The most notable of these is perhaps the oxazolidinone containing catalyst 
(III-04, figure III-03), which requires a catalyst loading of ≤5 mol%.25 Shi proposed that, due to the 
migratory aptitude of substituents in Baeyer–Villiger reactions being influenced by electronic factors, 
increasing the electron deficiency at the α carbon would result in in Baeyer–Villiger rearrangement of 
the catalyst being disfavoured.  Despite ketone III-04 also epoxidizing a range of olefins with high e.e., 




Figure III-03: Oxazolidinone containing epoxidation catalyst III-04 synthesised and tested by Shi.25
In 2001, Shi conducted some comparative studies to ascertain the effect on catalysis of replacing the 
ring oxygen of Shi catalyst III-03 with a carbon atom.26 Shi synthesised carbocyclic ketone III-05 in 10 
steps from (–)-quinic acid and found that it was significantly less active as an epoxidation catalyst than
o-heterocyclic III-03 (figure III-04).  Carbocyclic catalyst III-05 was found to epoxidize trans-stilbene 
with a 10% conversion after 8 hours, whereas Shi’s original catalyst III-03 achieved 75% conversion in 
just 1.5 hours.  Interestingly, in addition to this, the e.e. achieved in the epoxidation of trans-stilbene 
with carbocyclic III-05 was around 10% less than that achieved when using Shi’s original catalyst III-03.  
As a result of the decrease in yield when using carbocyclic III-05 as an epoxidation catalyst, Shi 
suggested that the pyranose oxygen is essential to the reactivity of Shi catalyst III-03, since the electron 
withdrawing nature of this oxygen activates the ketone towards nucleophilic attack from potassium 
peroxymonosulfate.
Figure III-04: Structure of Shi catalyst III-03 and its carbocyclic analogue III-04.26
Shi went on to research carbocyclic analogues of Shi catalysts in more detail following this and found
oxazolidinone bearing carbocycle III-07 to be more effective than its o-heterocyclic analogue III-06
(figure III-05) in the asymmetric epoxidation of styrene, with respective e.e.s of each transformation 
being 90% and 81%.27 Both these compounds, however, proved significantly superior in the 
epoxidation of styrene compared to Shi’s original catalyst III-03, which proceeded with an e.e. of just 
24%. Shi proposed that interaction between the π electrons of styrene with the oxazolidinone moiety 
of catalysts III-06 and III-07 in the transition state is the cause of the improved selectivity relative to 
Shi’s original catalyst III-03.
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Figure III-05: Structures oxazolidinone containing catalysts synthesised by Shi.27
Shi examined the possible transition states in the formation of styrene oxides using both catalysts III-
06 and III-07 and drew conclusions based on this.    Through analysis of both catalysts in the epoxidation 
of a range of olefins, Shi proposed that the removal of the pyranose oxygen of III-06 to form carbocyclic 
III-07 resulted in the spiro transition state being favoured to a greater extent than in the case of o-
heterocyclic III-06, resulting in carbocyclic ketone III-07 epoxidizing styrene with greater 
enantioselectivity (figure III-06).27 Shi’s comprehensive work in this regard demonstrates the potential 
utility of carbocyclic ketones as asymmetric epoxidation catalysis.
Figure III-06: Spiro-transition state preferentially adopted when using III-06 and III-07 in the epoxidation of 
styrene (left) compared to the less favoured planar transition state (right).27
Organocatalysts derived from arene diols
Arene dioxygenases allow the environmentally benign synthesis of enantiopure arene cis-diols from 
simple aromatics.28 Such aromatics tend to be both abundant and inexpensive, making the bulk 
synthesis of asymmetric organocatalysts from arene cis-diol is desirable. Whilst arene diols have 
shown utility in the synthesis of numerous natural products and compounds of biological interest,29-33
their use in the synthesis of organocatalysts has only been reported on a single occasion.
In 2011, Stevenson, Boyd and co-workers reported the synthesis of a phosphine–phosphine oxide 
catalyst from bromo-benzene (scheme III-07).34 Following the microbial oxidation of bromo-benzene 
to bromo-arene diol III-08 using Pseudomonas putida UV4, hydrogenation and acetonide protection 
gave bromo-alkene III-09. A palladium catalysed coupling reaction was then employed to install the 
first phosphorous group, which was subsequently reacted with borane to furnish ylide III-10.  After 
converting acetonide protected III-10 to TBDPS protected III-11, phosphination of the alcohol with 
chloro-diphenylphosphine resulted in immediate Arbuzov [2,3]-rearrangement to give phosphine 
oxide III-12, which was then converted to the phosphine-phosphine oxide III-13.
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Scheme III-07: Synthesis of phosphine–phosphine oxide III-13 as reported by Stevenson and Boyd.34 a) 
Rh/graphite, H2, MeOH.  b) pTSA, 2,2-DMP, acetone. c) HPPh2, Pd(OAc)2, Cs2CO3, DPPF, toluene.  d) BH3.THF.  e) 
TFA, THF, water.  f) TBDPSCl, imidazole, DMF.  g) ClPPh2, DMAP, THF.  h) Et2NH.
III-13 was subsequently tested as an asymmetric organocatalyst in the allylation of aromatic aldehydes
and as a chiral ligand in the hydrogenation of several olefins.34 Aromatic aldehydes were successfully 
allylated using allyltrimethylsilane and catalytic III-13, with benzaldehyde being converted in the 
highest e.e. of all tested substrates (scheme III-08).  In general, hydrogenation reactions of olefins using 
[Rh(cod)Cl]2 and III-13 as a chiral ligand proceeded with low enantioselectivity, however a standout 
result was seen in the hydrogenation of α-acetamidocinnamic acid.  Whilst the reported e.e.s of
products obtained from III-13 catalysed allylation and hydrogenation reactions tend to be modest.
Boyd has also previously reported the synthesis of an arene diol derived ligand that has been tested in 
metal catalysed asymmetric allylic oxidation and in the cyclopropanation of alkenes.35
Scheme III-08: Allylation of benzaldehyde catalysed by III-13.34 a) III-13 (15 mol%), allyltrimethylsilane, DIPEA, 
CH2Cl2. b) [Rh(cod)Cl]2 (1 mol%), III-13 (2 mol%), MeOH, EtOH, NaBF4.  c) H2, MeOH.
In addition to Boyd’s research in this field, Hudlický has also contributed through the synthesis of 
chiral auxiliary III-17 from arene diol III-14 (scheme III-09).36 The key step in the synthesis of chiral 
auxiliary III-14 is the intramolecular Diels–Alder reaction of III-15 to form poly-cyclic III-16. 
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Scheme III-09: Hudlický’s synthesis of chiral auxiliary III-17.36 a) THDMSCl, imidazole, DMF.  b) allyl bromide, 
NaH, THF.  c) THF, reflux.  d) Pd/C, H2, EtOH.  e) TBAF, THF.
III-17 has been used as a chiral auxiliary in an intermolecular Diels–Alder reaction, furnishing III-18 and 
III-19 (scheme III-10).36 Reductive cleavage of esters III-18 and III-19 gave alcohols which were shown 
to be entirely racemic.  Hudlický additionally reported the synthesis of a oxaziridine from III-17 which 
was used in the α-hydroxylation of 2-phenylacetophenone, furnished a product with an e.e. of just 
16%. Whilst the research of Hudlický and Boyd has thus far yielded asymmetric catalysts and chiral 
auxiliaries which are, in certain cases, marginally enantioselective, the modest e.e.s obtained do 
suggest that structural changes can be made to obtain more efficient catalysts from arene ortho,meta-
diols.
Scheme III-10: Diels–Alder reaction using III-17 as a chiral auxiliary. a) Acryloyl chloride, NEt3, THF.  b) 
cyclohexadiene, toluene.
The microbial dihydroxylation of sodium benzoate was first reported by Reiner in 1971, resulting in the 
formation of arene diol III-20 (scheme III-11).37 Upon examination of arene diol III-20, structural 
similarities between it and Shi’s catalyst III-03 can be easily identified.  Both compounds possess an 
enantiopure tetra-substituted carbon adjacent to a carbon bearing an oxygen atom.  Due to this 
similarity, Lewis et al. believed arene ipso,ortho-diol III-20 could be a precursor to a microbially derived 
epoxidation catalyst.38
Scheme III-11: Microbial de-aromative oxidation of sodium benzoate (left) and Shi’s catalyst III-03 (right).21, 37
Lewis et al. synthesised two carbocyclic Shi-like epoxidation catalysts for testing from arene diol III-21
(scheme III-12).39 Alcohol III-25 was synthesised serendipitously through reacting methyl ester III-24, 
a derivative of arene diol III-21, with NaOH.  This transformation was caused by base mediated 
hydrolysis of the methyl ester and subsequent isomerisation of the acetonide.  Oxidation of alcohol III-
25 with Dess–Martin periodinane then furnished ketone III-26.
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Scheme III-12: Synthesis of ketone III-26 from arene diol III-21.39 a) Pd/C, H2, MeOH, RT.  b) TMS-CHN2, MeOH, 
benzene, RT.  c) pTSA, 2,2-DMP, acetone, RT.  d) NaOH, water, THF, RT.  e) DMP, CH2Cl2, 0oC to RT.
Ketone III-31 was also synthesised by Lewis and co-workers. 39 After protection of the secondary 
alcohol of diol III-23 as its TBDMS ether, reduction of methyl ester III-27 was conducted, furnishing diol 
III-28.  Reacting diol III-28 with catalytic acid in 2,2-DMP and acetone resulted in formation of spiro-
cyclic acetonide III-29.  Deprotection of the TBDMS group and oxidation of the unmasked secondary 
alcohol then gave target ketone III-31.  Overall, the synthesis of ketone III-31 was achieved in a 20% 
yield over 7 steps from arene diol III-21 (scheme III-13).
Scheme III-13: Synthesis of ketone III-31 from diol III-23.39 a) TBDMSOTf, NEt3, CH2Cl2, -78oC to RT.  b) LiBH4, 
THF, -78oC to RT.  c) pTSA, 2,2-DMP, acetone, RT.  d) TBAF, THF, 0oC to RT.  e) DMP, CH2Cl2, 0oC to RT.
In the evaluation of ketones III-26 and III-31 as epoxidation catalysts, Lewis and co-workers chose 
trans-stilbene as a test substrate.38 Trans-stilbene has been shown to be epoxidized in good yields and 
with a high e.e. when using Shi’s catalyst, so conditions identical to those used by Shi were employed
when instead using ketones III-26 and III-31 as epoxidation catalysts.  Lewis and co-workers found that
ketones III-26 and III-31 both failed as epoxidation catalysts under these conditions (scheme III-14).  
Based on this observation, and those made by Shi in the testing of carbocyclic epoxidation catalysts, 
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Lewis concluded that both the pyranose oxygen and the C2 and C3 bound oxygens of Shi’s catalyst III-
03 are necessary to activate the ketone to electrophilic attack from peroxymonosulfate (Oxone®). 
Scheme III-14: Attempted epoxidation of trans-stilbene using III-31.  a) Oxone®, K2CO3, III-31, MeCN, water, 
0oC.
In continuation of this initial research, the synthesis of an arene diol-derived ketone that is more prone 
to electrophilic attack from peroxymonosulfate (Oxone®) was pursued.    This was to be achieved 
through the incorporation of an electron-withdrawing group onto the carbocyclic scaffold.  It was 
hoped that such a compound may possess catalytic activity that is complementary to current methods 




Following Reiner’s seminal paper on the microbial oxidation of sodium benzoate to arene diol III-20,37
iterative improvements to the biotransformation procedure have been made by several research 
groups.40-42 The procedure adopted in our research bears a high similarity to the most successful 
reported procedures.  Arene diol III-20 was thus synthesised from sodium benzoate using Ralstonia 
eutropha B9 (scheme III-15).
Carboxylate III-20 can be easily accessed from the concentrated supernatant of the biotransformation 
by affecting its precipitation as a mixed Na/K salt from addition of isopropanol, which was first 
demonstrated by Mihovilovic.41 Acid III-21 may be subsequently accessed through acidification of 
carboxylate III-20 (scheme III-15).  Acidifying carboxylate III-20, however, results in partial acid 
catalysed re-aromatisation of the arene diol, resulting in loss of valuable starting material.  As such, it 
is desirable to utilise synthetic methodology which can be performed on carboxylate III-20 in the 
synthesis of arene diol derivatives.
Scheme III-15: Microbial oxidation of sodium benzoate to afford carboxylate III-20 and acid III-21.  a) conc. HCl, 
water, 0oC.
At the outset of this project, it was supposed that developing conditions under which acetonide 
isomerisation may occur could be of utility.  Being able to synthesise non-spiro-cyclic acetonides and 
readily convert them to their spiro-cyclic regio-isomers could reduce the number of steps required to 
synthesise an epoxidation catalyst, as well as allowing its synthesis to start from carboxylate III-20. To 
this end, alcohol III-32 was synthesised as a substrate upon which to test acetonide isomerisation 
conditions (scheme III-16).  The synthesis of alcohol III-32 was achieved from both acid diol III-21 and 
carboxylate III-20.  Conditions developed using carboxylate III-20 as a starting material gave alcohol III-
32 in the greater overall yield (47% over 4 steps). 
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Scheme III-16: Synthesis of primary alcohol III-32. a) Pd/C, H2, MeOH, RT, 23 hours.  b) TMS-CHN2, MeOH, 
benzene, RT, 20 minutes.  c) pTSA, 2,2-DMP, acetone, RT, 18 hours.  d) LiBH4 (2.0 equiv.), THF, -78oC to RT, 18 
hours.  e) TFA (5.0 equiv.), 2,2-DMP, 0oC to RT, 24 hours.  f) TMS-CHN2, MeOH, benzene, RT, 20 minutes.  g) 
LiBH4 (2 equiv.), THF, 0oC to RT, 16 hours.  h) Pd/C, H2, MeOH, RT, 4 hours.
In the first step of the synthesis of Shi’s catalyst (scheme III-17), penta-ol III-36 is subjected to acetonide 
protection conditions resulting in preferential formation of spiro-acetonide III-37.21 In addition to this, 
Thiem reported exclusive spiro-cyclic acetonide formation when subjecting triol III-38 to similar 
acetonide protection conditions, giving III-39.43 Accordingly, it was envisaged that an acetonide 
isomerisation reaction on alcohol III-32 would result in spiro-cyclic III-30 being formed as the major 
product.  Reacting III-32 with pTSA in MeCN, acetone and 2,2-dimethoxypropane was found to furnish
2 new products in addition to the starting material (scheme III-17). 
Scheme III-17: Acid catalysed acetonide group migration of alcohol III-32. a) HClO4, acetone, 0oC.21 b) DOWEX 
50W, 2,2-DMP, acetone, RT.43 c) pTSA (1 mol%), MeCN, acetone, 2,2-DMP, RT, 75 minutes.
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Starting material III-32 was isolable from the mixture through column chromatography, however the 
remaining 2 compounds synthesised from the isomerisation reaction were inseparable by column 
chromatography.  Through comparison of the 1H NMR spectrum of the mixture of these compounds 
(figure III-07) with the 1H NMR spectrum of pure III-30 previously reported by Lewis et al.,39 spirocyclic 
III-30 was found to be the major constituent of the mixture.  Mass spectrometry suggested that
spirocyclic acetonide III-30 and the remaining unidentified component of the mixture are isomeric.  
Thus, the identity of this remaining component has been tentatively assigned as III-40 based on this 
observation and further examination of the 1D and 2D NMR spectra of the mixture.  AB protons H10
for minor product III-40 manifest themselves as doublet δ = 3.46 and doublet δ = 3.72, which overlaps 
with a doublet of the major regio-isomer III-30.   Methine proton H12 of minor product III-40 manifests 
itself as dd δ = 3.68, whereas doublet δ = 2.94 is thought to be a result of the hydroxyl proton H11, 
which seemingly shows long range coupling to another proton. These observations are supported by 
analysis of the HSQC spectrum of the mixture.
Figure III-07: 1H NMR spectrum of inseparable regio-isomers III-30 and III-40.
The presence of minor product III-40 was deemed unproblematic in achieving the synthesis of a ketone 
catalyst from arene diol III-30.  It was envisaged that, should similar products be formed when 
conducting this isomerisation reaction on more highly functionalised acetonides, the subsequent 
oxidation reaction to form a ketone would affect only the secondary alcohol III-30 whilst the tertiary 
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alcohol of III-40 would remain un-changed.  The difference in polarity between the resulting molecules 
would then be such that one would predict they would be separable by column chromatography.
With isomerisation conditions developed for the synthesis of spiro-acetonide III-32, attention was 
turned to incorporating functionality onto the carbocyclic scaffold of arene diol III-20 which would
confer an increase to the rings electrophilicity and rigidity.  In 1995, Widdowson reported the
cycloaddition of PTAD with arene diol derivatives.44 It was thought that the incorporation of a PTAD 
group may not only increase the electrophilicity of the ketone, but also act as a steric blocking group, 
inhibiting substrate approach from its face.  Ketone III-41a was therefore targeted for synthesis and 
testing as an epoxidation catalyst (figure III-08).
Figure III-08: Target epoxidation catalyst III-41a.
The cycloaddition of PTAD with dienes III-34 and III-43 proceeded as reported by Widdowson.44 The 
cyclo-addition reaction between acetonide protected III-34 and PTAD proceeded in an entirely 
diastereoselective fashion, affording cycloadduct III-42 in a very good yield (scheme III-18). This 
selectivity can be rationalised based on the steric blocking effect exerted by the acetonide group.
Scheme III-18: Diels–Alder reaction of PTAD with dienes III-34. a) PTAD (1.0 equiv.), acetone, RT, 90 minutes.
Also consistent with Widdowson’s findings, upon reaction of PTAD with diol III-43 (scheme III-19), a 
mixture of inseparable diastereomers III-44 and III-45 was obtained in a 80 : 20 ratio (as determined 
by 1H NMR of the mixture).44 Two factors may contribute to the observed diastereoselectivity of this 
reaction.  Firstly, a steric clash between the methyl ester of diene III-43 and the incoming PTAD group 
may disfavour addition of PTAD to the top face of the diene.  Secondly, hydrogen bonding interactions 
between the hydroxyl groups and PTAD may direct addition of PTAD to the bottom face of diene III-
43. Subsequent protection of diols III-44 and III-45 as their acetonides gave diastereomers III-46 and 
III-42, which were separable by column chromatography (scheme III-19).44
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Scheme III-19: Cycloaddition of diene III-43 and PTAD, with acetonide protection of the resulting 
diastereomers. a) TMSCHN2, MeOH, benzene, RT.  b) PTAD (1.0 equiv.), acetone, RT, 90 minutes.  c) pTSA (5 
mol%), 2,2-DMP, acetone, RT, 20 hours.
With pure diastereomers III-42 and III-46 in hand, synthetic transformations were conducted to furnish
primary alcohols III-48 and III-50 (scheme III-20).  The synthesis of III-48 was achieved first through
hydrogenation of alkene III-42 using Pd/C and hydrogen gas, followed by LiBH4 mediated reduction of 
the methyl ester III-47.  Similar experimental conditions were used in the synthesis of alcohol III-50.  
Both these compounds were valid candidates upon which to attempt an acetonide isomerisation 
reaction.
Scheme III-20: Synthesis of diastereomeric alcohols III-48 and III-50.  a) H2, Pd/C, MeOH, RT, 72 hours.  b) LiBH4




When attempting the acetonide isomerisation conditions developed previously on alcohol III-48, no 
reaction was observed (scheme III-21).  To the contrary, the acetonide of alcohol III-48 proved 
significantly more stable than that of test substrate III-32.  Stirring acetonide III-48 in acid (AcOH, 37% 
HCl, DOWEX 50W-X8, 20-50 mesh) and MeOH and/or water at room temperature produced no 
reaction.  Iodine mediated deprotection of the acetonide in MeOH also failed.  In order to deprotect 
acetonide III-48, it was necessary to heat a solution of III-48 in MeOH and conc. HCl to reflux for several 
hours (scheme III-21).  After removing the solvent under vacuum, formation of triol III-51 was 
confirmed by crude 1H NMR.  This material was immediately subjected to acetonide protection 
conditions, giving spirocyclic acetonide III-52 exclusively, albeit in a low yield.  The low yield for this 
reaction may be a consequence of the harsh conditions used in the deprotection step, resulting in 
starting material or product degradation.
Scheme III-21: Synthesis of spiro-cyclic acetonide III-52. a) pTSA (1 mol%), MeCN, 2,2-DMP, acetone, RT, 24 
hours. b) HCl (conc.), MeOH, reflux, 2 hours. c) pTSA (5 mol%), 2,2-DMP, RT, 16 hours.
Due to the low yielding synthesis of acetonide III-52, an alternative route to target ketone III-41 was 
devised.  The revised method relied upon a TBDMS protected secondary alcohol sterically inhibiting
approach of PTAD to the bottom face of the diene.  As such, diene III-54 was synthesised in 2 steps 
from methyl ester III-21, with the aim of using this diene in the synthesis of III-41a (scheme III-22).
Scheme III-22: Synthesis of diene III-54. a) TBDMSOTf (1.05 equiv.), NEt3 (1.2 equiv.), CH2Cl2, -78oC to RT, 5 
hours.  b) LiBH4 (2.0 equiv.), THF, 0oC to RT, 16 hours.
Despite diol III-54 being successfully synthesised, upon purification of the crude material by column 
chromatography an undesired side product was observed to form (scheme III-23).  It is believed that 
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this side product is a regioisomer of diol III-54 which arises due to TBDMS migration to the primary 
alcohol.  Mass spectrometry confirms that both components of the mixture have the same molecular 
mass, which helps to confirm this proposition.  Furthermore, the 1H NMR spectrum of the mixture 
indicates that both compounds possess the same functional groups (figure III-09). 4 alkene protons 
can be observed for each isomer in the region δ = 6.25-5.50.  The AB protons for the major product III-
54 can be seen as doublets δ = 3.52 and δ = 3.42, whilst the AB protons for the minor product III-55
manifest themselves as doublets δ = 3.73 and δ = 3.62.  Methine protons H5 for both products overlap 
to form doublet δ = 4.35.  TBDMS proton peaks are also present for both isomers.  
Scheme III-23: Proposed silica catalysed migration of TBDMS.  a) column chromatography on SiO2 at RT.
Figure III-09: 1H NMR spectrum of diol III-54 and its regioisomer III-55.
Further investigation into this isomerisation reaction has not yet been conducted, however achieving 
100% isomerisation of diol III-54 to III-55 may be desirable.  Oxidation of the secondary alcohol of III-
55 would in all probability lead to dimerization reaction, providing the (+)-grandifloracin scaffold III-
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56.29, 45, 46 (+)-Grandifloracin is known to exhibit activity against pancreatic cancer cells.  The described 
route (scheme III-24) may allow the synthesis of enantiopure (+)-grandifloracin and analogues thereof
without the need to employ iron complexation chemistry, as previously required.47
Scheme III-24: Proposed synthesis of (+)-grandifloracin scaffold III-56.
Due to the issues encountered in purifying diol III-54, the crude compound was instead telescoped 
through to the next stage of the synthetic sequence.  Diol III-54 was reacted with PTAD in a 
cycloaddition reaction, furnishing cycloadduct III-57 in a good yield.  The diastereoselectivity of this 
reaction was initially assumed based on the TBDMS group blocking the approach of PTAD from the 
bottom face, however this assumption was later found to be false through examination of the X-ray 
crystal structure of ketone III-41b (figure III-25).  Subsequent acetonide protection of III-57 resulted in 
spiro-cyclic acetonide III-58.  Removal of the TBDMS group through reaction with TBAF was then 
achieved, followed by oxidation of the secondary alcohol to give ketone III-60.  Finally, hydrogenation 
of the alkene of III-60 gave ketone III-41b in 32% yield from methyl ester III-21.
Scheme III-25: Synthesis of ketone III-41b.  a) PTAD (1.0 equiv.), acetone, RT, 3 hours.  b) pTSA (9 mol%), 2,2-
DMP, acetone, RT, 5 days.  c) TBAF (1.05 equiv.), THF, -78oC to RT, 16 hours.  d) DMSO (10 equiv.), oxalyl 
chloride (5.0 equiv.), NEt3 (20 equiv.), CH2Cl2, -78oC to RT, 18 hours.  e) Pd/C, H2, EtOAc, RT, 16 hours.
Following the purification of unsaturated ketone III-60 by column chromatography, a notable 
observation was also made.  NMR of the purified material indicated that a significant proportion of 
ketone hydrate III-61 (~20%) had been formed (scheme III-26).  Whilst it was possible to dehydrate III-
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61 to re-form ketone III-60, this finding suggested that incorporation of the PTAD group increased the 
electrophilicity of the ketone to the degree that the ketone is susceptible to electrophilic attack from 
water.
Scheme III-26: Observed ketone hydrate formed following purification by column chromatography of ketone 
III-60.
With a robust method for the synthesis of ketone III-41b developed, quantities of ketone III-41b could 
be synthesised that allow for the optimisation of an organo-catalytic epoxidation procedure using it as 
an organocatalyst.  Reaction optimisation was aimed at maximising substrate conversion.    4-
phenylstyrene was selected as the test substrate for reaction optimisation due to its ease of handling 
and lack of steric bulk around the alkene.  Table III-01 details efforts to optimise the reaction 
conditions, culminating in THF being selected as an ideal solvent with a catalyst loading of 10 mol%.  
Initial experiments suggest that a lower catalyst loading of ketone III-41b can be used for catalytic 
epoxidation compared to that recommended when employing Shi’s catalyst.  Upon reaction of ketone 
III-41b with Oxone® (KHSO5.½KHSO4.½K2SO4) and K2CO3 in D2O and CD3CN at RT for 16 hours, no 
Baeyer–Villager rearrangement or degradation of ketone III-41b was observed.  This suggests that 
ketone III-41b may possess higher stability than Shi’s catalyst under the reaction conditions, providing 
a possible explanation for the relatively low catalyst loadings required.
The conditions established for the epoxidation of 4-phenylstyrene using ketone III-41b were replicated 
in the epoxidation of trans-stilbene.  These substrates were selected because ketone III-41b may result 
in varying enantioselectivities depending on alkene substitution patterns, and HPLC methods for 
analysis of the epoxide products are well established.  A low conversion was observed in the 
epoxidation of trans-stilbene, with a conversion of only a 35% being achieved (determined by 1H NMR).  
Since trans-stilbene and its epoxide III-62 could not be separated by column chromatography, chiral 
HPLC of the mixture was instead conducted.  Chiral HPLC concluded that the e.e.s of epoxides III-62 















0 mol% DMM/MeCN (2:1) 8 7.2 15 25 3%
30 mol% DMM/MeCN (4:1) 8 2.4 5.0 25 7%




8 7.2 15 25 5%
30 mol% MeCN 8 7.2 15 25 50%
30 mol% DMM/MeCN (2:1) 0 7.2 15 25 66%
30 mol% THF 8 7.2 15 25 88%
30 mol% THF 8 7.2 15 0 100%
30 mol% THF 8 7.2 15 35 75%
30 mol% THF 0 7.2 15 0 100%
10 mol% THF 0 7.2 15 0 100%
Table III-01: Optimisation of epoxidation using ketone III-41b as a catalyst and 4-phenylstyrene as a substrate.  
Reactions done in 5 mL of organic solvent, with 0.250 mmol of 4-phenylstyrene, for a total reaction time of 14 
hours.  Conversions calculated by comparison of the integrals of 1H NMR peaks of the starting material and 
product.
Figure III-10: Structures of epoxides synthesised using ketone III-41b as a catalyst.
Due to failure in the enantioselective epoxidation of 4-phenylstyrene and trans-stilbene using ketone 
III-41b, the testing of further olefins was deemed unnecessary.  The X-ray crystal structures of ketone 
III-41b and alcohol III-52 (figure III-11) may provide insight as to why ketone III-41b failed to epoxidize 
the tested olefins enantioselectively.  Analysis of these two crystal structures is apt since they 
structurally bear the most similarity to the reactive dioxirane formed when reacting ketone III-41b with 
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Oxone®.  As observed in the X-ray crystal structures of ketone III-41b and alcohol III-52, the PTAD group 
is seemingly prone to inversion.  In the orientation shown in the crystal structure of alcohol III-41b, the 
steric effect exerted by the PTAD group on the catalytically important fragment of the molecule is 
significantly reduced compared to the orientation adopted in the crystal structure of alcohol III-52.
During catalysis, should the PTAD of the reactive dioxirane preferentially adopt an orientation similar 
to that shown in the crystal structure of alcohol III-52, the difference in steric bulk between the PTAD 
group and its opposing CH2 groups is expected to be minimal, resulting in poor stereocontrol.  Whilst 
the crystal structure of ketone III-41b and alcohol III-52 may not be entirely representative of the 
structure of the dioxirane in solution, these crystal structures may still be of use in making rational 
modifications to the ketone that could improve the enantioselectivity during epoxidation reactions.
Figure III-11: Single crystal X-ray structure of ketone III-41b (left, ellipsoids are shown at 50% probability. 
Hydrogens are shown as spheres of arbitrary radii. A disordered second molecule of III-41b and disordered 





Conclusions and future work
Significant progress has been made in achieving the synthesis of an enantioselective epoxidation 
catalyst from arene ipso,ortho-diol III-20.  Exploration of this research area commenced with 
investigation into an acetonide isomerisation reaction, which was believed could be of use in the 
synthesis of epoxidation catalysts from III-20. Acetonide isomerisation conditions were developed, 
allowing alcohol III-32 to be isomerised to furnish spiro-acetonide III-30 along with minor quantities of 
III-40 (scheme III-27).
Scheme III-27: Acid catalysed acetonide group migration of alcohol III-32.  a) pTSA (1 mol%), MeCN, acetone, 
2,2-DMP, RT, 75 minutes.
Utilising this acetonide isomerisation chemistry in the synthesis of target ketone III-41a, however, was 
unsuccessful.  Consequentially, an alternative method was employed for its synthesis (scheme III-28), 
which instead looked to employ a TBDMS ether as a face blocking group in the cycloaddition reaction
of diene III-54 with PTAD.  Contrary to this prediction, cycloadduct III-57 was in fact formed exclusively.  
Ketone III-41b was subsequently synthesised in a total of 8 steps from arene diol III-20.
Scheme III-28: Synthesis of target ketone III-41b.  a) PTAD (1.0 equiv.), acetone, RT, 3 hours.  b) pTSA (9 mol%), 
2,2-DMP, acetone, RT, 5 days.  c) TBAF (1.05 equiv.), THF, -78oC to RT, 16 hours.  d) DMSO (10 equiv.), oxalyl 
chloride (5.0 equiv.), NEt3 (20 equiv.), CH2Cl2, -78oC to RT, 18 hours.  e) Pd/C, H2, EtOAc, RT, 16 hours.
Conditions for olefin epoxidation using ketone III-41b were optimised when using 4-phenylstyrene as 
a substrate, eventually resulting in 100% conversion of the starting material and formation of epoxide 
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III-62.  These conditions were replicated in the epoxidation of trans-stilbene to give epoxide III-63 as 
well (figure III-12).  Enantiomeric excesses of each epoxide were calculated, using HPLC, to be 0%. This 
finding suggested that significant changes needed to be made to the structure of ketone III-41b in 
order to achieve enantioselectivity in epoxidation reactions.
Figure III-12: Structures of epoxides synthesised using ketone III-41b as a catalyst.
Ketone III-67 may be a suitable alternative and a synthetic route to this compound is proposed in 
scheme III-29. The rationale behind the design of ketone III-67 is that the newly incorporated methyl 
groups – installed through reaction of methyl ester III-64 with MeMgBr or a suitable methylating 
reagent – may impart a greater steric effect on the top face of ketone III-67.  In addition to this, reaction 
of diol III-65 with dimethoxymethane instead if 2,2-dimethoxypropane would result in a diol protecting 
group that may decrease non-constructive steric hinderance around the ketone moiety.
Scheme III-29: Proposed route to revised epoxidation catalyst III-67.
Whilst ketone III-67 may be a good candidate as an asymmetric epoxidation catalyst, there will
undoubtedly be other compounds derived from arene diol III-20 that may also serve this role.  Future 
research into this area could therefore lead to the synthesis of a broad range of poly-functional 





A sterile pipette tip was streaked across a frozen glycerol solution of Ralstonia eutropha B9 and added 
to a sterile solution of Hutner’s mineral base (100 mL) and sodium succinate (0.405 g) in an Erlenmeyer 
flask.  The flask was placed on an orbital shaker (250 rpm) at 27oC and shaken for 48 hours.  The 
resulting cloudy suspension was poured into Hutner’s mineral base (1.4 L) contained within an 
Erlenmeyer flask, which was heated to ca. 30oC and through which air was bubbled using an airstone.   
Aqueous D-fructose (10 mL, 10% w/v) was then added, and the culture was left to grow for 24 hours.  
Following this, the culture was induced with sodium benzoate (1.0 M, 8.0 mL) and fed a further 
quantity of D-fructose (8.0 mL).  After 16 h, repetitive feeding of sodium benzoate and D-fructose 
began, with a total of 200 mL of sodium benzoate and 200 mL of D-fructose being added to the culture 
over a period of 5 days (40 mL/ 24 h).  A final quantity of D-fructose (20 mL) was then added over the 
next 24 hours in order to ensure full conversion of all the added substrate.  
The culture was centrifuged (5000 rpm, 45 minutes, 4oC) and the supernatant collected.  The volume 
of the supernatant was reduced to ~150 mL through concentration under vacuum.  Isopropanol (850 
mL) was added, which effected precipitation of a brown solid. The solid was then filtered off, re-
dissolved in water (80 mL) and isopropanol (800 mL) added; this was found to aid in the removal of 
residual media salts and excess D-fructose. The product was again isolated by filtration, washed with 
CH2Cl2 and dried under vacuum to give a cream coloured solid (16.4 g), which contained III-20 as a
mixed sodium/potassium carboxylate salt and a variable proportion of growth medium salts.
1H NMR (500 MHz, DMSO) δ = 5.79 (1H, dd, J = 9.4, 5.2 Hz), 5.73-5.68 (1H, m), 5.61-5.54 (1H, m), 5.51 
(1H, d, J = 9.5 Hz), 4.68-4.64 (1H, m).  Data are in agreement with those previously reported.41
(1S,6R)-1,6-Dihydroxycyclohexa-2,4-diene-1-carboxylic acid III-21
Carboxylate III-20 (16.4 g, 92.1 mmol (assuming solid contains no residual media salts)) was dissolved 
in water (1.0 L).  The solution was cooled to ~0oC and carefully acidified to between pH 2.5 and 3.0 
with aq. conc. HCl.  Carboxylic acid III-21 was extracted with EtOAc (10 x 2.0 L), ensuring the pH of the 
aqueous phase remained between pH 2.5 and 3.0 after each extraction.  The solvent was removed 
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under vacuum (water bath 30oC), and the product triturated with CH2Cl2 (2 x 50 mL) to give pure acid 
diol III-21 as an off-white solid (8.00 g, 51.3 mmol, 56%).
1H NMR (500 MHz, CD3OD) δ = 6.10 (1H, dd, J = 9.7, 5.2 Hz), 5.93 (1H, dddd, J = 9.2, 5.2, 2.8, 1.2 Hz), 
5.83-5.76 (2H, m), 4.87-4.82 (1H, m); 13C NMR (126 MHz, CD3OD) δ = 178.0, 133.6, 127.3, 127.1, 123.5, 
75.4, 72.4.  Data are in agreement with those previously reported.39
(1S,2R)-1,2-Dihydroxycyclohexane-1-carboxylic acid II-22
To acid diol II-21 (5.48 g, 35.1 mmol) and Pd/C (0.700 g) was added MeOH (80 mL).  H2 gas (balloon) 
was bubbled through the suspension for 23 hours, and the suspension then filtered through Celite.  
The solvent was removed under vacuum, and the product triturated with cold CH2Cl2 (2 x 30 mL) to 
remove unwanted re-aromatisation products.  The off-white solid III-22 obtained (3.49 g, 21.8 mmol, 
62%) was of good purity, meaning that no purification was necessary.  
1H NMR (500 MHz, CD3OD) δ = 3.83 (1H, dd, J = 11.5, 4.5 Hz), 1.81-1.27 (8H, m); 13C NMR (126 MHz, 
CD3OD) δ = 179.1, 77.9, 73.6, 35.3, 30.8, 25.4, 21.1.  Data are in agreement with those previously 
reported.39
Methyl (1S,2R)-1,2-dihydroxycyclohexane-1-carboxylate III-23
To a solution of diol acid II-22 (1.28 g, 8.08 mmol) in MeOH (40 mL) and benzene (40 mL) was added 
TMS-CHN2 (~ 12.5 mL, “2M” in hexanes), until a yellow colour persisted in solution.  The solution was 
left to stir for 20 minutes, and the solvent was removed under vacuum.  The crude product was purified 
by column chromatography (30% EtOAc, 70% petroleum ether) to give III-23 as a white solid (0.975 g, 
5.60 mmol, 69%).
1H NMR (500 MHz, CDCl3) δ = 3.87-3.76 (1H, m), 3.81 (3H, s), 3.31 (1H, m, OH), 2.02 (1H, s, OH), 1.91-
1.21 (8H, m). HRMS (ESI+) m/z calculated for (C8H14O4Na)+ 197.0784, found 197.0861. Data are in 




To diol III-23 (0.181 g, 1.04 mmol, 1.0 equiv.) in acetone (2.0 mL) was added 2,2-dimethoxypropane 
(1.2 mL) and pTSA (10 mg).  The solution was stirred at room temperature for 18 hours.  Ethyl acetate 
(10 mL) was then added, followed by saturated aqueous NaHCO3 (10 mL).  The product was extracted 
with ethyl acetate (4 x 20 mL) and the combined organic layers dried over MgSO4.  The solvent was 
then removed to give III-24 as a pale yellow oil (0.151 g, 0.705 mmol, 68%).
1H NMR (500 MHz, CDCl3) δ = 4.39 (1H, t, J = 3.4 Hz), 3.79 (3H, s), 2.10-1.96 (2H, m), 1.82 (1H, dddd, J 
= 14.9, 11.9, 5.8, 3.8 Hz), 1.75-1.35 (5H, m), 1.54 (3H, s), 1.39 (3H, s); 13C NMR (126 MHz, CDCl3) δ = 
173.3, 109.0, 81.1, 75.1, 52.5, 32.4, 28.1, 26.1, 26.0, 20.5, 18.8.  Data are in agreement with those 
previously reported.39
((3aR,7aR)-2,2-Dimethyltetrahydrobenzo[d][1,3]dioxol-3a(4H)-yl)methanol III-32
To a solution of methyl ester III-24 (0.205 g, 0.957 mmol, 1.0 equiv.) in anhydrous THF (8 mL), cooled 
to -78oC, was added LiBH4 (4.0 M in THF, 0.48 mL, 1.92 mmol, 2.0 equiv.) slowly over 2 minutes.  The 
solution was allowed to warm to room temperature over 18 hours.  After this time, the reaction was 
quenched by slow addition of EtOAc (10 mL) followed by water (10 mL).  The organic layer was 
collected and the aqueous phase further extracted with EtOAc (2 x 10 mL).  Combined organic layers 
were dried over MgSO4 and the solvent was removed under vacuum.  The crude product was purified 
by column chromatography (20% EtOAc, 80% pentane) to give III-32 as a colourless oil (0.134 g, 0.720 
mmol, 75%).
Rf = 0.28 (30% EtOAc, 70% pentane); 1H NMR (500 MHz, CDCl3) δ = 4.17 (1H, t, J = 2.8 Hz), 3.57 (2H, d, 
J = 6.6 Hz), 2.17-2.06 (2H, m), 1.69-1.43 (6H, m), 1.51 (3H, s), 1.37 (3H, s); 13C NMR (126 MHz, CDCl3) δ
= 107.3, 81.4, 73.3, 64.1, 32.1, 28.6, 27.1, 26.0, 23.0, 20.1; νmax (film) 3459, 2966, 2935, 2864, 1455, 





A suspension of diol carboxylate III-20 (1.90 g, 9.69 mmol, 1.0 equiv.) in 2,2-DMP (70 mL) was cooled 
to 0oC and TFA (3.7 mL, 48.4 mmol, 5.0 equiv.) added dropwise over 10 minutes.  The suspension was 
allowed to warm to RT over 24 hours and then filtered through a pad of Celite®.  The solution was 
concentrated under vacuum and then resuspended in water (50 mL).  The product was extracted with 
CH2Cl2 (2 x 50 mL).  Organic extracts were combined, dried over MgSO4 and the solvent removed to 
give III-33 as a brown oil (1.69 g, 8.62 mmol, 89%).  This brown oil was of acceptable purity to use in 
subsequent synthetic steps.
1H NMR (500 MHz, CDCl3) δ = 6.19-6.12 (2H, m), 6.04-6.00 (1H, m), 5.81-5.78 (1H, m), 4.95 (1H, dd, J = 
4.1, 0.9 Hz), 1.49 (3H, s), 1.43 (3H, s).  HRMS (ESI-) m/z calculated for (C10H11O4)- 195.0663, found 
195.0674. Data are in agreement with those previously reported.41
Methyl (3aS,7aR)-2,2-dimethylbenzo[d][1,3]dioxole-3a(7aH)-carboxylate III-34
Acid diene III-33 (1.20 g, 6.10 mmol) was dissolved in MeOH (20 mL) and benzene (20 mL) and TMS-
diazomethane (~6 mL, “2M” in hexanes) added slowly until a yellow colour persisted in solution and 
effervescence ceased.  The solution was stirred for 20 minutes, the solvent removed under vacuum 
and the product purified by column chromatography (15% EtOAc, 85% petroleum ether) to give III-34 
as a colourless oil (0.843 g, 4.01 mmol, 66%).
1H NMR (500 MHz, CDCl3) δ = 6.11-6.02 (2H, m), 6.02-5.93 (1H, m), 5.82-5.74 (1H, m), 4.93 (1H, dd, J = 
4.2, 0.7 Hz), 3.75 (3H, s), 1.40 (3H, s), 1.38 (3H, s); HRMS (ESI+) m/z calculated (C11H14O4Na)+ 233.0784, 




Methyl ester III-34 (1.41 g, 6.71 mmol, 1.0 equiv.) was dissolved in anhydrous THF (15 mL) and cooled 
to 0oC.  LiBH4 (4.0 M in THF, 3.4 mL, 13.4 mmol, 2.0 equiv.) was added dropwise and the solution 
allowed to warm to room temperature over 16 hours.  The reaction was quenched through addition 
of EtOAc (20 mL) followed by water (20 mL).  The organic phase was collected and the product further 
extracted from the aqueous phase using EtOAc (2 x 20 mL).  Organic phases were combined and dried 
over MgSO4.  The solvent was removed under vacuum to give III-35 as a colourless oil (1.03 g, 0.566 
mmol, 84%).  The product obtained was of good purity, so no further purification was necessary.
1H NMR (500 MHz, CDCl3) δ = 6.06 (1H, dd, J = 9.7, 5.2 Hz), 6.02-5.95 (2H, m), 5.67 (1H, d, J = 9.9 Hz), 
4.46 (1H, d, J = 4.7 Hz), 3.56 (1H, dd, J = 12.0, 2.9 Hz), 3.34 (1H, dd, J = 11.9, 7.1 Hz), 2.22-2.15 (1H, m), 
1.42 (3H, s), 1.34 (3H, s); HRMS (ESI+) m/z calculated (C10H14O3Na)+ 205.0835, found 205.0841. Data 
are in agreement with those previously reported.41
((3aR,7aR)-2,2-Dimethyltetrahydrobenzo[d][1,3]dioxol-3a(4H)-yl)methanol III-32
Through a suspension of diene III-35 (1.07 g, 5.85 mmol) and Pd/C (11 mg) in MeOH (20 mL) was 
bubbled H2 gas (balloon) for 4 hours.  The suspension was filtered through Celite® and the solvent 
removed under vacuum to give III-32 as a pale yellow oil (1.05 g, 5.64 mmol, 96%) which required no
purification. For data, see previous synthetic route to III-32.
(5R,6R)-2,2-dimethyl-1,3-dioxaspiro[4.5]decan-6-ol III-30
To primary alcohol III-32 (1.23 g, 6.63 mmol, 1.0 equiv.) and pTSA (13 mg, 0.066 mmol, 1 mol%) was 
added acetonitrile (20 mL).  The solution was stirred for 15 minutes, before acetone (10 mL) and 2,2-
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dimethoxypropane (5.0 mL) were added.  The solution was stirred for a further hour until TLC (30% 
EtOAc, 70% pentane) suggested the reaction had reached equilibrium.  Sodium acetate (20 mg) was 
added and the solvent was removed under vacuum.  The resulting oil was purified by column 
chromatography (30% EtOAc, 70% pentane) to give white, crystalline solid, which was found to contain
III-30 and III-40 (0.697 g, 3.74 mmol, 56%), and starting material III-32.  Starting material III-32 was re-
subjected to the isomerization conditions outlined above. Following purification by flash column 
chromatography (30% EtOAc, 70% pentane), another quantity of white crystalline solid was obtained 
(0.104 g).  The products from both isomerization reactions were combined and weighed (0.801 g, 0.430 
mmol, 65%).  NMR showed the white solid to contain the title compound III-30 and around 20% of 
isomerization product III-40.
1H NMR (500 MHz, CDCl3) δ = 4.00 (1H, d, J = 8.4 Hz), 3.73 (1H, d, J = 8.5 Hz), 3.53-3.47 (1H, m), 2.07 
(1H, d, J = 6.1 Hz), 1.97 (1H, ddd, J = 13.4, 8.2, 3.5 Hz), 1.86-1.50 (4H, m), 1.42 (3H, s), 1.41 (3H, s), 1.35-
1.23 (2H, m); HRMS (ESI+) m/z calculated for (C10H18O3Na)+ 209.1148; found 209.1156. Data are in 
agreement with those previously reported.39
Methyl (3aS,4R,10S,10aR)-2,2-dimethyl-6,8-dioxo-7-phenyl-7,8,10,10a-tetrahydro-6H-4,10-
etheno[1,3]dioxolo[4,5-d][1,2,4]triazolo[1,2-a]pyridazine-3a(4H)-carboxylate III-42
To methyl ester III-34 (0.255 g, 1.21 mmol, 1.0 equiv.) in acetone (4.0 mL) was added dropwise a 
solution of PTAD (0.244 g, 1.39 mmol, 1.15 equiv.) until a red colour persisted in solution.  After stirring 
for 90 minutes, the solvent was removed under vacuum and the resulting red/orange solid was purified 
by column chromatography (30% EtOAc, 70% pentane) to give III-42 as a white solid (0.401 g, 1.04 
mmol, 86%).
1H NMR (500 MHz, CDCl3) δ = 7.48-7.32 (5H, m), 6.51-6.43 (2H, m), 5.35 (1H, dd, J = 4.2, 3.2 Hz), 5.30 
(1H, d, J = 4.2 Hz), 5.22 (1H, q, J = 3.9 Hz), 3.91 (3H, s), 1.36 (3H, s), 1.32 (3H, s); HRMS (ESI+) m/z 





To a solution of diol acid III-21 (0.546 g, 3.50 mmol) in MeOH (10 mL) and benzene (10 mL) was added 
TMS-diazomethane (~3.5 mL, “2M” in hexanes) slowly until a yellow colour persisted in solution and 
effervescence ceased.  The yellow solution was stirred for 20 minutes before the solvent was removed 
under vacuum and the crude product purified by column chromatography (30% EtOAc, 70% petroleum 
ether → 50% EtOAc, 50% petroleum ether) to give methyl ester III-43 as a white solid (0.492 g, 2.89 
mmol, 83%).
1H NMR (500 MHz, CDCl3) δ = 6.11 (1H, ddt, J = 9.5, 5.3, 0.8 Hz), 5.92 (1H, dddd, J = 9.8, 5.4, 2.8, 1.1 
Hz), 5.79 (1H, ddt, J = 9.7, 2.3, 1.0 Hz), 5.74 (1H, dq, J = 9.6, 1.1 Hz), 4.81 (1H, dt, J = 9.0, 2.9 Hz), 3.84 
(3H, s), 3.71 (1H, s, OH), 3.00 (1H, d, J = 10.2 Hz).  HRMS (ESI+) m/z calculated for (C8H10O4Na)+ 
193.0471; found 195.0499. Data are in agreement with those previously reported.48
Methyl (3aS,4S,10R,10aR)-2,2-dimethyl-6,8-dioxo-7-phenyl-7,8,10,10a-tetrahydro-6H-4,10-
etheno[1,3]dioxolo[4,5-d][1,2,4]triazolo[1,2-a]pyridazine-3a(4H)-carboxylate III-46
To a solution of diene III-43 (0.874 g, 5.14 mmol, 1.0 equiv.) in acetone (8.0 mL) was added slowly a 
solution of PTAD (0.900 g, 5.14 mmol, 1 equiv.) in acetone (8.0 mL) until a red colour persisted.  The 
solution was then allowed to stir at room temperature for 90 mins.  The solvent was removed under 
vacuum to give an orange oil, which was found to contain a mixture of 2 diastereomers (III-44 and III-
45).  As such, this crude mixture dissolved in acetone (10 mL) and 2,2-dimethoxypropane (10 mL) and 
pTSA (50 mg, 0.263 mmol, 5 mol%) added.  The solution was stirred at room temperature for 20 hours.  
NaOAc (100 mg) was added and the mixture was filtered.  The solvent was removed and the product 
purified by column chromatography (30% EtOAc, 70% pentane → 50% EtOAc, 50% pentane) to give 
title compound III-46 (1.31 g, 3.40 mmol, 66%) as a white crystalline solid and its diastereomer III-42
(0.292 g, 0.758 mmol, 15%) as an off-white crystalline solid.  
1H NMR (500 MHz, CDCl3) δ = 7.59-7.52 (2H, m), 7.49-7.41 (2H, m), 7.34 (1H, ddt, J = 8.0, 6.8, 1.2 Hz), 
6.60 (1H, ddd, J = 8.1, 6.0, 1.2 Hz), 6.50 (1H, ddd, J = 8.1, 6.0, 1.3 Hz), 5.31 (1H, ddd, J = 5.9, 1.3, 0.7 Hz), 
5.18 (1H, ddd, J = 6.1, 3.4, 1.3 Hz), 4.87 (1H, dd, J = 3.4, 0.7 Hz), 3.83 (3H, s), 1.53 (3H, s), 1.41 (3H, s); 
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13C NMR (126 MHz, CDCl3) δ = 170.0, 153.8, 153.3, 131.9, 131.1, 130.2, 129.2, 128.1, 125.2, 117.1, 83.3, 
76.2, 54.1, 53.5, 53.0, 26.8, 25.9.  Data are in agreement with those previously reported.44
Methyl (3aS,4R,10S,10aR)-2,2-dimethyl-6,8-dioxo-7-phenyltetrahydro-6H-4,10-
ethano[1,3]dioxolo[4,5-d][1,2,4]triazolo[1,2-a]pyridazine-3a(4H)-carboxylate III-47
Through a suspension of alkene III-42 (0.401 g, 1.04 mmol) and Pd/C (24 mg) in MeOH (15 mL) was 
bubbled H2 gas (balloon).  After 72 hours, EtOAc (40 mL) was added to the suspension and it was 
filtered through a pad of Celite®.  The solvent was removed under vacuum to give III-47 as a white solid 
(0.358 g, 0.925 mmol, 89%) which required no purification.
Rf = 0.27 (30% EtOAc, 70% pentane); melting point = 200-202oC; [α]D25 = +52 (CH2Cl2, c. 0.5 g/100 mL);
1H NMR (500 MHz, CDCl3) δ = 7.53-7.43 (4H, m), 7.41-7.35 (1H, m), 4.97 (1H, dd, J = 4.5, 1.1 Hz), 4.72-
4.65 (2H, m), 3.82 (3H, s), 2.37.2.21 (2H, m), 2.01-1.82 (2H, m), 1.59 (3H, s), 1.30 (3H, s); 13C NMR (126 
MHz, CDCl3) δ = 172.2, 152.4, 152.1, 131.6, 129.3, 128.5, 126.2, 112.8, 80.6, 73.5, 53.8, 52.9, 49.7, 26.1, 
25.1, 18.1, 17.2; νmax (film) 2994, 2981, 2950, 1764, 1735, 1699, 1410, 1095, 1062, 758 cm-1; HRMS 
(ESI+) m/z calculated for (C19H22O6N3H)+ 388.1503; found 388.1586. 
(3aR,4R,10S,10aR)-3a-(Hydroxymethyl)-2,2-dimethyl-7-phenyltetrahydro-6H-4,10-
ethano[1,3]dioxolo[4,5-d][1,2,4]triazolo[1,2-a]pyridazine-6,8(7H)-dione III-48
Methyl ester III-47 (0.170 g, 0.439 mmol, 1.0 equiv.) was dissolved in anhydrous THF (10 mL) and 
cooled to 0oC.  LiBH4 (4.0 M in THF, 0.26 mL, 1.05 mmol, 2.4 equiv.) was added dropwise and the 
solution allowed to warm to room temperature over 20 hours.  At this point, TLC indicated the reaction 
had not reached completion, so the solution was again cooled to 0oC and a further quantity of LiBH4 
(0.13 mL, 0.520 mmol, 1.2 equiv.) added.  The reaction was allowed to warm to room temperature
over 72 hours.  The reaction was then quenched through careful addition of EtOAc (10 mL) followed 
by water (15 mL).  The biphasic solution was extracted with EtOAc (3 x 20 mL). Combined organic 
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layers were washed with brine (40 mL), dried over MgSO4 and the solvent removed under vacuum to 
give III-48 as a white solid (0.155 g, 0.432 mmol, 98%).
Rf = 0.08 (30% EtOAc, 70% petroleum ether); melting point = 189-192oC; [α]D25 = -5 (CH2Cl2, c. 1 g/100 
mL); 1H NMR (500 MHz, CDCl3) δ = 7.55-7.45 (4H, m), 7.38 (1H, t, J = 7.3, 1.3 Hz), 4.69 (1H, dd, J = 4.2, 
1.6 Hz), 4.60 (1H, dt, J = 4.8, 2.7 Hz), 4.15 (1H, d, J = 4.6 Hz), 3.80 (1H, dd, J = 12.4, 4.9 Hz), 3.70 (1H, dd, 
J = 12.3, 7.8 Hz), 2.35-2.16 (3H, m, contains OH), 1.97 (1H, tt, J = 14.0, 3.5 Hz), 1.84-1.73 (1H, m), 1.58 
(3H, s), 1.51 (3H, s); 13C NMR (126 MHz, CDCl3) δ = 152.1, 152.1, 131.6, 129.2, 128.3, 125.6, 112.9, 82.9, 
74.7, 65.4, 51.2, 50.8, 27.3, 27.0, 18.3, 18.3; νmax (neat) 3577, 2997, 2982, 2950, 1760, 1702, 1412, 
1134, 1035, 744 cm-1; HRMS (ESI+) m/z calculated for (C18H22O5N3H)+ 360.1554, found 360.1556. 
Methyl (3aS,4S,10R,10aR)-2,2-dimethyl-6,8-dioxo-7-phenyltetrahydro-6H-4,10-
ethano[1,3]dioxolo[4,5-d][1,2,4]triazolo[1,2-a]pyridazine-3a(4H)-carboxylate III-49
Through a suspension of diene III-46 (0.957 g, 2.48 mmol) and Pd/C (70 mg) in MeOH (40 mL) was 
bubbled H2 gas (balloon) for 16 hours.  The suspension was filtered through a pad of Celite® and the 
solvent removed to give a III-49 as white solid (0.700 g, 1.81 mmol, 73%) which required no further 
purification. 
Rf = 0.18 (50% EtOAc, 50% petroleum ether); [α]D25 = +50 (CH2Cl2, c. 1.0 g/100 mL); melting point = 211-
213oC; 1H NMR (500 MHz, CDCl3) δ = 7.63-7.56 (2H, m), 7.49-7.41 (2H, m), 7.33 (1H, tt, J = 7.4, 1.6 Hz), 
4.81 (1H, d, J = 3.1 Hz), 4.70-4.64 (2H, m), 3.87 (3H, s), 2.26 (1H, dddd, J = 13.4, 11.1, 4.5, 2.7 Hz), 2.22-
2.12 (1H, m), 1.91-1.81 (1H, m), 1.73 (1H, ddt, J = 14.3, 11.6, 2.7 Hz), 1.41 (3H, s), 1.26 (3H, s); 13C NMR 
(126 MHz, CDCl3) δ = 171.3, 153.4, 151.9, 132.1, 129.2, 127.7, 125.0, 111.1, 82.9, 76.0, 53.5, 51.4, 50.7, 
25.5, 24.3, 20.4, 20.0; νmax (film) 2982, 2953, 1772, 1706, 1408, 1267, 1110, 731 cm-1; HRMS (ESI+) m/z 





To a solution of methyl ester III-49 (0.256 g, 0.661 mmol, 1.0 equiv.) in THF (15 mL), cooled to 0oC, was 
added LiBH4 (4.0 M in THF, 0.66 mL, 2.64 mmol, 4.0 equiv.) dropwise.  The solution was allowed to 
warm to room temperature over 18 hours.  Since TLC indicated the reaction hadn’t reached 
completion, the solution was again cooled to 0oC and a further quantity of LiBH4 (0.41 mL, 1.64 mmol, 
2.5 equiv.) was added dropwise.  After allowing the solution to again warm to room temperature over 
48 hours, the reaction was quenched through careful addition of EtOAc (10 mL) and water (15 mL).  
The biphasic solution was extracted with EtOAc (5 x 15 mL).  Organic layers were combined, dried over 
MgSO4 and the solvent removed under vacuum.  The product was purified by column chromatography 
(100% EtOAc) to give III-50 as a white, crystalline solid (0.185 g, 0.515 mmol, 78%).
Rf = 0.18 (100% EtOAc); [α]D25 = +7 (CH2Cl2, c. 0.28 g/100 mL); melting point = 103-106oC; 1H NMR (500 
MHz, CDCl3) δ = 7.61-7.55 (2H, m), 7.48-7.42 (2H, m), 7.33 (1H, t, J = 7.4, 1.7 Hz), 4.71 (1H, t, J = 3.0 Hz), 
4.66 (1H, ddd, J = 4.8, 3.7, 1.3 Hz), 3.94-3.86 (2H, m), 3.63 (1H, dd, J = 12.2, 9.0 Hz), 2.38-2.05 (4H, m, 
1 x OH), 1.69-1.55 (1H, m), 1.40 (6H, s); 13C NMR (126 MHz, CDCl3) δ = 153.4, 150.5, 132.1, 129.2, 127.7, 
125.2, 110.6, 83.9, 76.4, 66.6, 51.1, 50.9, 26.5, 26.3, 21.3, 20.1; νmax (film) 3443, 2988, 2947, 1761, 




A suspension of alcohol III-48 (0.481 g, 1.34 mmol, 1.0 equiv.), MeOH (5.0 mL) and aqueous HCl (37%, 
0.20 mL) was heated to reflux, at which point full dissolution of alcohol III-48 was observed.  The 
solution was stirred at reflux for a further 2 hours, before being allowed to cool to room temperature
over 1 hour.    The solvent was removed under vacuum.  Crude 1H NMR of this material showed 
acetonide deprotection, to form triol III-51, had occurred.  As such, this product was immediately re-
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dissolved in 2,2-dimethoxypropane (10 mL) and was pTSA (13 mg, 67 μmol, 5 mol%) added.  This 
solution was stirred at room temperature for 16 hours and the solvent removed under vacuum.  The 
crude product was purified by column chromatography (50% EtOAc, 50% petroleum ether) to give III-
52 as a white, crystalline solid (88 mg, 0.245 mmol, 18%).
Rf = 0.23 (50% EtOAc, 50% petroleum ether); [α]D25 = -9 (CH2Cl2, c. 0.44 g/100 mL); melting point = 263-
265oC; 1H NMR (500 MHz, CDCl3) δ = 7.55-7.43 (4H, m), 7.40-7.33 (1H, m), 4.43-4.34 (2H, m), 4.27 (1H, 
t, J = 2.7 Hz), 3.93-3.83 (2H, m), 3.29 (1H, d, J = 6.3 Hz, OH), 2.20 (1H, ddt, J = 14.2, 11.6, 3.0 Hz), 2.06 
(1H, td, J = 12.2, 5.7 Hz), 1.97-1.85 (1H, m), 1.84-1.68 (1H, m), 1.52 (3H, s), 1.47 (3H, s); 13C NMR (126 
MHz, CDCl3) δ = 152.6, 151.9, 131.6, 129.2, 128.3, 125.5, 112.4, 78.8, 72.8, 69.0, 54.4, 52.8, 27.2, 25.4, 
19.7, 17.2; νmax (neat) 3490, 2974, 2924, 1757, 1703, 1413, 1277, 1251, 1104, 1056, 737 cm-1; HRMS 
(ESI+) m/z calculated for (C18H21O5N3H)+ 360.1554, found 360.1560. 
Crystal structure data for III-52 can be found in the appendix.
Methyl (1S,6R)-6-((tert-butyldimethylsilyl)oxy)-1-hydroxycyclohexa-2,4-diene-1-carboxylate III-53
Diol III-21 (0.624 g, 3.67mmol, 1.0 equiv.) was dissolved in anhydrous CH2Cl2 (10 mL) and cooled to -
78oC.  NEt3 (0.61 mL, 4.40 mmol, 1.2 equiv.) was added dropwise followed by TBDMSOTf (0.88 mL, 3.85 
mmol, 1.05 equiv.).  The resulting solution was stirred at -78oC for 2 hours before being allowed to 
warm to room temperature over 3 hours.  Water (40 mL) was added and the aqueous phase extracted 
with CH2Cl2 (3 x 40 mL).  Combined organic layers were washed with brine (60 mL), dried over MgSO4
and the solvent removed under vacuum.  The product was purified by column chromatography (10% 
EtOAc, 90% petroleum ether) to give III-53 as a colourless oil (1.03 g, 3.61 mmol, 98%).
1H NMR (500 MHz, CDCl3) δ = 6.13 (1H, ddt, J = 9.6, 5.3, 0.8 Hz), 5.96-5.89 (1H, m), 5.81 (1H, dq, J = 9.6, 
1.1 Hz), 5.70 (1H, ddt, J = 9.8, 1.9, 0.9 Hz), 4.98 (1H, dddd, J = 2.6, 1.9, 1.3, 0.6 Hz), 3.81 (3H, s), 0.90 
(9H, s), 0.12 (3H, s), 0.04 (3H, s); HRMS (ESI+) m/z calculated for (C14H24O4SiNa)+ 307.1336, found




A solution of methyl ester III-53 (0.464 g, 1.63 mmol, 1.0 equiv.) in anhydrous THF (15 mL) was cooled 
to 0oC and LiBH4 (4.0 M in THF, 0.82 mL, 3.26 mmol, 2.0 equiv.) was added slowly over 5 minutes.  The 
solution was allowed to warm to room temperature over 16 hours and the reaction quenched through 
careful addition of EtOAc (25 mL) followed by water (25 mL).  The organic layer was collected and the 
aqueous layer further extracted with EtOAc (2 x 25 mL).  Combined organic phases were dried over 
MgSO4 and the solvent removed under vacuum to give III-54 as a pale yellow oil (0.353 g, 1.38 mmol, 
85%).  Crude 1H NMR indicated that this material consisted of title compound III-53 along with a minute 
quantity of unidentifiable impurities.  Attempted purification of this compound by column 
chromatography (30% EtOAc, 70% petroleum ether) resulted in minor formation (~15%) of a 
compound which was inseparable from title compound III-54.  As such, the crude material was used in 
the synthesis of III-54 without further purification.
1H NMR (300 MHz, CDCl3) δ = 6.00-5.87 (2H, m), 5.82-5.73 (1H, m), 5.72-5.64 (1H, m), 4.35 (1H, d, J = 
4.3 Hz), 3.53 (1H, d, J = 11.3 Hz), 3.42 (1H, d, J = 11.4 Hz), 3.32 (1H, s, OH), 0.91 (9H, s), 0.13 (3H, s), 
0.12 (3H, s); m/z calculated for (C13H24O3SiNa)+ 279.1387, found 279.1423.
(5R,8S,10R,11R)-11-((tert-Butyldimethylsilyl)oxy)-10-hydroxy-10-(hydroxymethyl)-2-phenyl-5,8-
dihydro-1H-5,8-ethano[1,2,4]triazolo[1,2-a]pyridazine-1,3(2H)-dione III-57
To a solution of diene III-54 (0.657 g, 2.57 mmol, 1.0 equiv.) in acetone (15 mL) was added a solution 
of PTAD (0.449 g, 2.57 mmol, 1.0 equiv.) in acetone (10 mL) slowly until a red colour persisted in 
solution.  The solution was stirred for a further 3 hours before the solvent was removed under vacuum.  
The crude product was purified by column chromatography (50% EtOAc, 50% petroleum ether) to give
III-57 as a white solid (0.731 g, 1.70 mmol, 66%).
Rf = 0.32 (75% EtOAc, 25% petroleum ether); melting point = 170-173oC; [α]D25 = -14 (CH2Cl2, c. 1 g/100 
mL); 1H NMR (500 MHz, CDCl3) δ = 7.50-7.41 (4H, m), 7.37-7.32 (1H, m), 6.55 (1H, ddd, J = 8.2, 5.8, 1.5 
Hz), 6.46 (1H, ddd, J = 8.2, 5.9, 1.6 Hz), 5.00 (1H, dd, J = 5.9, 1.6 Hz), 4.84 (1H, ddd, J =  6.0, 2.6, 1.5 Hz), 
3.61 (1H, d, J = 2.6 Hz), 3.45 (1H, dd, J = 11.5, 7.8 Hz), 3.35 (1H, dd, J = 11.4, 5.8 Hz), 2.26 (1H, dd, J = 
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7.9, 6.0 Hz), 0.95 (9H, s), 0.25 (3H, s), 0.19 (3H, s); 13C NMR (126 MHz, CDCl3) δ = 155.0, 154.8, 131.8, 
131.5, 129.2, 129.0, 128.3, 125.6, 70.6, 68.4, 67.5, 56.3, 56.0, 25.8, 18.2, -4.3, -4.8; νmax (film) 3555, 
3426, 2955, 2928, 2858, 1764, 1695, 1413, 1253, 1097, 833 cm-1; HRMS (ESI+) m/z calculated for 
(C21H29O5N3SiNa)+ 454.1769; found 454.1817. 
(4R,5'R,8'S,11'R)-11'-((tert-Butyldimethylsilyl)oxy)-2,2-dimethyl-2'-phenyl-5',8'-dihydro-1'H-
spiro[[1,3]dioxolane-4,10'-[5,8]ethano[1,2,4]triazolo[1,2-a]pyridazine]-1',3'(2'H)-dione III-58
A solution of diol III-57 (0.685 g, 1.59 mmol, 1.0 equiv.) and pTSA (28 mg, 0.147 mmol, 9 mol%) in 2,2-
dimethoxypropane (20 mL) and acetone (10 mL) was stirred at room temperature for 5 days.  After 
this time, the reaction mixture was poured in saturated aqueous NaHCO3 (30 mL) and extracted with 
CH2Cl2 (3 x 30 mL).  Combined organic layers were dried over MgSO4 and the solvent removed under 
vacuum.  The crude product was purified by recrystallisation with the minimum amount of hot EtOAc.  
Addition of petroleum ether was found to aid crystallisation of the product.  III-58 was obtained as a
white solid (0.613 g, 1.30 mmol, 82%).
Rf = 0.32 (50% EtOAc, 50% petroleum ether); melting point = 198-201oC; [α]D25 = -5.0 (CHCl3, c. 1 g/100 
mL); 1H NMR (500 MHz, CDCl3) δ = 7.47-7.40 (4H, m), 7.36-7.31 (1H, m), 6.53-6.44 (2H, m), 4.88 (1H, 
dt, J = 5.6, 2.1 Hz), 4.80 (1H, dd, J = 5.5, 1.9 Hz), 3.85 (1H, d, J = 9.4 Hz), 3.72 (1H, d, J = 2.4 Hz), 3.69 
(1H, d, J = 9.3 Hz), 1.60 (3H, s), 1.43 (3H, s), 0.95 (9H, s), 0.20 (3H, s), 0.17 (3H, s); 13C NMR (126 MHz, 
CDCl3) δ = 155.2, 154.8, 131.8, 130.7, 130.4, 129.2, 128.2, 125.8, 112.0, 77.6, 73.3, 69.7, 57.8, 56.9, 




A solution of silyl protected alcohol III-58 (0.607 g, 1.29 mmol, 1.0 equiv.) in anhydrous THF (20 mL) 
was cooled to -78oC.  TBAF (1.0 M in THF, 1.35 mL, 1.35 mmol, 1.05 equiv.) was added dropwise and 
the solution stirred at -78oC for 1 hour, before being allowed to warm to room temperature over 16 
hours.  EtOAc (5.0 mL) was added, followed by saturated aqueous NaHCO3 (5.0 mL) and water (15 mL).  
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The biphasic solution was extracted with EtOAc (3 x 20 mL).  Organic layers were combined, washed 
with brine (50 mL) and dried over MgSO4.  The solvent was removed under vacuum and the crude
product purified by column chromatography (50% EtOAc, 50% petroleum ether) to give III-59 as a 
white solid (0.413 g, 1.16 mmol, 90%).
Rf = 0.17 (50% EtOAc, 50% petroleum ether); melting point = 190-193oC; [α]D25 = -9.0 (CH2Cl2, c. 0.5
g/100 mL); 1H NMR (500 MHz, CDCl3) δ =7.47-7.41 (4H, m), 7.37-7.33 (1H, m), 6.57-6.54 (2H, m), 5.02 
(1H, dt, J = 5.1, 2.4 Hz), 4.81 (1H, dd, J = 5.2, 2.1 Hz), 3.95 (1H, d, J = 9.6 Hz), 3.80 (1H, d, J = 9.6 Hz), 
3.64 (1H, dd, J = 7.3, 2.6 Hz), 3.33 (1H, d, J = 7.3 Hz), 1.62 (3H, s), 1.47 (3H, s); 13C NMR (126 MHz, 
CDCl3) δ = 155.5, 154.9, 131.5, 131.4, 129.7, 129.2, 128.3, 125.6, 112.7, 77.0, 73.5, 68.5, 57.3, 56.7, 
27.1, 25.5; νmax (film) 3554, 2998, 2941, 2891, 1763, 1708, 1406, 1082, 767 cm-1; HRMS (ESI+) m/z 
calculated for (C18H19O5N3Na)+ 380.1217; found 380.1206.
(4R,5'S,8'R)-2,2-Dimethyl-2'-phenyl-5',8'-dihydro-1'H-spiro[[1,3]dioxolane-4,11'-
[5,8]ethano[1,2,4]triazolo[1,2-a]pyridazine]-1',3',10'(2'H)-trione III-60
A solution of DMSO (0.82 mL, 11.5 mmol, 10 equiv.) in CH2Cl2 (30 mL) was cooled to -78oC and oxalyl 
chloride (0.49 mL, 5.75 mmol, 5.0 equiv.) added dropwise.  This solution was stirred at -78oC for 30 
minutes before alcohol III-59 (0.413 g, 1.16 mmol, 1.0 equiv.) was added dropwise. After stirring at -
78oC for 1 hour, NEt3 (3.19 mL, 23.0 mmol, 20 equiv.) was added dropwise.  The solution was stirred at 
-78oC for a final hour before the reaction was allowed to warm to room temperature over 16 hours.  
The solution was poured into EtOAc (60 mL) and the organic phase washed with saturated aqueous 
NH4Cl (60 mL), water (60 mL), saturated aqueous NaHCO3 (60 mL) and brine (60 mL).  The organic layer 
was dried over MgSO4 and the solvent removed under vacuum.  The crude product was purified by 
column chromatography (50% EtOAc, 50% petroleum ether → 75% EtOAc, 25% petroleum ether) to 
give a white solid.  Due to the propensity of ketone III-60 to form its corresponding hydrate, it was
then necessary to stir this solid in anhydrous CH2Cl2 (10 mL) with molecular sieves for 3 days.  
Removing the solvent under vacuum resulted in the isolation of a white solid (0.390 g, 1.01 mmol, 87%)
which was shown to be pure ketone III-60.
Rf = 0.39 (50% EtOAc, 50% petroleum ether); melting point = 157-160oC; [α]D26 = +158 (CHCl3, c. 1.0
g/100 mL); 1H NMR (500 MHz, CDCl3) δ = 7.50-7.42 (4H, m), 7.41-7.37 (1H, m), 6.81 (1H, ddd, J = 8.2, 
6.0, 1.6 Hz), 6.70 (1H, ddd, J = 8.2, 6.1, 1.9 Hz), 5.21 (1H, dd, J = 6.1, 1.6 Hz), 5.10 (1H, dd, J = 6.0, 1.9 
Hz), 4.19 (1H, d, J = 9.4 Hz), 3.80 (1H, d, J = 9.4 Hz), 1.58 (3H, s), 1.49 (3H, s); 13C NMR (126 MHz, CDCl3) 
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δ = 194.5, 155.3, 154.0, 134.9, 131.4, 129.4, 129.2, 128.8, 125.7, 114.4, 78.2, 71.4, 59.7, 59.2, 27.1, 
25.4; νmax (film) 3097, 3032, 2993, 2938, 1772, 1749, 1706, 1405, 1275, 1055, 753 cm-1; HRMS (ESI+) 
m/z calculated for (C19H21O6N3Na)+ 410.1323; found 410.1346.* 




Through a suspension of alkene III-60 (0.375 g, 1.06 mmol) and Pd/C (80 mg) in EtOAc (20 mL) was 
bubbled H2 gas (balloon) for 16 hours.  The suspension was then filtered through a pad of Celite® and 
the solvent removed under vacuum to give III-41b as a white solid (0.378 g, 1.06 mmol, 100%).  This 
solid required no further purification.
Rf = 0.25 (50% EtOAc, 50% petroleum ether); melting point = 185-187oC; [α]D27 = -96 (CHCl3, c. 1.0 g/100 
mL); 1H NMR (500 MHz, CDCl3) δ = 7.50-7.42 (4H, m), 7.41-7.36 (1H, m), 4.68 (1H, t, J = 2.9 Hz), 4.57 
(1H, dd, J = 4.5, 1.3 Hz), 4.34 (1H, d, J = 9.3 Hz), 4.07 (1H, d, J = 9.3 Hz), 2.54-2.39 (2H, m), 2.24-2.12 
(1H, m), 1.84-1.71 (1H, m), 1.46 (3H, s), 1.39 (3H, s); 13C NMR (126 MHz, CDCl3) δ = 200.7, 156.2, 152.9, 
131.7, 129.4, 128.5, 125.9, 114.2, 82.7, 66.8, 59.2, 56.3, 26.8, 25.3, 23.3, 20.2; νmax (film) 3040, 2994, 
2948, 2892, 1757, 1704, 1413, 1140, 1050, 861 cm-1; HRMS (ESI+) m/z calculated for (C18H19O5N3Na)+ 
380.1217; found 380.1218.
Crystal structure data for III-41b can be found in the appendix.
2-([1,1'-Biphenyl]-4-yl)oxirane III-62
A solution of THF (5.0 mL) and aq. Na2EDTA (0.4 mM, 2.0 mL) was cooled to 0oC and 4-phenylstyrene 
(45 mg, 0.250 mmol, 1.0 equiv.) added, followed by ketone III-41 (9 mg, 25.2 μmol, 10 mol%). Solutions 
of Oxone® (50% KHSO5, 1.107 g, 0.360 mmol, 7.2 equiv.) in aq. Na2EDTA (0.4 mM, 8.0 mL) and K2CO3 
(0.519 g, 3.76 mmol, 15 equiv.) in aq. Na2EDTA (0.4 mM, 8.0 mL) were added simultaneously by syringe 
over 6 hours, whilst maintaining the reaction temperature at 0oC.  Over the following 8 hours, the 
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reaction was allowed to warm to room temperature.  Water (20 mL) was added to the reaction and 
the aqueous phase extracted with EtOAc (3 x 20 mL). Combined organic layers were washed with brine 
(30 mL), dried over MgSO4 and the solvent removed under vacuum.  1H NMR of the crude product 
showed full conversion of the starting material to product III-62.  The crude product was purified by 
column chromatography (5% Et2O, 5% NEt3, 90% petroleum ether) to give III-62 as a white solid (37 
mg, 0.189 mmol, 76%). HPLC analysis of the product was conducted using a Chiralcel OD column (250 
mm) with a mixture of 90% hexane, 10% isopropanol used as an eluent (1.2 mL/min flow rate). 
Retention times of the synthesised enantiomers of III-62 were 4.5 minutes and 5.0 minutes, with both 
being detected using U.V. light (254 nm).  The product was shown to be racemic.
1H NMR (500 MHz, CDCl3) δ = 7.62-7.56 (4H, m), 7.45 (2H, tt, J = 7.0,0.7 Hz), 7.39-7.33 (3H, m), 3.92 
(1H, dd, J = 4.1, 2.6 Hz), 3.19 (1H, dd, J = 5.5, 4.1 Hz), 2.86 (1H, dd, J = 5.5, 2.6 Hz); 13C NMR (126 MHz, 
CDCl3) δ = 141.2, 140.7, 136.6, 128.8, 127.4, 127.3, 127.1, 126.0, 52.2, 51.2. Data are in agreement 
with those previously reported.49
2,3-Diphenyloxirane
A solution of THF (5.0 mL) and aq. Na2EDTA (0.4 mM, 2.0 mL) was cooled to 0oC and trans-stilbene (45 
mg, 0.250 mmol, 1.0 equiv.) added, followed by ketone III-41 (9 mg, 25.2 μmol, 10 mol%).  Solutions 
of Oxone® (50% KHSO5, 1.107 g, 0.360 mmol, 7.2 equiv.) in aq. Na2EDTA (0.4 mM, 8.0 mL)   and K2CO3 
(0.519 g, 3.76 mmol, 15 equiv.) in aq. Na2EDTA (0.4 mM, 8.0 mL) were added simultaneously by syringe 
over 6 hours, whilst maintaining the reaction temperature at 0oC.  Over the following 8 hours, the 
reaction was allowed to warm to room temperature.  Water (20 mL) was added to the reaction and 
the aqueous phase extracted with EtOAc (3 x 20 mL).  Combined organic layers were washed with brine 
(30 mL), dried over MgSO4 and the solvent removed under vacuum.  1H NMR of the crude product 
showed incomplete conversion of the starting material to product III-63 (41 mg), however separation 
of the starting material and the epoxide product by column chromatography was not possible.  HPLC 
analysis of the crude product was conducted using a Chiralcel OD column (250 mm) with a mixture of 
90% hexane, 10% isopropanol used as an eluent (1.0 mL/min flow rate).  Retention times of the 
synthesised enantiomers of III-63 were 5.60 minutes and 7.68 minutes, with both being detected using 
U.V. light (220 nm).  The product was shown to be racemic.  
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Exploiting a fluoro-arene ipso,ortho-diol in synthesis
An introduction to fluoro-alkenes and substituted arene diols
The biology of fluorine containing compounds has been subject to intense research over the last few 
decades, primarily due to the significant effect that fluorine can have on a compound’s biological 
activity and stability.  These affects have been documented in a number of comprehensive reviews.1-3
The changes in, for example, membrane permeability, log P, pKa, and metabolic stability that fluorine 
can confer has resulted in fluorine containing compounds garnering widespread use as
pharmaceuticals.  Maraviroc (figure IV-01, prescribed as an antiretroviral drug in the treatment of 
H.I.V.)4, 5 and Tafluprost (figure IV-01, prescribed to treat open-angle glaucoma)6 are just two examples 
of fluorine containing pharmaceuticals. Aside from the biological significance of fluorination chemistry, 
fluorine containing molecules have also been used widely in liquid crystal displays of smart phones, 
further demonstrating their application.7
Figure IV-01: Structures of Maraviroc (left) and Tafluprost (right).
Fluoro-alkenes specifically have been reported to act as isosteric and isopolar amide mimics,8 whilst 
still exhibiting distinct biophysical properties from amides.  For example, fluoro-alkenes have 
decreased hydrogen bonding donating and accepting capabilities relative to amides,9 whilst also being 
non-hydrolysable, thus conferring greater metabolic stability.
The chemical and biological utility of fluoro-alkenes has consequently led to interest in their synthesis.  
A variety of methods are now available for the synthesis of acyclic fluoro-alkenes, which have been 
comprehensively documented by Hara.10 Strategies for the synthesis of cyclic fluoro-alkenes are less 
established, however. This is most commonly achieved by 1 of 3 methods (scheme IV-01): elimination 
reactions,11 coupling reactions12, 13 or the dehydrative fluorination of cyclohexanones.14
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Scheme IV-01: Methods of 1-fluoro-cylcohexene synthesis.  a) t-BuOK, acetone, 85oC. b) t-BuOK, t-BuOH, 70oC.
c) NaOH, AgOTf, Selectfluor, RT.  d) DAST, H2SO4, diglyme, RT.11, 12, 14
Microbial oxidation of fluoro-aromatics offers the scalable and environmentally benign synthesis of 
enantiopure cyclic fluoro-alkenes (and, through derivatisation, of organofluorine compounds in 
general).  The first paper documenting this transformation was published by Gibson in 1977.15 Gibson 
achieved the ortho, meta-dihydroxylation of 4-fluorotoleune using Pseudomonas putida 39/D – a 
bacterium known to express the TDO enzyme (scheme IV-02). One of Gibson’s research aims was to 
ascertain the effect of 4-halo substituents on the enantioselectivity in the microbial oxidation of 
toluenes. It was tentatively concluded that the enantioselectivity in the microbial oxidation of 4-
fluorotoluene did not differ from the enantioselectivity observed when using toluene as a substrate, 
with diol IV-01 being produced.  This was conclusively confirmed by Boyd in 1991 after analysing the 
crystal structure of a derivative of diol IV-01.16 The microbial ortho, meta-dihydroxylation of several 
other fluoro-aromatics has subsequently been reported, including 4-fluoro-iodobenzene17 and 
fluorobenzene.18, 19
Scheme IV-02: Microbial oxidation of 4-fluorotoluene with Pseudomonas putida 39/D.
One of the first published examples of a fluoro-arene diol being used in synthesis was reported by 
Carless in 1990. Carless’ work predominantly focussed on epoxidation reactions of fluoro-arene diol 
IV-02, leading to the synthesis of 6-fluoro-conduritol, IV-03, from fluorobenzene (scheme IV-03).  
Cyclitols in general are known to possess a diverse range of biological functions,20, 21 and addition of 
fluorine may alter their function, making Carless’ work of interest to synthetic and medicinal chemists.
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Furthermore, Carless also exploited the tendency of α-fluoro-alcohols to spontaneously eliminate 
fluoride in the synthesis of enone IV-05, which was achieved through the ring opening of fluoro-furan 
IV-04 with water.
Scheme IV-03: Elaboration of fluoro-arene diol IV-02 demonstrated by Carless.18 a) mCPBA, CH2Cl2, RT. b) 
water.  c) mCPBA, Na2CO3, CH2Cl2, RT.  d) TFA, water, acetone, RT.
Further research into the synthetic utility of fluoro-arene ortho, meta-diols was conducted by Boyd in 
the early 21st century.22, 23 Similarly to Carless, Boyd too chose to focus on oxidative transformations 
of fluoro-arene ortho, meta-diol IV-02; however, Boyd and co-workers researched the dihydroxylation 
of these compounds.  They reported that the dihydroxylation of IV-06 was both regioselective for the 
non-fluorinated alkene and stereoselective, resulting in IV-07 (scheme IV-04).  Boyd subsequently
demonstrated how this diol could be transformed further to access fluoro-arene trans-diol IV-08.
Scheme IV-04: Dihydroxylation of fluoro-arene diol IV-06, and subsequent transformation to fluoro-arene 
trans-diol IV-08.  a) pTSA, 2,2-DMP, acetone, 0oC to RT.  b) OsO4, NMO, acetone, water, RT.
Hudlický has also conducted research into fluoro-arene ortho, meta-diols.24 Hudlický, instead of 
conserving the fluorine, exploited its innate reactivity in the attempted synthesis of ent-7-
deoxypancratistatin, IV-12.  Following its production through the microbial oxidation of 4-
fluoroiodobenzene, diol IV-09 was protected as an acetonide (scheme IV-05).  A Diels–Alder reaction 
of fluoro-diene IV-10 with methyl hydroxycarbamate was subsequently conducted, which is reported 
to have afforded cycloadduct IV-11 (scheme IV-06).  Treating IV-11 with mercury/sodium amalgam 
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reportedly gave γ-amino-enone IV-12 (scheme IV-05).  This is likely to have arisen from the reductive 
cleavage of the N–O bond, followed by immediate elimination of fluoride from the resulting α-fluoro-
hydroxyl group.
Scheme IV-05: First stages of Hudlický’s attempted synthesis of ent-7-deoxypancratistatin when using fluoro-
arene diol IV-09 as a starting material.24 a) Bu3SnH, AIBN, THF.  b) pTSA, 2,2-DMP.  c) HONHCO2Me, NaIO4, H2O, 
MeOH.  d) Na(Hg), THF, H2O.  Yields and reaction temperatures not reported.
Whilst the microbial oxidation of a range of substituted benzoic acids – including fluoro-benzoic acids 
- has also been achieved in the past, 25-27 little synthetic chemistry has been conducted on their 
resulting arene diols.  To the best of our knowledge, there are only 2 examples of substituted arene 
ipso, ortho-diols being used in synthesis.28, 29 A contributing factor to the lack of literature in this area 
is likely the poor substrate scope of the BZDO enzyme; substituted benzoic acids are known to be 
microbially oxidized at a significantly slower rate their non-substituted counterparts, resulting in 
substrate yields that may not be considered synthetically useful.30
Nonetheless, in 2009 Lewis et al. reported the microbial oxidation of sodium 3-bromobenzoate
(scheme IV-06).28 Depending on the orientation of sodium 3-bromobenzoate in the active site of the 
BZDO enzyme, two regioisomeric products may be obtained through this biotransformation: IV-13 and 
IV-14.  Lewis et al. found that the formation of bromo-arene diol IV-13 predominated.
Scheme IV-06: Microbial oxidation of sodium 3-bromobenzoate.28
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Uses of bromo-arene diol IV-13 in synthesis were then investigated.28 Lewis et al. performed a diverse 
range of reactions on bromo-arene diol IV-13, demonstrating its versatility as a chiral starting material. 
After converting arene diol IV-13 to its acetonide protected methyl ester IV-15, dihydroxylation was 
conducted to give diol IV-16 (scheme IV-07). Additionally, Lewis and co-workers conducted the Diels–
Alder reaction of diene IV-15 with PTAD yielding cycloadduct IV-17, as well as synthesising iron 
complexes IV-18 and IV-19 through treatment of IV-15 with nonacarbonyldiiron and (scheme IV-07).
It should be noted that the reactivity of bromo-diene IV-15 with nonacarbonyldiiron is distinct for that 
when reacting the analogous non-brominated diene with nonacarbonyl-diiron.31
Scheme IV-07: Synthesis of a range of enantiopure brominated compounds from bromo-arene diol IV-13.28 a) 
TMS-CHN2, MeOH, benzene, RT.  b) pTSA, 2,2-DMP, RT.  c) OsO4, NMO, acetone, H2O, RT.  d) PTAD, acetone, RT.  
e) Fe2(CO)9, THF, RT.
Lewis et al. have also investigated the use of bromo-arene diol derived diene IV-13 in cross coupling 
reactions (scheme IV-08).  They showed that a variety of groups could be incorporated at C3 using this
cross-coupling approach, infinitely multiplying the number of compounds accessible through the 
microbial oxidation of 3-bromobenzoic acid.28
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Scheme IV-08: Cross coupling reactions of bromo-arene diol IV-13.28 a) p-tolylboronic acid, Pd(PPh3)4, DMF, 
H2O, K2CO3, RT.  b) TMS-CHN2, MeOH, benzene, RT.  c) (TIPS)acetylene, Pd(PPh3)4, CuI, BuNH2, THF, RT.
In 2005, Banwell reported the microbial oxidation of 3-ethyltoluene to ethyl-arene diol IV-20.29 The 
organism used in this biotransformation, Pseudomonas putida strain BGXM1, was capable of effecting
both the oxidation of the methyl group of 3-ethyltoluene to a carboxylic acid, as well as dearomative 
oxidation to form arene diol IV-20 (scheme IV-09).  Whilst this strategy differs slightly from the 
microbial oxidation of benzoic acids using BZDO expressing organisms, the good substrate yields
obtained using this method make this an equally feasible alternative to such organisms.
Scheme IV-09: Microbial oxidation of 3-ethyltoluene.29
Following their synthesis of ethyl-arene diol IV-20, Banwell and co-workers conducted preliminary 
studies into its uses in synthesis.  Lactone IV-22 was formed through alkene bromination of diene IV-
21 followed by spontaneous intra-molecular attack of the proximal carboxylic acid on the resulting 
bromonium ion (scheme IV-10). This reaction had been previously reported by Myer’s on the non-
ethylated analogue of IV-21.32 The alkylation of the carboxylic acid of IV-20 was also demonstrated to 
give IV-23 (scheme IV-10).  Lewis’ and Banwell’s research concludes the synthetic studies into 
substituted arene ipso,ortho-diols, with both examples focussing on arene diols substituted at C3.
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Scheme IV-10: Derivatisation of 3-ethyl-arene diol IV-20.  a) CH2N2, CH2Cl2, EtOH, 18oC.  b) pTSA, 2,2-DMP, 18oC.  
c) K2CO3, MeOH, 18oC.  d) Br2, NaHCO3, CH2Cl2, 0oC. e) α,p-dibromoacetophenone, NEt3, acetone, 18oC.
In 1971, Reiner reported the microbial oxidation of sodium 4-fluorobenzoate using Ralstonia eutropha
B9 (formerly classified Alcaligenes eutrophus B9).25 The resulting fluoro-arene diol IV-24 was never 
isolated by Reiner, and instead the success of the microbial oxidation was based on the formation of 
fluoro-catechol IV-25 when reacting an aqueous solution of suspected fluoro-arene diol IV-24 with 
3,5-cyclohexadiene-1,2-diol-1-carboxylic dehydrogenase (CHDCD), an enzyme known to catalyse the 
formation of catechols from arene ipso, ortho-diols (scheme IV-11).  
Scheme IV-11: Initial report of the microbial oxidation of sodium 4-fluorobenzoate by Reiner.25
The precedent set by Reiner was expanded upon by Reineke in 1978.26 The isolation and 
characterisation fluoro-diene IV-27, a protected derivative of fluoro-arene diol IV-26, was achieved,
which was found to possess greater stability than IV-26.  Similarly to Reiner’s research, the fluoro-
arene diol was never isolated by Reineke.  Instead, following the extraction of acid IV-26 from the 
biotransformation supernatant with EtOAc, the organic solution of acid IV-26 was methylated using 
diazomethane and subsequently stirred with pyridine and acetic anhydride to afford fluoro-diene IV-
27 (scheme IV-12). 
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Scheme IV-12: Reineke’s synthesis of fluoro-diene IV-27. a) CH2N2, EtOAc, RT.  b) Ac2O, pyridine, RT.  Yields not 
quantifiable.
Since Reineke’s research, there has been a lack of synthetic chemistry conducted in this field.  We
envisaged that, through isolation of fluoro-arene diol IV-24 and subsequent derivatisation, a wide 
range of novel, fluorinated compounds could be easily accessed in synthetically useful quantities.  In 
addition, vital information on the reactivity of fluoro-dienes could be ascertained.  Information gained 




Conditions for the microbial dearomatisation of sodium benzoate are widely reported in the literature
and are now well established.32-34 After growing a culture of R. eutropha B9 cells in Hutner’s mineral 
base, sodium benzoate and D-fructose are fed to the aerated culture continuously over several days.  
Conversion of sodium benzoate to arene diol IV-28 can be monitored either by HPLC or by the 
concentration of oxygen in the fermentation broth. Typically, the quantity of arene diol obtained is 
>10 g/L of culture (scheme IV-13).  When conducting the microbial dearomatisation of sodium 4-
fluorobenzoate, it was discovered that only minor changes to the reported procedures were required 
to furnish fluoro-arene diol IV-24 in reasonable quantities (scheme IV-14).35
Scheme IV-13: Microbial arene oxidation of sodium benzoates using Ralstonia eutropha B9.
During the fermentation, the consumption of sodium 4-fluorobenzoate was monitored using 19F NMR 
(figure IV-02, chemical shifts for sodium 4-fluorobenzaote and product IV-24 were observed to drift 
slightly between each assay, with the resonance for sodium 4-fluorobenzoate being observed between 
δ –117.7 and –116.7 ppm, whereas the resonance for IV-24 was observed between δ –122.9 and –
123.8 ppm).35 Using 19F NMR, it was judged that dearomative oxidation of sodium 4-fluorobenzoate
proceeds at a significantly slower rate than sodium benzoate, resulting in the quantity of fluoro-arene 
diol IV-24 obtained from the biotransformation being ~1 g/L.  This observed difference in reactivity is 
consistent with the work of Lipscomb et al., who reported the relatively slow dearomative oxidation 
of sodium fluorobenzoates in single turnover experiments with BZDO and BZDR enzyme extracts.30
Lipscomb determined that the observed difference in reactivity was not a consequence of poorer 
substrate binding in the enzyme active site. An alternative proposed explanation for the slower 
dearomative oxidation of sodium 4-fluorobenzoate could be the decreased electron density at C2
disfavouring biocatalytic oxidation, however this hypothesis has not yet been conclusively proven.
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Figure IV-02: 19F NMR spectra of sodium 4-fluorobenzoate fermentation broth after 1 day (red, bottom), 2 days 
(green), 3 days (turquoise) and 7 days (blue, top).
Re-aromatisation of fluoro-arene diol IV-24 was also found to occur far more readily than the
corresponding re-aromatisation of its non-fluorinated analogue IV-28.35 In order to isolate the non-
fluorinated free acid IV-29, an aqueous solution of carboxylate IV-28 can be cooled to 0oC and acidified 
to around pH 3 with conc. HCl.  Acid IV-29 may then be extracted with EtOAc and the solvent removed 
under vacuum.32 When attempting to isolate the free acid of fluoro-carboxylate IV-24, following this 
procedure results in complete re-aromatisation of the fluoro-arene diol to give 4-fluoro-phenol
(scheme IV-14).  This is consistent with what Reineke observed when trying to isolate such fluoro-arene 
diols in 1978.26 As such, it was necessary to isolate the product as its mixed sodium/potassium salt IV-
24 prior to derivatisation, which was achieved by adding isopropanol to an aqueous solution of IV-24, 
effecting precipitation of the crude product. This precipitation strategy has previously been used to 
isolate non-fluorinated arene diol IV-28.33, 36
Scheme IV-14: Acidification of fluoro-arene diol IV-24 and its non-fluorinated analogue IV-28. a) HCl, water, 
0oC.
The diol of arene diol IV-28 is commonly protected as an acetonide, prior to esterification of the 
carboxylic acid to a methyl ester.  The resulting compound has been used as a starting material in the 
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synthesis of multiple enantiopure compounds.32, 37-39 Fluoro-arene diol IV-24 was therefore derivatised 
as its acetonide protected methyl ester (scheme IV-15),35 which was then elaborated oxidatively to 
yield various novel, enantiopure compounds. Additionally, it was found that methyl ester IV-30 could 
be reduced to primary alcohol IV-31 (scheme IV-15), however synthetic research based on this 
compound is ongoing.
Scheme IV-15: Acetonide protection and esterification of arene diol IV-24. a) Trifluoroacetic acid (5.0 equiv.),
2,2-dimethoxypropane, acetone, 0oC to RT, 16 hours.  b) TMS-diazomethane, MeOH, benzene, RT, 20 minutes.
c) LiBH4 (2.0 equiv.), THF, 0oC to RT, 16 hours.
Fluoro-diene IV-30 was dihydroxylated using OsO4, which gave a mixture of 2 products: IV-32 and IV-
33 (scheme IV-16).35 Dihydroxylation of the non-fluorinated alkene of diene IV-30 seemingly
proceeded at a significantly faster rate than dihydroxylation of the fluorinated alkene, resulting in IV-
32 as the major product.  Interestingly, dihydroxylation of the analogous non-fluorinated diene IV-34
shows the exact opposite regioselectivity (scheme IV-16),40 which suggests that the electronics of the 
diene are significantly affected by the introduction of fluorine at C4.  The preference for 
dihydroxylation at the non-fluorinated alkene is in agreement with Boyd’s research on the 
dihydroxylation of fluoro-dienes derived from fluoro-arene ortho,meta-diols.22, 23
Scheme IV-16: Dihydroxylation of fluoro-diene IV-30 compared to reported dihydroxylation of non-fluorinated 
diene IV-34.40 a) OsO4 (2.5 wt% in tBuOH, 5 mol%), NMO (1.3 equiv.), acetone, water, RT, 16 hours.
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Boyd did not report, however, the formation of a product resulting from the dihydroxylation of the 
fluoro-alkene.  In the present case, elimination of fluoride from the regioisomeric diol of IV-32 occurs,
and subsequent oxidation of the resulting α-hydroxy ketone then ensues (Scheme IV-17).  This 
unwanted side reaction gives dienone IV-33 as a minor product.  It should be noted that the 
discrepancy between the isolated yield of dienone IV-33 and the observed ratio of diol IV-32 to
dienone IV-33 by NMR is likely a result of its low stability.  Dihydroxylations of fluoro-alkenes have
been reported previously, with elimination of fluoride also occurring on these occasions.5, 41
Scheme IV-17: Proposed intermediates for the formation of diene-one IV-33.
Cyclitols in general are known to possess a rich variety of biological functions,20, 21, 42 whilst the 
introduction of fluorine into cyclitols is thought to prevent metabolic degradation and increase 
lipophilicity.43 The synthesis of fluoro-cycitols, however, is known to be arduous. Consequentially,
fluoro-cyclitol IV-37 was selected as a synthetic target.  Protection of diol IV-32 as an acetonide and 
reduction of the methyl ester furnished primary alcohol IV-36, a protected fluoro-cyclitol (scheme IV-
18).35 Deprotection of (bis)acetonide IV-36 has been successfully conducted by refluxing a solution of 
IV-36 in TFA and MeOH, as evidenced by 1H NMR of the crude product (figure IV-03), however 
successful purification of the resulting fluoro-cyclitol IV-37 has not yet been achieved.
Scheme IV-18: Attempted synthesis of fluoro-cyclitol precursor IV-37. a) pTSA (13 mol%), 2,2-
dimethoxypropane, acetone, RT, 48 hours. b) LiBH4 (2.0 equiv.), THF, 0oC to RT, 16 hours.
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Figure IV-03: Crude 1H NMR spectrum of fluoro-cyclitol IV-37.
In 1990, Carless reported the epoxidation of a fluoro-arene ortho,meta-diol derived fluoro-diene.18
This reaction yielded 2 products, with the relative ratios of each product unreported.  Contrary to 
Carless’ findings, mono-epoxidation of fluoro-diene IV-30 gave fluoro-epoxide IV-38 exclusively.35
Furthermore, epoxidation of the analogous non-fluorinated diene IV-39 has been shown to give a 
mixture of regioisomers (scheme IV-19).32 This unique selectivity may be a result of hydrogen bonding 
between the fluorine and mCPBA, thus directing epoxidation to the fluoro-alkene.
The reported regio-selectivity of fluoro-epoxide IV-38 has been assigned based on analysis of its 1H and 
13C NMR spectra (figure IV-04).  J values for the alkene carbon doublets 131.6 and 123.5 are 12.9 and 
41.1 Hz respectively.  In contrast to this, J values for epoxide carbon doublets 89.9 and 53.6 are 261.9 
and 17.6 Hz respectively.  These J values are consistent with the fluoro-alkene being epoxidized, 
confirming the stated regio-selectivity.  The stereo-chemistry of IV-38 was initially assigned based on 
the reported stereo-selectivity when epoxidizing the analogous non-fluorinated compound.32 This was 
conclusively confirmed by obtaining an X-ray crystal structure of a derivative of fluoro-epoxide IV-38
(figure IV-06, page 156).
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Scheme IV-19: Epoxidation of fluoro-diene IV-30 compared to non-fluorinated diene IV-39.32 a) mCPBA (1.3 
equiv.), CH2Cl2, RT, 16 hours.
Figure IV-04: Segment of the 13C NMR spectrum of fluoro-epoxide IV-38.
Currently, there are few examples of ring opening reactions on fluoro-epoxides in the literature.  
Reported reactions tend to focus on ring opening using either a halogen, water or an alcohol as 
nucleophiles, with ring opening occurring at the non-fluorinated carbon of the epoxide.44, 45 This leads
to elimination of fluoride to form α-substituted ketones (scheme IV-20). Research into the ring 
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opening reactions of allylic fluoro-epoxides, however, has not yet been conducted, possibly due to 
difficulty in their preparation.
Scheme IV-20: General selectivity observed when reacting fluoro-epoxides with nucleophiles.44, 45
Reacting epoxide IV-38 with LiBH4 resulted in the reduction of the methyl ester to give primary alcohol 
IV-40, whereas reaction with LiAlH4 resulted in epoxide ring opening in addition to methyl ester 
reduction (scheme IV-21).  Allylic epoxide opening of fluoro-epoxide IV-38 yielded fluoro-alkene IV-41.  
Compounds IV-42 and IV-43 are a result of epoxide ring opening from nucleophilic attack of LiAlH4 at 
the non-fluorinated epoxide carbon. It is noteworthy that epoxide ring opening at the highly sterically 
encumbered non-fluorinated epoxide carbon predominates over ring opening at the less sterically 
encumbered fluorinated epoxide carbon.
Scheme IV-21: Reactions of epoxide IV-38 with LiBH4 and LiAlH4.  a) LiBH4 (2.1 equiv.), THF, 0oC to RT, 24 hours.  
b) LiAlH4 (3.2 equiv.), Et2O, 0oC to RT, 16 hours.
A proposed mechanism for formation of products allylic alcohols IV-42 and IV-43 commences with
epoxide opening at the non-fluorinated epoxide carbon of IV-38 giving α-fluoro-alcohol IV-44, which
rapidly eliminates fluoride to give enone IV-45 (scheme IV-22).  Non-diastereoselective 1,2-reduction
of the resulting enone then provides a diastereo-isomeric mixture of allylic diols IV-42 and IV-43
(scheme IV-22). 
Scheme IV-22: Proposed intermediates in the formation of allylic alcohols IV-42 and IV-43.
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The stereochemistry of allylic alcohols IV-42 and IV-43 could be assigned using 1H NMR.  Since the 
Karplus equation shows that the strength of coupling between vicinal protons is dependent on their 
dihedral angle,46 J values in the 1H NMR spectra of IV-42 and IV-43 could be used for this purpose.
Analysis of the 3D structure of diastereomer IV-43 shows that the dihedral angles between H3 and each 
H4 proton are significantly different.  Indeed, the 1H NMR spectrum of IV-43 shows that H3 couples with 
protons H4A and H4B to different extents, resulting in respective J values of 5.5 and 10.0 Hz (figure IV-
05).  These differing J values are consistent with what is predicted for IV-43 based on the Karplus 
equation, allowing the stereochemistry of this compound to be assigned.
Figure IV-05: Segment of the 1H NMR spectrum of IV-43.
In contrast, the 3D structure of IV-42 shows the dihedral angle between H3 and both H4 to be similar, 
which should result in similar J values between each.  Whilst the splitting pattern of proton H3 cannot 
be unambiguously assigned – meaning J values for H3 cannot be calculated – the splitting patterns of 
both H4 protons suggest that this is the case.  The J values resulting from coupling with H3 are seemingly
3.5 Hz and 4.7 Hz for H4a and H4b respectively (figure IV-06), once more corroborating what was 
predicted base on the Karplus equation.46
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Figure IV-06: Segment of 1H NMR spectrum of diastereomer II-42.
Dihydroxylation of fluoro-epoxide IV-38 has been attempted using OsO4, however this reaction was 
found to proceed at an extremely slow rate, forming only a small quantity of product after 3 days.  As 
such, the epoxidation of diol IV-32 was instead pursued, which proceeded at a more acceptable rate, 
to furnish fluoro-epoxide IV-46 (scheme IV-23).  Comparison of the crude 1H NMR spectra of the 
product obtained through each method showed that the same diastereomer was formed in both
instances.  It was originally envisaged that treating fluoro-epoxide IV-46 with LiAlH4 could aid in the 
synthesis of a saturated fluoro-cyclitol, however, based on our previous observations in the reaction 
of fluoro-epoxide IV-38 with LiAlH4, this synthetic sequence was not attempted.  The synthesis of 
saturated fluoro-cyclitols is ongoing.
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Scheme IV-23: Synthesis of poly-hydroxylated fluoro-epoxide IV-46.  a) OsO4 (2.5 wt% in tBuOH, 5 mol%), NMO
(1.3 equiv.), acetone, water, RT, 3 days.  b) mCPBA (3.0 equiv.), CH2Cl2, RT, 5 days.
Despite fluoro-epoxide IV-46 not finding use in the synthesis of saturated fluoro-cyclitols, it was 
possible to obtain the crystal structure of IV-46 through X-ray diffraction (figure IV-06).  This allowed 
the confirmation of the stereo-chemistry of both fluoro-epoxide IV-38, diol IV-32 and dehydroxylated 
epoxide IV-46.
Figure IV-06: Crystal structure of fluoro-epoxide IV-46.
Singlet oxygen cycloadditions are an established methodology for the incorporation of oxygen into 
carbon frameworks bearing dienes.  Utilising this reactivity, Lewis et al. reported the synthesis of a 
range of highly oxygenated compounds from non-fluorinated arene diol IV-28 in 2012 and 2014.47, 48
Singlet oxygen cycloadditions on fluoro-dienes, however, have not been reported to date, and could 
allow access to an array of highly oxygenated, fluorine containing compounds.  As such, endoperoxide 
IV-47 was synthesised from fluoro-diene IV-30 (scheme IV-24). Both Methylene Blue and TPP were 
tested as photosensitisers for this transformation, however TPP was found to give endoperoxide IV-47
in the greater yield.
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Scheme IV-24: Cycloaddition of singlet oxygen to fluoro-arene diol IV-30. a) TPP, O2, hν, CH2Cl2, 0oC, 12 hours.
Treating endoperoxide IV-47 with Co(TPP) results in a facile isomerisation reaction affording 
(bis)epoxide IV-48, whereas reductive cleavage of endoperoxide IV-47 was achieved using thiourea to 
give diol IV-49 (scheme IV-25).  Both these transformations proceeded as predicted by previous 
experiments conducted on the analogous non-fluorinated compound.48 Diol IV-49 is of interest as it 
could be used in the synthesis of a fluoro-cyclitol, whereas investigation into the epoxide ring opening 
reactivity of (bis)epoxide IV-48 may provide insight into the reactivity differences between fluorinated
and non-fluorinated epoxides.
Scheme IV-25: Derivatisation of endo-peroxide IV-47.  a) Co(TPP), CH2Cl2, RT, 16 hours.  b) Thiourea (1.1 equiv.), 
CH2Cl2, MeOH, RT, 16 hours.
The Kornblum–Delamare rearrangement can provide access to γ-hydroxyenones from endoperoxides.  
Through reacting fluoro-endoperoxide IV-47 with DIPEA, α-fluoro-γ-hydroxy-enone IV-50 was 
synthesised (scheme IV-26).  Low yields were observed for this reaction, which is likely a result of the 
low stability of γ-hydroxyenone IV-50. This is consistent with the observations made by Lewis et al. 
when synthesising similar, non-fluorinated γ-hydoxyenones.47 The tendency of the γ-hydroxyenone 
motif to undergo side reactions was also noted by Spivey, who found γ-hydroxyenones to undergo a 
dimerization reaction through an oxy-Michael addition.49 Through its use as an alkene in Diels–Alder 
reactions or in conjugate additions, this highly functional motif could be of utility in gaining access to 
an immense range of novel, enantiopure compounds.  Furthermore, due to the reported biological 
activity of (–)-zeylenones and related compounds,50, 51 it may be of interest to synthesise (+)-fluoro-
zeylenone IV-51 using similar chemistry.  
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Scheme IV-26: Synthesis of 4-hydroxy-2-fluoro-enone IV-50 (left).  Potential target compound (+)-fluoro-
zeylenone IV-51 and natural product (–)-zeylenone IV-52 (right).50 a) DIPEA, CH2Cl2, RT, 20 hours.
In order to circumvent undesired side reactions of γ-hydroxy-enone IV-50, protection of its secondary 
alcohol was attempted. Interestingly however, trying to affect the one-pot Kornblum–Delamare and 
subsequent silyl protection of fluoro-endoperoxide IV-47 resulted not in the formation of IV-53, but
instead the formation of fluoro-diene IV-54 (scheme IV-27).  Similarly to the formation of γ-
hydroxyenone IV-50, the yield of this reaction was also less than optimal; this may also be attributed 
to the low stability of IV-50, which is a likely intermediate in the formation of fluoro-diene IV-54.  
Similar dienes have been reported to undergo cycloaddition reactions with, for example, singlet 
oxygen or mono-substituted alkynes.52, 53
Scheme IV-27: Derivatisation of endoperoxide IV-47.  a) NEt3 (3.6 equiv.), TBDMSOTf (1.3 equiv.), DMAP, 
CH2Cl2, 0oC to RT, 16 hours.
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Conclusions and future work
The synthesis of cyclic fluoro-alkenes is a non-trivial pursuit; however, it has been demonstrated that, 
through microbial oxidation, enantiopure fluoro-dienes can be synthesised from sodium 4-
fluorobenzoate in synthetically useful quantities (scheme IV-28).  This microbial oxidation can be 
achieved using Ralstonia eutropha B9 and conversion of substrate into the desired arene diol can be 
followed by 19F NMR.
Scheme IV-28: Microbial arene oxidation of sodium 4-fluorobenzoate to fluoro-arene diol IV-24.
Various oxidative transformations have been conducted on fluoro-arene diol IV-24, resulting in an 
array of novel, highly oxygenated fluoro-carbocycles being synthesised, including fluoro-cyclitol 
precursor IV-36, fluoro-epoxide IV-40 and α-fluoro-γ-hydroxyenone IV-50 (scheme IV-29).  The 
synthesised compounds could be further functionalised in numerous number of ways.  This essential 
research lays the foundations for further work on fluoro-arene diols, paving the way to the synthesis 
of more complex or biologically active fluoro-carbocycles.
Scheme IV-29: Syntheses of a selection of highly oxygenated compounds from fluoro-arene diol IV-24.
Whilst researching the syntheses of these compounds, the unique reactivity of fluoro-alkenes and 
fluoro-epoxides was also investigated, which has added to the known chemistry of these motifs.  Of 
particular interest is the difference in regioselectivity of epoxidation versus dihydroxylation of fluoro-




Scheme IV-30: Dihydroxylation and epoxidation of fluoro-diene IV-30.  a) OsO4, NMO, acetone, water, RT.  b) 
mCPBA, CH2Cl2, RT.
Despite the previously detailed research into oxidative reactions on fluoro-arene diols, a wide expanse 
of synthetic chemistry relating to fluoro-arene diols remains unexplored. Having already reported the 
partial allylic epoxide opening of fluoro-epoxide IV-38 with LiAlH4, it would be of interest to explore 
whether exclusive allylic epoxide opening of the fluoro-epoxide IV-38 could be achieved with “softer” 
nucleophiles. Following this, oxidation of the allylic alcohol to α-fluoro-enone IV-55 be desirable to 
allow for further functionalisation (scheme IV-31).  Achieving this would not only allow the control of 
functionality at C6, but also allow further functionalisation of the fluoro-enone.
Scheme IV-31: Proposed allylic ring opening of IV-38 with a soft nucleophile, followed by oxidation of the 
resulting allylic alcohol to α-fluoro-enone IV-55.
Due to the potential biological applications of fluoro-cyclitols,20, 21, 42, 43 the synthesis of fluoro-cyclitols 
from arene diol IV-24 should be brought to a conclusion.  In addition to fluoro-cyclitols, it may also be 
desirable to synthesise aminofluoro-cyclitols using previously established cycloaddition chemistry to 
install an amine onto the carbocyclic scaffold (scheme IV-32).54
Scheme IV-32: Proposed cyclo-addition of fluoro-diene IV-30, using conditions developed by Lewis.54 a) Benzyl 
hydroxycarbamate, Bu4N.NaIO4, CH2Cl2, -78oC.
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In addition to continued synthetic chemistry research on sodium 4-fluorobenzoate derived fluoro-
arene diols, microbial oxidations of alternative sodium fluorobenzoates should also be investigated.  
Sodium 3,5-difluorobenzoate was microbially dearomatised by Ribbons et al. in 1987 (scheme IV-33),27
however, following isolation of the product as its methyl ester, the synthetic chemistry of the product 
was not investigated.  Of particular interest would be the use of fluoro-dienes – derived from fluoro-
arene diol IV-56 – in cyclo-additions.  This could provide access to enantiopure compounds bearing 
tetra-substituted, fluoro-carbons.  Such compounds would, otherwise, be extremely challenging to 
synthesise.
Scheme IV-33: Dearomative dihydroxylation of sodium 3,5-difluorobenzoate.
The previously documented research describes synthetic sequences which allow the synthesis of 
enantiopure, poly-oxygenated fluoro-carbocycles.  This work constitutes the first example of fluoro-
arene diol IV-24 being used in synthesis.  Whilst oxidative chemistry of fluoro-arene diol IV-24 has 
begun to be explored, continued research into this field is likely to result in the synthesis of novel 







A sterile pipette tip was streaked across a frozen glycerol solution of Ralstonia eutropha B9 and added 
to a sterile solution of Hutner’s mineral base (100 mL) and sodium succinate (0.405 g).  The solution 
was placed on an orbital shaker (250 rpm) at 27oC and shaken for 72 h.  The resulting cloudy suspension
was poured into Hutner’s mineral base (1.5 L), which was heated to ca. 30oC and through which air 
was bubbled. Aqueous D-fructose (10 mL, 10% w/v) was then added.  A further quantity of D-fructose 
was added over the following 24 hours via syringe pump.  Following this, the culture was induced with 
sodium 4-fluorobenzoate solution (1.0 M, 5.0 mL) and fed a further quantity of D-fructose (30 mL).  19F 
NMR showed full conversion of 4-fluorobenzoate to the corresponding cis-diol.  Repetitive feeding of 
sodium 4-fluorobenzoate began, with a total of 30 mL of sodium 4-fluorobenzoate being added to the 
culture over a period of 5 days.  The culture was simultaneously fed D-fructose at a rate of 30 mL/24 
h.
After full consumption of sodium 4-fluorobenzoate was observed by 19F NMR, the culture was 
centrifuged (5000 rpm, 45 minutes) and the supernatant collected.  The solvent was then removed 
under vacuum to give a green solid.  This solid was found, by 1H NMR, to contain a mixture of the 
desired product and unconsumed D-fructose.  Thus, the material was re-dissolved in water (80 mL), to 
which isopropanol (800 mL) was added.  After 10 min, the cloudy solution was decanted off, leaving 
behind a brown sludge.  A further quantity of water (80 mL) was added to the brown sludge, and 
isopropanol (800 mL) added.  Again, the cloudy solution was decanted off leaving a brown sludge 
behind.  The decanted solutions were cooled to 4°C for 1 h to aid precipitation of the solid.  The solid 
was then filtered off and dried under vacuum to give a cream coloured solid, which contained IV-28 as 
the mixed sodium/potassium carboxylate salt and a variable proportion of growth medium salts. 1.35 





To a suspension of cis-diol carboxylate IV-24 (0.287 g, 1.46 mmol, 1.0 equiv.) in 2,2-dimethoxypropane 
(10 mL) and acetone (1.0 mL), cooled to ~0oC, was added TFA (0.56 mL, 7.32 mmol, 5.0 equiv.) dropwise 
via syringe pump over 10 minutes.  Following addition of TFA, the reaction was allowed to warm to 
room temperature over 16 hours.  The suspension was then filtered through a pad of Celite® and the 
solution concentrated under vacuum, before being dispersed in H2O (30 mL) and extracted with CH2Cl2
(2 x 30 mL).  The organic layers were combined, dried over MgSO4 and the solvent removed to give a 
dark brown oil.  This brown oil was re-suspended in CH2Cl2 and the solvent again removed under 
vacuum to aid excess TFA removal.  This was repeated several times.  The crude product was re-
dissolved in a mixture of MeOH (5.0 mL) and benzene (5.0 mL).  TMS-diazomethane (~1.46 mL, 
apparent 2.0 M solution in hexanes) was added slowly to the resulting solution until a yellow colour 
persisted and effervescence ceased.  After stirring for 20 minutes, the solvent was removed to give a 
brown oil, which was purified by column chromatography (5% EtOAc, 95% petroleum ether) to give IV-
30 as a colourless oil (0.216 g, 0.947 mmol, 65%).
Rf = 0.28 (10% EtOAc, 90% petroleum ether); [α]D24 = -242 (c. 1 g/100 mL, CH2Cl2); 1H NMR (500 MHz, 
CDCl3) δ = 6.01 (1H, ddd, J = 10.0, 7.5, 2.0 Hz), 5.91 (1H, ddt, J = 10.0, 5.0, 1.0 Hz), 5.48 (1H, dddd, J = 
11.0, 5.0, 2.0, 1.0 Hz), 5.05 (1H, ddd, J = 6.0, 5.0, 1.0 Hz), 3.78 (3H, s), 1.43 (3H, s), 1.41 (3H, s); 13C NMR 
(126 MHz, CDCl3) δ = 171.2 (s), 157.8 (d, J = 254.5 Hz), 129.8 (d, J = 10.0 Hz), 121.1 (d, J = 38.5 Hz), 107.5 
(s), 99.1 (d, J = 18.0 Hz), 79.6 (d, J = 2.0 Hz), 74.0 (d, J = 12.5 Hz), 53.2 (s), 27.0 (s), 25.0 (s); 19F NMR 
(500 MHz, CDCl3) δ = -111.7 (dq, J = 11.5, 6.0 Hz); νmax (neat) 2991, 2957, 1737, 1683, 1252, 1040, 802 
cm-1; HRMS (ESI+) m/z calculated for (C11H13O4FNa)+ 251.0690, found 251.0707.
((3aR,7aR)-6-Fluoro-2,2-dimethylbenzo[d][1,3]dioxol-3a(7aH)-yl)methanol IV-31
Methyl ester IV-30 (37 mg, 0.162 mmol, 1 equiv.) was dissolved in anhydrous THF (5.0 mL) and cooled 
to 0oC.  LiBH4 (4.0 M in THF, 0.08 mL, 0.324 mmol, 2.0 equiv.) was added slowly, and the solution 
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allowed to warm to room temperature over 16 hours.  The reaction was quenched with EtOAc (15 mL) 
and water (15 mL).  The organic layer was collected, and the aqueous layer further extracted with 
EtOAc (2 x 15 mL).  Organic layers were combined, dried over MgSO4 and the solvent removed to give 
IV-31 as a yellow/orange oil (31 mg, 0.155 mmol, 96%). No purification of the crude product was 
necessary.
Rf = 0.32 (30% EtOAc, 70% petroleum ether); [α]D26 = -127 (c. 1 g/100 mL, CH2Cl2); 1H NMR (500 MHz, 
CDCl3) δ = 5.94 (1H, ddt, J = 10.7, 6.9, 2.0 Hz), 5.81 (1H, dd, J = 10.3, 5.3 Hz), 5.47 (1H, ddd, J = 10.8, 5.6, 
2.0 Hz), 4.65 (1H, t, J = 5.8 Hz), 3.60 (1H, d, J = 11.9 Hz), 3.38 (1H, dd, J = 12.0, 7.2 Hz), 2.08-2.01 (1H, 
m, OH), 1.43 (3H, s), 1.38 (3H, s); 13C NMR (500 MHz, CDCl3) δ = 158.5 (d, J = 255.7 Hz), 133.7 (d, J = 
10.1 Hz), 120.7 (d, J = 37.7 Hz), 106.9 (s), 99.2 (d, J = 17.2 Hz), 80.9 (d, J = 1.4 Hz), 71.9 (d, J = 12.6 Hz), 
63.7 (s), 27.3 (s), 26.7 (s); 19F NMR (500 MHz, CDCl3) δ = -111.4 (dq, J = 12.1, 6.2 Hz); νmax (film) 3440, 





To a solution of diene IV-30 (105 mg, 0.460 mmol, 1.0 equiv.) in acetone (5.0 mL) was added NMO (70 
mg, 0.598 mmol, 1.3 equiv.).  Water (~0.4 mL) was added until full dissolution of the NMO occurred, 
and then OsO4 (2.5 wt% in tBuOH, 0.23 mL, 23.0 μmol, 5 mol%) was added.  The solution was stirred 
for 16 hours, during which the solution turned dark brown in colour.  The reaction was quenched with 
addition of aq. Na2S2O3 (1.0 M, 10 mL) followed by aq. sat. NaHCO3 (5.0 mL).  The product was extracted 
with EtOAc (3 x 15 mL).  Organic layers were combined, washed with brine (30 mL), dried over MgSO4
and the solvent removed to give a dark brown oil, which was a mixture of 2 different products.  These 
were separated by column chromatography (30% EtOAc, 70% petroleum ether → 50% EtOAc, 50% 
petroleum ether) to give white solid IV-32 (80 mg, 0.305 mmol, 66%) and yellow oil IV-33 (6 mg, 25.0
μmol, 5%).
Data for IV-32: Rf = 0.27 (50% EtOAc, 50% petroleum ether); [α]D24 = -24 (c. 0.25 g / 100 mL, CH2Cl2); 1H 
NMR (500 MHz, CDCl3) δ = 5.52 (1H, dd, J = 14.0, 4.5 Hz), 5.01 (1H, t, J = 5.0 Hz), 4.42-4.36 (1H, m), 
4.29-4.24 (1H, m), 3.86 (3H, s), 3.63 (1H, d, J = 9.0 Hz), 3.10-3.02 (1H, m), 1.50 (3H, s), 1.41 (3H, s); 13C 
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NMR (126 MHz, CDCl3) δ = 172.9 (s), 159.6 (d, J = 269.0 Hz), 111.8 (s), 102.2 (d, J = 17.5 Hz), 83.8 (d, J = 
2.0 Hz), 74.0 (d, J = 13.0 Hz), 72.4 (d, J = 8.0 Hz), 65.3 (d, J = 24.5 Hz), 53.4 (s), 27.9 (s), 25.8 (s); 19F NMR 
(500 MHz, CDCl3) δ = -110.1--110.4 (m); νmax (film) 3405, 3327, 2991, 2950, 1748, 1703, 1257, 1241, 
1088, 1053, 857 cm-1; HRMS (ESI+) m/z calculated for (C11H15O6FNa)+ 285.0745, found 285.0728.
Data for IV-33: Rf =  0.30 (30% EtOAc, 70% petroleum ether); [α]D26 = -120 (c. 0.2 g/100 mL, CH2Cl2); 1H 
NMR (500 MHz, CDCl3) δ = 6.88 (1H, d, J = 9.7 Hz), 6.34 (1H, d, J = 9.7 Hz), 5.67 (1H, s), 3.77 (3H, s), 1.66 
(3H, s), 1.61 (3H, s); 13C NMR (126 MHz, CDCl3) δ = 183.0, 169.0, 145.8, 137.8, 129.9, 128.6, 120.1, 83.4, 
54.2, 28.6, 25.7; νmax (film) 3392, 3000, 2956, 1744, 1649, 1598, 1380, 1220, 1140, 1111, 823    cm-1; 
HRMS (ESI+) m/z calculated for (C11H12O6Na)+ 263.0526, found 263.0537.
Methyl (3aS,5aR,8aR,8bR)-4-fluoro-2,2,7,7-tetramethyl-3a,8b-dihydrobenzo[1,2-d:3,4-
d']bis([1,3]dioxole)-8a(5aH)-carboxylate IV-35
Diol IV-32 (31 mg, 0.122 mmol, 1.0 equiv.) was dissolved in 2,2-dimethoxypropane (5.0 mL) and pTSA 
added (monohydrate, 3 mg, 15.8 μmol, 13 mol%).  The solution was stirred for 48 h.  Aqueous saturated 
NaHCO3 (15 mL) was added and the aqueous phase extracted with CH2Cl2 (3 x 15 mL).  The organic 
phases were combined, dried over MgSO4 and the solvent removed.  The resulting oil was purified by 
column chromatography (20% EtOAc, 80% petroleum ether) to give IV-35 as a colourless oil (30 mg, 
99.3 μmol, 81%).
Rf = 0.29 (20% EtOAc, 80% petroleum ether); [α]D24 = -34 (c. 1 g/100 mL, CH2Cl2); 1H NMR (500 MHz, 
CDCl3) δ = 5.43 (1H, ddd, J = 6.2, 3.3, 1.5 Hz), 5.31 (1H, dd, J = 15.1, 3.3 Hz), 4.76 (1H, t, J = 5.9 Hz), 4.70 
(1H, dd, J = 5.6, 1.5 Hz), 3.85 (3H, s), 1.39 (3H, s), 1.36 (3H, s), 1.35 (3H, s), 1.30 (3H, s); 13C NMR (126 
MHz, CDCl3) δ = 170.9 (s), 156.2 (d, J = 265.1 Hz), 111.55 (s), 111.53 (s), 103.9 (d, J = 14.0 Hz), 82.3 (d, 
J = 2.1 Hz), 75.8 (d, J = 7.2 Hz), 73.1 (d, J = 11.0 Hz), 70.1 (d, J = 24.0), 53.2 (s), 28.3 (s), 27.84 (s), 27.78 
(s), 26.5 (s); 19F NMR (500 MHz, CDCl3) δ = -117.7 (dt, J = 15.1, 6.2 Hz); νmax (film) 2991, 2943, 1747, 
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Methyl ester IV-35 (18 mg, 59.6 μmol, 1.0 equiv.) was dissolved in anhydrous THF (5.0 mL) and the 
solution was cooled to 0oC.  LiBH4 (4.0 M, 0.03 mL, 0.119 mmol, 2.0 equiv.) was added dropwise and 
the solution allowed to warm to room temperature over 16 hours.  EtOAc (15 mL) was added slowly, 
followed by water (15 mL).  The Organic layer was collected and the product further extracted from 
the aqueous layer with EtOAc (2 x 15 mL).  Organic layers were combined, washed with brine (20 mL), 
dried over MgSO4 and the solvent removed.  The resulting oil was purified by column chromatography 
(30% EtOAc, 70% petroleum ether) to IV-36 as a colourless oil (15 mg, 54.7 μmol, 92%).
Rf = 0.29 (30% EtOAc, 70% petroleum ether); [α]D24 = -26 (c. 0.5 g/100 mL, CH2Cl2); 1H NMR (500 MHz, 
CDCl3) δ = 5.33 (1H, dd, J = 15.2, 3.3 Hz), 4.70 (1H, dd, J = 6.6, 5.2 Hz), 4.68-4.64 (2H, m), 3.86 (1H, t, J 
= 10.6 Hz), 3.79 (1H, d, J = 11.4 Hz), 2.25 (1H, d, J = 9.7, OH), 1.45 (3H, s), 1.41 (6H, s), 1.36 (3H, s); 13C 
NMR (126 MHz, CDCl3) δ = 157.3 (d, J = 266 Hz), 110.7 (s), 111.0 (s), 103.8 (d, J = 14.2), 81.6 (s), 75.6 (d, 
J = 7.3 Hz), 73.6 (d, J = 10.9 Hz), 70.1 (d, J = 22.8), 64.6 (s), 29.8 (s), 28.8 (s), 27.9 (s), 26.6 (s); 19F NMR 
(500 MHz, CDCl3) δ = 117.0 (dt, J = 15.6, 6.3 Hz); νmax (film) 3511, 2990, 2937, 1706, 1371, 1230, 1174, 
1085, 1042, 917, 859 cm-1; HRMS (ESI+) m/z calculated for (C13H19O5FNa)+ 297.1109, found 297.1122.
Methyl (3aS,5aR,6aR,6bR)-5a-fluoro-2,2-dimethyl-6a,6b-dihydrooxireno[2',3':3,4]benzo[1,2-
d][1,3]dioxole-3a(5aH)-carboxylate IV-38
Diene IV-30 (0.031 g, 0.136 mmol, 1.0 equiv.) was dissolved in CH2Cl2 (3.0 mL) and the solution was 
cooled to ~0oC.  mCPBA (77%, 0.040 g, 0.177 mmol, 1.3 equiv.) was added and the solution was allowed 
to warm to room temperature over 16 hours.  The reaction was quenched with the addition of aqueous 
Na2S2O3 (1.0 M, 10 mL) and the product extracted with CH2Cl2 (3 x 10 mL).  Organic layers were 
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combined and washed with a saturated aqueous solution of NaHCO3 (15 mL), before being dried over 
MgSO4.  The solvent was removed to give a yellow/orange liquid, which was purified by column 
chromatography (10% EtOAc, 90% petroleum ether) to give IV-38 as a colourless liquid (26 mg, 0.107 
mmol, 79%).
Rf = 0.44 (20% EtOAc, 80% petroleum ether); [α]D24 = -64 (c. 0.25 g/100 mL, CH2Cl2); 1H NMR (500 MHz, 
CDCl3) δ = 6.29 (1H, dd, J = 10.5, 4.0 Hz), 5.89 (1H, ddd, J = 10.5, 5.5, 1.0 Hz), 5.05 (1H, dt, J = 5.0, 1.5 
Hz), 3.90 (1H, t, J = 1.5 Hz), 3.78 (3H, s), 1.46 (3H, s), 1.44 (3H, s); 13C NMR (126 MHz, CDCl3) δ = 170.0 
(s), 131.6 (d, J = 13.0 Hz), 123.46 (d, J = 41.0 Hz), 112.9 (s), 89.9 (d, J = 262.0 Hz), 79.8 (s), 74.2 (d, J = 
4.0 Hz), 53.6 (d, J = 17.5 Hz), 53.4 (s), 27.6 (s), 25.7 (s); 19F NMR (500 MHz, CDCl3) δ = -148.0 (q, J = 5.0 
Hz); νmax (film) 2992, 2957, 1745, 1378, 1263, 1192, 1057, 969 cm-1; HRMS (ESI+) m/z calculated for 
(C11H13O5FNa)+ 267.0639, found 267.0649.
((3aR,5aR,6aR,6bR)-5a-Fluoro-2,2-dimethyl-6a,6b-dihydrooxireno[2',3':3,4]benzo[1,2-d][1,3]dioxol-
3a(5aH)-yl)methanol IV-40
Methyl ester IV-38 (64 mg, 0.259 mmol, 1.0 equiv.) was dissolved in anhydrous THF (3.0 mL) and the 
solution was cooled to ~0oC.  LiBH4 (4.0 M in THF, 0.13 mL, 0.518 mmol, 2.0 equiv.) was added slowly 
over 5 minutes.  The solution was allowed to warm to room temperature over 24 hours, after which
EtOAc (10 mL) was added slowly, followed by H2O (10 mL).  The organic layer was collected, and the 
aqueous layer further extracted with EtOAc (2 x 10 mL).  Organic layers were combined and dried over 
MgSO4.  The solvent was removed to give IV-40 as a pale yellow oil (41 mg, 0.190 mmol, 73%).
Rf = 0.34 (25% EtOAc, 75% petroleum ether); [α]D24 = -28 (c. 1 g/100 mL, CHCl3); 1H NMR (500 MHz, 
CDCl3) δ = 6.24 (1H, dd, J = 10.5, 4.0 Hz), 5.74 (1H, ddd, J = 10.5, 5.5, 1.5 Hz), 4.61 (1H, ddd, J = 5.0, 2.0, 
1.5 Hz), 3.92 (1H, t, J = 1.5 Hz), 3.59 (1H, d, J = 12.0 Hz), 3.34 (1H, br. d, J = 11.5 Hz), 1.89 (1H, m, OH), 
1.43 (3H, s), 1.41 (3H, s); 13C NMR (126 MHz, CDCl3) δ = 134.2 (d, J = 13.0 Hz), 123.3 (d, J = 41.0 Hz), 
111.1 (s), 90.3 (d, J = 262.0 Hz), 81.5 (s), 71.2 (d, J = 4.0 Hz), 64.9 (s), 54.5 (d, J = 17.5 Hz), 28.1 (s), 27.0 
(s); 19F NMR (500 MHz, CDCl3) δ = -146.7 (q, J = 5.0 Hz); νmax (film) 3461, 2993, 2930, 2856, 1459, 1196, 







To solid LiAlH4 (59 mg, 1.55 mmol, 3.2 equiv.) was added anhydrous Et2O (5.0 mL).  The suspension 
was cooled to 0oC.  A solution of epoxide IV-38 (0.120 g, 0.486 mmol, 1.0 equiv.) in anhydrous Et2O
(2.0 mL) was then added, and the suspension allowed to warm to room temperature over 16 hours.  
After this time, the suspension was again cooled to 0oC and EtOAc (5.0 mL) added slowly to quench 
the reaction, followed by water (5.0 mL).  The biphasic solution was filtered.  The organic layer was 
collected, and the product further extracted from the aqueous phase with EtOAc (3 x 5.0 mL).  Organic 
layers were combined, dried over MgSO4 and the solvent removed.  The crude product was purified by 
column chromatography (50% EtOAc, 50% petroleum ether → 100% EtOAc) to give 3 products: IV-41
(23 mg, 0.105 mmol, 22%), IV-42 (15 mg, 75 μmol, 15%), IV-43 (21 mg, 0.105 mmol, 22%).
Data for IV-41.  Rf = 0.29 (50% EtOAc, 50% petroleum ether); [α]D25 = +35 (c. 0.67 g/100 mL, CHCl3); 1H
NMR (500 MHz, CDCl3) δ = 5.31 (1H, dt, J = 14.5, 4.4 Hz), 4.25 (1H, dd, J = 6.1, 2.0 Hz), 3.69 (1H, d, J = 
11.0 Hz), 3.65 (1H, d, J = 11.0 Hz), 2.46 (1H, dddd, J = 18.0, 5.1, 4.4, 0.6 Hz), 2.39 (1H, dddd, J = 18.1, 
5.5, 4.4, 1.0 Hz), 1.43 (3H, s), 1.39 (3H, s); 13C NMR (126 MHz, CDCl3) δ = 157.7 (d, J = 256.0 Hz), 108.9 
(s), 102.6 (d, J = 16.7 Hz), 81.9 (d, J = 8.6 Hz), 79.3 (d, J = 1.5 Hz), 67.3 (s), 65.5 (d, J = 28.6 Hz), 31.5 (d, 
J = 6.8 Hz), 28.0 (s), 26.9 (s); 19F NMR (500 MHz, CDCl3) δ = -117.3 (tt, J = 13.9, 5.7 Hz); νmax (film) 3379, 
2991, 2931, 1441, 1373, 1218, 1173, 1148, 908 cm-1; HRMS (ESI+) m/z calculated for (C10H15O4FNa)+
241.0847, found 241.0852.
Data for IV-42.  Rf = 0.14 (50% EtOAc, 50% petroleum ether); [α]D25 = +23 (CH2Cl2, c. 0.667 g/100 mL); 
1H NMR (500 MHz, CDCl3) δ = 5.92 (1H, dt, J = 10.4, 1.8 Hz), 5.43 (1H, dt, J = 10.4, 2.0 Hz), 4.49 (1H, ddt, 
J = 10.0, 5.5, 2.1 Hz), 4.40 (1H, dt, J = 3.9, 2.0 Hz), 3.61 (1H, d, J = 12.0 Hz), 3.44 (1H, d, J = 12.0 Hz), 2.54 
(1H, dddd, J = 14.0, 5.5, 3.8, 1.6 Hz), 1.60 (1H, ddd, J = 14.0, 10.0, 2.2 Hz), 1.38 (3H, s), 1.35 (3H, s); 13C 
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NMR (126 MHz, CDCl3) δ = 134.9, 127.6, 108.2, 79.4, 73.8, 63.8, 63.7, 34.1, 27.7, 27.1; νmax (film) 3355, 
2987, 2931, 2871, 1371, 1220, 997 cm-1; HRMS (ESI+) m/z calculated for (C10H16O4Na)+ 223.0941, found 
223.0950.
Data for IV-43.  Rf = 0.17 (50% EtOAc, 50% petroleum ether); [α]D25 = -60 (c. 0.5 g/100 mL, CHCl3); 1H 
NMR (500 MHz, CDCl3) δ = 6.09 (1H, ddd, J = 10.2, 5.1, 1.5 Hz), 5.49 (1H, dd, J = 10.2, 1.7 Hz), 4.53-4.46 
(1H, m), 4.10-4.03 (1H, m), 3.62 (1H, d, J = 12.1 Hz), 3.39 (1H, dd, J = 12.4, 6.6 Hz), 3.08 (1H, d, J = 11.2 
Hz), 2.45 (1H, ddt, J = 15.6, 3.5, 1.7 Hz), 2.00 (1H, d, J = 7.8 Hz), 1.95 (1H, ddd, J = 15.6, 4.7, 2.2 Hz), 1.46 
(3H, s), 1.39 (3H, s); 13C NMR (126 MHz, CDCl3) 131.6, 128.0, 108.9, 79.8, 73.5, 62.9, 62.4, 30.8, 28.0, 
26.9; ); νmax (film) 3405, 2988, 2930, 1380, 1226, 1167, 818 cm-1; HRMS (ESI+) m/z calculated for 
(C10H16O4Na)+ 223.0941, found 223.0948.
Methyl (3aS,4R,5S,5aR,6aR,6bR)-5a-fluoro-4,5-dihydroxy-2,2-
dimethyltetrahydrooxireno[2',3':3,4]benzo[1,2-d][1,3]dioxole-3a(4H)-carboxylate IV-46
Diol IV-32 (37 mg, 0.141 mmol, 1.0 equiv.) was dissolved in CH2Cl2 (5.0 mL) and mCPBA (100%, 37 mg, 
0.212 mmol, 1.5 equiv.) added.  After 24 h, a further quantity of mCPBA (100%, 37 mg, 0.212 mmol, 
1.5 equiv.) was added.  The solution was stirred for 5 days.  Aqueous sodium thiosulfate (1.0 M, 10 mL) 
was added, and the product extracted with CH2Cl2 (3 x 15 mL).  Organic layers were combined, dried 
over MgSO4 and the solvent removed.  The resulting solid was purified by column chromatography 
(50% EtOAc, 50% petroleum ether) to give IV-46 as a white solid (22 mg, 79.1 μmol, 56%).
Rf = 0.30 (50% EtOAc, 50% petroleum ether); [α]D24 = +9.3 (c. 0.75 g/100 mL, CH2Cl2); melting point = 
133-135oC; 1H NMR (500 MHz, CDCl3) δ = 5.15 (1H, dd, J = 5.8, 0.9 Hz), 4.70 (1H, d, J = 4.5 Hz), 4.35-
4.28 (1H, m), 3.84 (3H, s), 3.72 (1H, s), 2.94 (s, OH), 2.54 (1H, d, J = 11.3 Hz, OH), 1.45 (3H, s), 1.33 (3H, 
s); 13C NMR (126 MHz, CDCl3) δ = 170.8 (s), 112.8 (s), 93.8 (d, J = 280.3 Hz), 85.4 (s), 72.5 (d, J = 3.1 Hz), 
70.4 (d, J = 6.7 Hz), 64.3 (d, J = 23.5 Hz), 59.6 (d, J = 17.6 Hz), 53.4 (s), 28.1 (s), 26.8 (s); 19F NMR (500 
MHz, CDCl3) δ -146.5 (t, J = 5.3 Hz) ; νmax (film) 3504, 3490, 2994, 2959, 1741, 1727, 1235, 1208, 1094, 





A solution of diene IV-30 (0.114 g, 0.500 mmol) and TPP (3 mg) in CH2Cl2 (10 mL) in Schlenk tube was 
cooled to ~2oC.  Five white 12 V LED lights, attached to the outside of the vessel using an elastic band, 
were used to irradiate the solution.  O2 gas from a cylinder was bubbled through the solution for 12 
hours.  During this period, care was taken to ensure the solvent volume remained at around 10 mL, 
with additional solvent being added as necessary to replace that which had evaporated.  After 12 
hours, the solvent was removed under vacuum.  Crude 1H NMR indicated ~70% conversion of the 
starting material, which was not improved upon through longer reaction times or increasing quantity 
of photosensitiser.  As such, the solvent was removed and the crude product purified by column 
chromatography (10% EtOAc, 90% petroleum ether) to give IV-47 as a colourless oil (77 mg, 0.296 
mmol, 59%).
Rf = 0.31 (10% EtOAc, 90% petroleum ether); [α]D25 = -41 (CH2Cl2, c. 1 g/100 mL); 1H NMR (500 MHz, 
CDCl3) δ = 5.76 (1H, ddd, J = 7.1, 4.1, 2.7 Hz), 5.33 (1H, ddt, J = 7.1, 5.4, 0.8 Hz), 5.18 (1H, dd, J = 5.2, 
3.7 Hz), 4.94 (1H, dddd, J = 9.7, 5.2, 2.8, 1.0 Hz), 3.88 (3H, s), 1.38 (3H, s), 1.34 (3H, s); 13C NMR (126 
MHz, CDCl3) δ = 170.5 (s), 159.6 (d, J = 294.8 Hz), 113.0 (s), 101.4 (d, J = 4.4 Hz), 80.9 (s), 75.2 (d, J = 9.1 
Hz), 73.5 (d, J = 3.0 Hz), 53.5 (s), 26.4 (s), 26.4 (s); 19F NMR (500 MHz, CDCl3) δ = -102.7 to -102.9 (m); 
νmax (film) 2960, 1742, 1686, 1376, 1261, 1066, 1063, 811 cm-1; HRMS (ESI+) m/z calculated 




To a solution of endoperoxide IV-47 (32 mg, 124 μmol) in CH2Cl2 (2.0 mL) was added Co(TPP) (1 mg).  
The solution was stirred at RT for 16 h.  The solvent was removed under vacuum and the product 
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purified by column chromatography (10% EtOAc, 90% petroleum ether) to give fluoro-(bis)epoxide IV-
48 as a colourless oil (22 mg, 84 μmol, 68%).
Rf = 0.17 (10% EtOAc, 90% petroleum ether); [α]D25 = -51 (CH2Cl2, c. = 0.667 g/100 mL); 1H NMR (500 
MHz, CDCl3) δ = 4.89 (1H, dd, J = 5.8, 1.1 Hz), 3.86 (3H, s), 3.85 (1H, d, J = 3.8 Hz), 3.67 (1H, dd, J = 2.9, 
1.1 Hz), 3.52 (1H, d, J = 3.7 Hz), 1.48 (3H, s), 1.40 (3H, s); 13C NMR (500 MHz, CDCl3) δ = 169.6 (s), 112.3 
(s), 91.1 (d, J = 269.4 Hz), 79.9 (s), 73.6 (d, J = 3.5 Hz), 55.2 (d, J = 19.5 Hz), 53.5 (s), 52.7 (d, J = 5.7 Hz), 
49.7 (d, J = 54.1 Hz), 27.7 (s), 25.7 (s); 19F NMR (500 MHz, CDCl3) δ = -140.8 (dt, J = 6.4, 3.5 Hz); νmax




To a solution of endoperoxide IV-47 (39 mg, 0.150 mmol, 1.0 equiv.) in CH2Cl2 (3.0 mL) and MeOH (1.5 
mL) was added thiourea (13 mg, 0.168 mmol, 1.1 equiv.).  The solution was stirred for 16 h and filtered.  
The solvent was then removed, and the crude product purified by column chromatography (50% 
EtOAc, 50% petroleum ether) to give IV-49 as a colourless oil (32 mg, 0.122 mmol, 81%).
Rf = 0.43 (50% EtOAc, 50% petroleum ether); [α]D25 = -23 (CH2Cl2, c. 1 g/100 mL); 1H NMR (500 MHz, 
CD3OD) δ = 5.64 (1H, ddd, J = 12.2, 6.1, 1.0 Hz), 5.01 (1H, dd, J = 5.6, 2.3 Hz), 4.44 (1H, dd, J = 6.1, 4.3 
Hz), 4.18 (1H, dd, J = 10.5, 2.4, 1.0 Hz), 3.80 (3H, s), 1.34 (3H, s), 1.24 (3H, s); 13C NMR (126 MHz,CD3OD) 
δ = 173.8 (s), 164.6 (d, J = 271.7 Hz), 110.8 (s), 106.8 (d, J = 13.6 Hz), 86.7 (d, J = 1.4 Hz), 82.6 (d, J = 8.1 
Hz), 70.0 (d, J = 11.5 Hz), 68.4 (d, J = 27.6 Hz), 53.1 (s), 27.1 (s), 25.5 (s); 19F NMR (500 MHz,CD3OD) δ = 
-109.1 (tt, J = 10.2, 5.0 Hz); νmax (film) 3414, 2991, 2958, 1736, 1691, 1377, 1261, 1162, 1046, 728 cm-





To a solution of endoperoxide IV-47 (77 mg, 0.296 mmol) in CH2Cl2 (5.0 mL) was added DIPEA (10 μL).  
The solution was stirred for 20 h and the solvent removed under vacuum to give a crude product, 
which was purified by column chromatography (30% EtOAc, 70% petroleum ether) to give IV-50 as a 
colourless oil (8 mg, 30.8 μmol, 13%).
Rf = 0.13 (30% EtOAc, 70% petroleum ether); [α]D26 = -60 (CH2Cl2, c. 0.333 g/100 mL); 1H NMR (500 
MHz, CDCl3) δ = 6.49 (1H, dd, J = 11.9, 4.7 Hz), 4.99 (1H, d, J = 3.6 Hz), 4.91 (1H, q, J = 5.5 Hz), 3.85 (3H, 
s), 2.84 (1H, d, J = 7.1 Hz, OH), 1.41 (3H, s), 1.41 (3H, s); 13C NMR (126 MHz, CDCl3) δ = 185.7 (d, J = 20.3 
Hz), 170.0 (s), 152.6 (d, J = 271.1 Hz), 123.0 (d, J = 13.8 Hz), 113.0 (s), 86.7 (d, J = 1.5 Hz), 77.2 (apparent 
s), 67.5 (d, J = 9.1 Hz), 53.4 (s), 28.0 (s), 26.4 (s); 19F NMR (500 MHz, CDCl3) δ = -127.7 (ddd, J = 12.2, 
5.5, 4.0 Hz); νmax (film) 3451, 2994, 2957, 2854, 1741, 1708, 1377, 1259, 1225, 1015, 729 cm-1; HRMS 
(ESI+) m/z calculated (C11H13O6FNa)+ 283.0588, found 283.0585.
Methyl (3aR,4R,7aS)-4-((tert-butyldimethylsilyl)oxy)-6-fluoro-2,2-dimethyl-7-oxo-7,7a-
dihydrobenzo[d][1,3]dioxole-3a(4H)-carboxylate IV-54
To a solution of endoperoxide IV-47 (34 mg, 0.131 mmol, 1.0 equiv.) and DMAP (4 mg) in anhydrous 
CH2Cl2 (5.0 mL) was slowly added NEt3 (0.05 mL, 0.361 mmol, 3.6 equiv.) and TBDMSOTf (0.04 mL, 1.74 
mmol, 1.3 equiv.) at 0oC.  The solution was allowed to warm to room temperature over 16 h.  The 
reaction was quenched with water (10 mL) and the product extracted with CH2Cl2 (3 x 10 mL).  Organic 
layers were combined, dried over MgSO4, and the solvent removed under vacuum to give an orange 
oil.  This oil was purified by column chromatography (5% EtOAc, 95% petroleum ether) to give IV-54 as
a colourless oil (14 mg, 29.8 μmol, 23%).
Rf = 0.35 (5% EtOAc, 95% petroleum ether); [α]D25 = +112 (CH2Cl2, c. 0.5 g/100 mL ); 1H NMR (500 MHz, 
CDCl3) δ = 4.94 (1H, dd, J = 5.8, 2.0 Hz), 4.83 (1H, dd, J = 11.4, 2.0 Hz), 3.74 (3H, s), 1.53 (3H, s), 1.48 
(3H, s), 0.94 (9H, s), 0.86 (9H, s), 0.16 (3H, s), 0.16 (3H, s), 0.09 (3H, s), 0.07 (3H, s); 13C NMR (126 MHz, 
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CDCl3) δ = 169.3 (s), 153.9 (d, J = 259.8 Hz), 135.8 (d, J = 7.7 Hz), 119.9 (d, J = 30.7 Hz), 117.5 (s), 102.2 
(d, J = 16.3 Hz), 90.0 (s), 75.3 (d, J = 8.6 Hz), 52.2 (s), 27.9 (s), 26.4 (s), 18.4 (s), 18.2 (s), -4.6 (d, J = 0.8 
Hz), -4.7 (s), -4.8 (d, J = 1.2 Hz), -5.0 (s); 19F NMR (500 MHz, CDCl3) δ = -126.9 (dd, J = 11.4, 5.8 Hz); νmax
(film) 2954, 2930, 2858, 1760, 1737, 1698, 1655, 1250, 1117, 943 cm-1; HRMS (ESI+) m/z calculated 
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All anhydrous reactions were carried out under an atmosphere of N2 or argon, through the use of a 
Schlenk line, unless otherwise stated. Anhydrous solvents were either purchased from Fisher Scientific 
or Sigma-Aldrich, or purified through anhydrous alumina columns using an Innovative Technology Inc. 
PS-400-7 solvent purification system. Thin layer chromatography (TLC) was carried out on aluminium 
plates coated with silica gel (Alugram®SIL G/UV 254 nm), and visualisation was achieved with UV light 
or KMnO4, ceric ammonium molybdate and iodine dips, followed by gentle heating. Solvents were 
removed using Büchi rotary evaporators and under vacuum on a Schlenk line. Flash column 
chromatography was carried out using Davisil LC 60 Å silica gel (35-70 micron) purchased from Sigma-
Aldrich. 
NMR spectra were run in CDCl3 unless otherwise stated, on Bruker Avance 250, Bruker Avance 300, 
Bruker Avance 400, Bruker Avance 500 II+ or Agilent A500a instruments. IR spectra were recorded on 
a Perkin-Elmer 1600 FT-IR instrument. Capillary melting points were recorded on a Büchi 535 melting 
point apparatus and are uncorrected. High resolution mass spectrometry (HRMS) was carried out using 
a micrOTOF ESI-TOF spectrometer coupled to an Agilent 1200 LC system for autosampling. X-ray 

























































































Crystal structure data for II-30
Table 1.  Crystal data and structure refinement for s15sel3.
Identification code s15sel3





Space group P 21
Unit cell dimensions a = 6.87780(10) Å = 90°.
b = 9.14210(10) Å = 108.648(2)°.
c = 7.55690(10) Å  = 90°.
Volume 450.214(11) Å3
Z 2
Density (calculated) 1.381 Mg/m3
Absorption coefficient 0.940 mm-1
F(000) 200
Crystal size 0.400 x 0.200 x 0.100 mm3
Theta range for data collection 6.181 to 72.443°.
Index ranges -8<=h<=8, -11<=k<=9, -9<=l<=9
Reflections collected 5256
Independent reflections 1501 [R(int) = 0.0202]
Completeness to theta = 67.684° 99.9 % 
Absorption correction Semi-empirical from equivalents
Max. and min. transmission 1.00000 and 0.69487
Refinement method Full-matrix least-squares on F2
Data / restraints / parameters 1501 / 1 / 125
Goodness-of-fit on F2 1.113
Final R indices [I>2sigma(I)] R1 = 0.0256, wR2 = 0.0661
R indices (all data) R1 = 0.0258, wR2 = 0.0663
Absolute structure parameter -0.02(11)
Extinction coefficient n/a
Largest diff. peak and hole 0.138 and -0.184 e.Å-3
Appendix
200
Table 2.  Atomic coordinates  ( x 104) and equivalent  isotropic displacement parameters (Å2x 103)
for s15sel3.  U(eq) is defined as one third of the trace of the orthogonalized Uij tensor.
________________________________________________________________________________ 
x y z U(eq)
________________________________________________________________________________ 
N 6174(2) 6666(2) 7381(2) 19(1)
O(1) 6344(2) 3698(2) 5510(2) 22(1)
O(2) 7533(2) 7640(2) 8620(2) 26(1)
O(3) 2657(2) 4930(2) 3658(2) 27(1)
O(4) 2025(2) 5464(2) 6296(2) 28(1)
C(1) 5148(3) 4207(2) 6606(2) 19(1)
C(2) 6495(2) 5345(2) 7914(2) 19(1)
C(3) 8160(3) 4809(2) 9613(2) 28(1)
C(4) 7409(3) 3587(2) 10613(2) 28(1)
C(5) 6439(3) 2365(2) 9253(2) 27(1)
C(6) 4579(3) 2944(2) 7705(2) 24(1)
C(7) 3163(3) 4915(2) 5340(2) 20(1)






















































































Table 5.   Anisotropic displacement parameters  (Å2x 103) for s15sel3.  The anisotropic
displacement factor exponent takes the form:  -22[ h2 a*2U11 + ...  + 2 h k a* b* U12 ]
______________________________________________________________________________ 
U11 U22 U33 U23 U13 U12
______________________________________________________________________________ 
N 19(1) 20(1) 18(1) -1(1) 6(1) -3(1)
O(1) 21(1) 24(1) 23(1) -4(1) 10(1) 0(1)
O(2) 31(1) 19(1) 24(1) -1(1) 4(1) -7(1)
O(3) 33(1) 24(1) 20(1) -1(1) 4(1) 7(1)
O(4) 18(1) 41(1) 25(1) -5(1) 6(1) 3(1)
C(1) 18(1) 20(1) 19(1) 0(1) 7(1) -1(1)
C(2) 18(1) 22(1) 18(1) 1(1) 6(1) 0(1)
C(3) 24(1) 26(1) 26(1) 4(1) -1(1) -3(1)
C(4) 31(1) 27(1) 22(1) 6(1) 3(1) 0(1)
C(5) 34(1) 22(1) 25(1) 6(1) 10(1) -2(1)
C(6) 26(1) 24(1) 24(1) 2(1) 9(1) -6(1)
C(7) 20(1) 17(1) 22(1) -3(1) 6(1) -3(1)




Table 6.   Hydrogen coordinates ( x 104) and isotropic  displacement parameters (Å2x 10 3)
for s15sel3.
________________________________________________________________________________ 
x y z U(eq)
________________________________________________________________________________ 
H(1) 5710(40) 3040(30) 4790(30) 33
H(2) 7320(40) 8480(30) 8060(30) 39
H(3A) 8662 5635 10487 33
H(3B) 9324 4444 9235 33
H(4A) 8578 3194 11642 33
H(4B) 6389 3984 11160 33
H(5A) 6009 1562 9926 32
H(5B) 7456 1969 8703 32
H(6A) 3540 3293 8260 29
H(6B) 3960 2137 6833 29
H(8A) 386 6936 4453 47
H(8B) -632 6492 6007 47

































Table 8.  Hydrogen bonds for s15sel3  [Å and °].
____________________________________________________________________________ 
D-H...A d(D-H) d(H...A) d(D...A) <(DHA)
____________________________________________________________________________ 
O(1)-H(1)...N#1 0.83(3) 2.14(3) 2.967(2) 170(2)
O(2)-H(2)...O(3)#2 0.87(3) 1.86(3) 2.6866(18) 159(3)
____________________________________________________________________________ 
Symmetry transformations used to generate equivalent atoms: 


























































































Crystal structure data for II-48
Table 1.  Crystal data and structure refinement for s18sel8.
Identification code s18sel8






Unit cell dimensions a = 7.96710(10) Å = 90°.
b = 8.28570(10) Å = 90°.
c = 26.8889(2) Å  = 90°.
Volume 1775.02(3) Å3
Z 4
Density (calculated) 1.229 Mg/m3
Absorption coefficient 1.340 mm-1
F(000) 712
Crystal size 0.220 x 0.200 x 0.080 mm3
Theta range for data collection 3.287 to 73.054°.
Index ranges -9<=h<=7, -10<=k<=10, -33<=l<=33
Reflections collected 35371
Independent reflections 3550 [R(int) = 0.0345]
Completeness to theta = 67.684° 100.0 % 
Absorption correction Semi-empirical from equivalents
Max. and min. transmission 1.00000 and 0.86421
Refinement method Full-matrix least-squares on F2
Data / restraints / parameters 3550 / 0 / 206
Goodness-of-fit on F2 1.060
Final R indices [I>2sigma(I)] R1 = 0.0246, wR2 = 0.0657
R indices (all data) R1 = 0.0247, wR2 = 0.0659
Absolute structure parameter 0.003(7)
Extinction coefficient n/a
Largest diff. peak and hole 0.205 and -0.241 e.Å-3
Appendix
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Table 2.  Atomic coordinates  ( x 104) and equivalent  isotropic displacement parameters (Å2x 103)
for s18sel8.  U(eq) is defined as one third of  the trace of the orthogonalized Uij tensor.
________________________________________________________________________________ 
x y z U(eq)
________________________________________________________________________________ 
Si 6554(1) 5542(1) 3300(1) 17(1)
O(1) 3528(2) 3495(1) 3914(1) 19(1)
O(2) 2993(2) 1969(1) 4608(1) 23(1)
O(3) 1536(2) 5461(1) 4557(1) 20(1)
O(4) 2517(2) 5545(2) 5377(1) 24(1)
O(5) 6452(2) 5785(1) 3909(1) 21(1)
C(1) 2779(2) 2019(2) 4078(1) 21(1)
C(2) 943(3) 2013(3) 3940(1) 30(1)
C(3) 3729(3) 604(2) 3857(1) 32(1)
C(4) 3503(2) 3502(2) 4786(1) 18(1)
C(5) 2021(2) 4528(2) 4970(1) 20(1)
C(6) 3527(2) 6804(2) 5227(1) 24(1)
C(7) 3899(2) 7092(2) 4755(1) 21(1)
C(8) 3143(2) 6009(2) 4365(1) 17(1)
C(9) 4137(2) 4430(2) 4323(1) 16(1)
C(10) 6027(2) 4645(2) 4283(1) 20(1)
C(11) 4504(2) 6054(3) 3007(1) 30(1)
C(12) 7129(3) 3425(2) 3143(1) 29(1)
C(13) 8210(2) 7015(2) 3090(1) 22(1)
C(14) 8354(3) 6991(3) 2519(1) 35(1)
C(15) 9914(2) 6565(3) 3313(1) 35(1)













































































































































































Table 5.   Anisotropic displacement parameters  (Å2x 103) for s18sel8.  The anisotropic
displacement factor exponent takes the form:  -22[ h2 a*2U11 + ...  + 2 h k a* b* U12 ]
______________________________________________________________________________ 
U11 U22 U33 U23 U13 U12
______________________________________________________________________________ 
Si 14(1) 23(1) 15(1) 0(1) 0(1) 1(1)
O(1) 26(1) 17(1) 13(1) 1(1) -1(1) -3(1)
O(2) 40(1) 15(1) 15(1) 1(1) -1(1) -3(1)
O(3) 16(1) 22(1) 23(1) 0(1) 0(1) 1(1)
O(4) 29(1) 24(1) 18(1) -4(1) 4(1) -2(1)
O(5) 22(1) 24(1) 16(1) 1(1) 2(1) -3(1)
C(1) 31(1) 16(1) 15(1) 1(1) 1(1) -3(1)
C(2) 31(1) 35(1) 23(1) 1(1) 0(1) -10(1)
C(3) 52(1) 21(1) 24(1) -4(1) -1(1) 7(1)
C(4) 23(1) 16(1) 15(1) 1(1) -1(1) -2(1)
C(5) 21(1) 20(1) 18(1) -1(1) 3(1) -3(1)
C(6) 24(1) 22(1) 26(1) -6(1) 0(1) -1(1)
C(7) 22(1) 16(1) 26(1) -1(1) -1(1) -2(1)
C(8) 17(1) 17(1) 18(1) 2(1) 1(1) 0(1)
C(9) 19(1) 16(1) 12(1) 1(1) -1(1) 1(1)
C(10) 18(1) 24(1) 16(1) 2(1) 1(1) 2(1)
C(11) 20(1) 44(1) 26(1) 8(1) -4(1) 0(1)
C(12) 31(1) 29(1) 28(1) -7(1) 2(1) 1(1)
C(13) 20(1) 29(1) 18(1) 0(1) 3(1) -2(1)
C(14) 40(1) 46(1) 21(1) 2(1) 10(1) -8(1)
C(15) 16(1) 50(1) 39(1) 2(1) 2(1) -2(1)




Table 6.   Hydrogen coordinates ( x 104) and isotropic  displacement parameters (Å2x 10 3)
for s18sel8.
________________________________________________________________________________ 
x y z U(eq)
________________________________________________________________________________ 
H(2A) 829 2057 3578 45
H(2B) 391 2954 4089 45
H(2C) 417 1024 4065 45
H(3A) 3673 657 3493 49
H(3B) 3223 -408 3971 49
H(3C) 4904 648 3963 49
H(4) 4398 3405 5044 21
H(5) 1076 3811 5075 24
H(6) 3978 7500 5474 29
H(7) 4621 7957 4665 26
H(8) 3027 6566 4037 21
H(10A) 6476 5014 4607 23
H(10B) 6553 3594 4203 23
H(11A) 4597 5947 2645 45
H(11B) 4200 7167 3091 45
H(11C) 3636 5317 3130 45
H(12A) 7338 3339 2784 44
H(12B) 6208 2702 3236 44
H(12C) 8145 3119 3325 44
H(14A) 7270 7284 2372 53
H(14B) 8673 5907 2408 53
H(14C) 9210 7768 2413 53
H(15A) 10280 5523 3179 52
H(15B) 9813 6489 3676 52
H(15C) 10741 7396 3228 52
H(16A) 8604 9493 3141 48
H(16B) 7664 8774 3618 48



















































































































Crystal structure data for II-69
Table 1.  Crystal data and structure refinement for s15sel4.
Identification code s15sel4






Unit cell dimensions a = 7.21530(10) Å = 90°.
b = 7.08780(10) Å = 92.9010(10)°.
c = 12.35680(10) Å  = 90°.
Volume 631.124(13) Å3
Z 2
Density (calculated) 1.422 Mg/m3
Absorption coefficient 0.952 mm-1
F(000) 288
Crystal size 0.200 x 0.200 x 0.050 mm3
Theta range for data collection 3.582 to 72.581°.
Index ranges -8<=h<=8, -8<=k<=8, -13<=l<=15
Reflections collected 12567
Independent reflections 2502 [R(int) = 0.0213]
Completeness to theta = 67.684° 100.0 % 
Absorption correction Semi-empirical from equivalents
Max. and min. transmission 1.00000 and 0.84877
Refinement method Full-matrix least-squares on F2
Data / restraints / parameters 2502 / 1 / 200
Goodness-of-fit on F2 1.078
Final R indices [I>2sigma(I)] R1 = 0.0235, wR2 = 0.0614
R indices (all data) R1 = 0.0236, wR2 = 0.0614
Absolute structure parameter -0.02(4)
Extinction coefficient n/a
Largest diff. peak and hole 0.145 and -0.176 e.Å-3
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Table 2.  Atomic coordinates  ( x 104) and equivalent  isotropic displacement parameters (Å2x 103)
for s15sel4.  U(eq) is defined as one third of  the trace of the orthogonalized Uij tensor.
________________________________________________________________________________ 
x y z U(eq)
________________________________________________________________________________ 
C(1) 7485(2) 6950(2) 7540(1) 17(1)
C(2) 6382(2) 5379(2) 6958(1) 13(1)
C(3) 6661(2) 3508(2) 7615(1) 16(1)
C(4) 4753(2) 2601(2) 7793(1) 15(1)
C(5) 3673(2) 2357(2) 6691(1) 14(1)
C(6) 3301(2) 4339(2) 6164(1) 14(1)
C(7) 4290(2) 5861(2) 6865(1) 13(1)
C(8) 3517(2) 5767(2) 7975(1) 14(1)
C(9) 2623(2) 7216(2) 8496(1) 18(1)
C(10) 1942(2) 6880(3) 9519(1) 22(1)
C(11) 2159(2) 5124(3) 10004(1) 25(1)
C(12) 3054(2) 3666(3) 9480(1) 22(1)
C(13) 3732(2) 3995(2) 8463(1) 15(1)
O(1) 7398(2) 8652(2) 6932(1) 22(1)
O(2) 6997(2) 5211(2) 5889(1) 18(1)
O(3) 7909(2) 2344(2) 7063(1) 25(1)
O(4) 1989(2) 1341(2) 6836(1) 19(1)
O(5) 1364(2) 4793(2) 6131(1) 17(1)

























































































































Table 5.   Anisotropic displacement parameters  (Å2x 103) for s15sel4.  The anisotropic
displacement factor exponent takes the form:  -22[ h2 a*2U11 + ...  + 2 h k a* b* U12 ]
______________________________________________________________________________ 
U11 U22 U33 U23 U13 U12
______________________________________________________________________________ 
C(1) 16(1) 13(1) 21(1) -2(1) 0(1) -3(1)
C(2) 13(1) 10(1) 16(1) -1(1) 1(1) -1(1)
C(3) 14(1) 12(1) 23(1) 1(1) -1(1) 0(1)
C(4) 16(1) 12(1) 18(1) 2(1) 0(1) -1(1)
C(5) 13(1) 12(1) 18(1) -2(1) 1(1) -2(1)
C(6) 14(1) 14(1) 15(1) -1(1) 0(1) 0(1)
C(7) 13(1) 10(1) 14(1) 1(1) 0(1) -1(1)
C(8) 12(1) 16(1) 14(1) -2(1) -1(1) -3(1)
C(9) 15(1) 17(1) 20(1) -3(1) -2(1) 1(1)
C(10) 19(1) 29(1) 19(1) -8(1) 1(1) 2(1)
C(11) 24(1) 36(1) 15(1) -1(1) 3(1) -2(1)
C(12) 24(1) 23(1) 18(1) 4(1) 1(1) -3(1)
C(13) 15(1) 15(1) 16(1) 0(1) -1(1) -2(1)
O(1) 24(1) 11(1) 32(1) -1(1) 7(1) -3(1)
O(2) 19(1) 18(1) 18(1) -2(1) 6(1) 2(1)
O(3) 19(1) 10(1) 48(1) 2(1) 10(1) 2(1)
O(4) 15(1) 13(1) 30(1) -1(1) 1(1) -4(1)
O(5) 13(1) 16(1) 22(1) -1(1) -4(1) 1(1)




Table 6.   Hydrogen coordinates ( x 104) and isotropic  displacement parameters (Å2x 10 3)
for s15sel4.
________________________________________________________________________________ 
x y z U(eq)
________________________________________________________________________________ 
H(1A) 6980 7171 8259 20
H(1B) 8796 6554 7654 20
H(3) 7253 3829 8341 19
H(4) 4901 1364 8177 18
H(5) 4456 1607 6203 17
H(6) 3765 4363 5415 17
H(7) 4085 7140 6538 15
H(9) 2477 8418 8163 21
H(10A) 1327 7860 9883 27
H(11) 1694 4912 10699 30
H(12) 3199 2464 9814 26
H(1) 8140(40) 8440(40) 6430(20) 43(7)
H(2A) 7580(40) 4250(40) 5870(20) 35(7)
H(3A) 7650(30) 1140(40) 7160(20) 35(7)
H(4A) 1140(40) 2130(40) 6935(19) 31(6)
H(5A) 890(40) 4210(40) 5530(20) 43(7)
H(6A) -780(40) 2330(40) 4180(20) 36(7)



























































Table 8.  Hydrogen bonds for s15sel4  [Å and °].
____________________________________________________________________________ 
D-H...A d(D-H) d(H...A) d(D...A) <(DHA)
____________________________________________________________________________ 
O(1)-H(1)...O(6)#1 0.85(3) 1.94(3) 2.7506(18) 160(3)
O(2)-H(2A)...O(3) 0.80(3) 2.01(3) 2.5626(18) 126(2)
O(2)-H(2A)...O(6)#2 0.80(3) 2.50(3) 3.0148(16) 123(2)
O(3)-H(3A)...O(1)#3 0.89(3) 1.79(3) 2.6471(17) 161(2)
O(4)-H(4A)...O(3)#4 0.85(3) 2.35(3) 3.0555(16) 141(2)
O(4)-H(4A)...O(5) 0.85(3) 2.14(3) 2.6281(17) 116(2)
O(5)-H(5A)...O(6) 0.90(3) 1.79(3) 2.6698(16) 168(3)
O(6)-H(6A)...O(5)#5 0.85(3) 1.88(3) 2.7322(17) 174(3)
O(6)-H(6B)...O(4)#6 0.88(3) 1.88(3) 2.7392(17) 165(3)
____________________________________________________________________________ 
Symmetry transformations used to generate equivalent atoms: 











































































































Crystal structure data for III-52
Table 1.  Crystal data and structure refinement for s16sel2.
Identification code s16sel2






Unit cell dimensions a = 6.69840(10) Å = 90°.
b = 11.9848(2) Å = 90°.
c = 21.2306(3) Å  = 90°.
Volume 1704.37(5) Å3
Z 4
Density (calculated) 1.401 Mg/m3
Absorption coefficient 0.862 mm-1
F(000) 760
Crystal size 0.300 x 0.200 x 0.080 mm3
Theta range for data collection 4.165 to 73.004°.
Index ranges -8<=h<=6, -14<=k<=14, -26<=l<=26
Reflections collected 26309
Independent reflections 3394 [R(int) = 0.0366]
Completeness to theta = 67.684° 99.8 % 
Absorption correction Semi-empirical from equivalents
Max. and min. transmission 1.00000 and 0.68979
Refinement method Full-matrix least-squares on F2
Data / restraints / parameters 3394 / 1 / 240
Goodness-of-fit on F2 1.124
Final R indices [I>2sigma(I)] R1 = 0.0460, wR2 = 0.1039
R indices (all data) R1 = 0.0475, wR2 = 0.1050
Absolute structure parameter 0.05(6)
Extinction coefficient n/a
Largest diff. peak and hole 0.232 and -0.262 e.Å-3
Appendix
336
Table 2.  Atomic coordinates  ( x 104) and equivalent  isotropic displacement parameters (Å2x 103)
for s16sel2.  U(eq) is defined as one third of  the trace of the orthogonalized Uij tensor.
________________________________________________________________________________ 
x y z U(eq)
________________________________________________________________________________ 
C(1) 8447(6) 7547(3) 2237(2) 24(1)
C(2) 8056(8) 7088(3) 1208(2) 39(1)
C(3) 10189(10) 7018(4) 980(3) 69(2)
C(4) 6545(11) 7223(4) 698(2) 74(2)
C(5) 7786(5) 6328(3) 2223(1) 18(1)
C(6) 9349(5) 5537(3) 2541(2) 20(1)
C(7) 8280(5) 4812(3) 3035(1) 19(1)
C(8) 6622(5) 4128(3) 2733(2) 24(1)
C(9) 5068(6) 4932(3) 2441(2) 27(1)
C(10) 5750(5) 6134(3) 2529(1) 18(1)
C(11) 6743(5) 5316(3) 4076(1) 20(1)
C(12) 3986(5) 6038(3) 4755(2) 20(1)
C(13) 4937(6) 6560(3) 5254(2) 24(1)
C(14) 3917(6) 6675(3) 5820(2) 28(1)
C(15) 2008(6) 6269(3) 5880(2) 29(1)
C(16) 1079(6) 5743(3) 5378(2) 29(1)
C(17) 2062(6) 5618(3) 4810(2) 26(1)
C(18) 4463(5) 6503(3) 3616(2) 19(1)
N(1) 7446(4) 5608(2) 3486(1) 18(1)
N(2) 5020(4) 5950(2) 4166(1) 21(1)
N(3) 6027(4) 6351(2) 3203(1) 16(1)
O(1) 7791(5) 7976(2) 1647(1) 32(1)
O(2) 7588(4) 6088(2) 1565(1) 23(1)
O(3) 10303(4) 4848(2) 2095(1) 32(1)
O(4) 7505(4) 4661(2) 4439(1) 30(1)





































































































































































Symmetry transformations used to generate equivalent atoms: 
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Table 5.   Anisotropic displacement parameters  (Å2x 103) for s16sel2.  The anisotropic
displacement factor exponent takes the form:  -22[ h2 a*2U11 + ...  + 2 h k a* b* U12 ]
______________________________________________________________________________ 
U11 U22 U33 U23 U13 U12
______________________________________________________________________________ 
C(1) 32(2) 17(2) 25(2) -1(1) 4(2) -3(1)
C(2) 76(3) 20(2) 21(2) 3(1) 15(2) 2(2)
C(3) 105(5) 34(2) 67(3) -3(2) 58(4) -11(3)
C(4) 163(7) 38(3) 21(2) 0(2) -29(3) 23(3)
C(5) 24(2) 16(1) 14(1) -2(1) 0(1) 0(1)
C(6) 17(2) 23(2) 22(2) -2(1) -1(1) 1(1)
C(7) 19(2) 18(2) 18(1) -3(1) 1(1) 3(1)
C(8) 30(2) 17(2) 25(2) -3(1) 0(1) -4(1)
C(9) 31(2) 26(2) 26(2) 1(1) -7(2) -7(2)
C(10) 19(2) 21(2) 12(1) -1(1) -4(1) 2(1)
C(11) 20(2) 22(2) 17(1) -2(1) -2(1) 0(1)
C(12) 23(2) 21(2) 15(1) 2(1) 1(1) 1(1)
C(13) 25(2) 26(2) 21(2) 1(1) -2(2) -4(2)
C(14) 40(2) 26(2) 18(2) 1(1) -2(2) -1(2)
C(15) 36(2) 30(2) 20(2) 6(1) 11(2) 1(2)
C(16) 25(2) 32(2) 31(2) 4(2) 8(2) -6(2)
C(17) 30(2) 28(2) 21(2) -2(1) 1(1) 0(2)
C(18) 16(2) 25(2) 17(2) 0(1) 0(1) 1(1)
N(1) 19(1) 19(1) 15(1) 0(1) -3(1) 7(1)
N(2) 24(1) 25(1) 14(1) 1(1) 1(1) 3(1)
N(3) 14(1) 20(1) 12(1) 1(1) 0(1) 5(1)
O(1) 56(2) 16(1) 22(1) 3(1) 12(1) 4(1)
O(2) 36(1) 21(1) 12(1) -1(1) 2(1) 0(1)
O(3) 38(2) 37(1) 22(1) -2(1) 7(1) 15(1)
O(4) 39(2) 33(1) 19(1) 7(1) -2(1) 9(1)




Table 6.   Hydrogen coordinates ( x 104) and isotropic  displacement parameters (Å2x 10 3)
for s16sel2.
________________________________________________________________________________ 
x y z U(eq)
________________________________________________________________________________ 
H(1A) 7812 7951 2590 29
H(1B) 9915 7606 2277 29
H(3A) 11084 6933 1342 103
H(3B) 10530 7702 751 103
H(3C) 10336 6374 699 103
H(4A) 5201 7200 880 111
H(4B) 6691 6616 391 111
H(4C) 6748 7941 486 111
H(6) 10380 6002 2758 24
H(7) 9258 4309 3249 22
H(8A) 5975 3652 3054 29
H(8B) 7185 3639 2402 29
H(9A) 4915 4769 1986 33
H(9B) 3756 4823 2647 33
H(10) 4740 6659 2349 21
H(13) 6261 6834 5210 28
H(14) 4541 7035 6166 34
H(15) 1319 6350 6268 35
H(16) -241 5466 5425 35
H(17) 1436 5253 4465 32





















































































Table 8.  Hydrogen bonds for s16sel2  [Å and °].
____________________________________________________________________________ 
D-H...A d(D-H) d(H...A) d(D...A) <(DHA)
____________________________________________________________________________ 
O(3)-H(3)...O(2) 0.84(2) 2.08(4) 2.604(4) 121(4)
____________________________________________________________________________ 

















































Crystal structure data for III-41
Table 1.  Crystal data and structure refinement for s16sel13.
Identification code s16sel13






Unit cell dimensions a = 15.7782(8) Å = 90°.
b = 8.2483(5) Å = 91.280(5)°.
c = 28.5263(19) Å  = 90°.
Volume 3711.6(4) Å3
Z 4
Density (calculated) 1.344 Mg/m3
Absorption coefficient 0.816 mm-1
F(000) 1588
Crystal size 0.230 x 0.090 x 0.030 mm3
Theta range for data collection 3.171 to 66.864°.
Index ranges -18<=h<=18, -9<=k<=6, -33<=l<=33
Reflections collected 9558
Independent reflections 4650 [R(int) = 0.0551]
Completeness to theta = 66.864° 99.1 % 
Refinement method Full-matrix least-squares on F2
Data / restraints / parameters 4650 / 56 / 539
Goodness-of-fit on F2 1.040
Final R indices [I>2sigma(I)] R1 = 0.0732, wR2 = 0.1927
R indices (all data) R1 = 0.0859, wR2 = 0.2065
Absolute structure parameter 0.0(4)
Extinction coefficient 0.00092(18)
Largest diff. peak and hole 0.436 and -0.290 e.Å-3
Appendix
365
Table 2.  Atomic coordinates  ( x 104) and equivalent  isotropic displacement parameters (Å2x 103)
for s16sel13.  U(eq) is defined as one third of  the trace of the orthogonalized Uij tensor.
________________________________________________________________________________ 
x y z U(eq)
________________________________________________________________________________ 
N(1) 10665(3) 4449(7) 5513(2) 40(1)
N(2) 9983(3) 5610(7) 5578(2) 47(1)
N(3) 9480(3) 3130(7) 5666(2) 40(1)
N(4) 5010(3) 4456(7) 5582(2) 36(1)
N(5) 5705(3) 5584(7) 5552(2) 44(1)
N(6) 4562(3) 6929(7) 5717(2) 44(1)
O(1) 12028(3) 3945(7) 6796(2) 63(2)
O(2) 10725(3) 4164(6) 6467(2) 48(1)
O(3) 10531(4) 7775(7) 6585(2) 68(2)
O(4) 10730(3) 1669(6) 5600(2) 51(1)
O(5) 8592(3) 5363(7) 5795(2) 66(2)
O(6) 5109(3) 2013(8) 6902(2) 69(2)
O(7) 5143(3) 4423(7) 6532(2) 51(1)
O(8) 7005(6) 4340(20) 6519(4) 53(4)
O(8A) 6575(9) 6039(17) 6414(4) 41(3)
O(8B) 7230(7) 3686(17) 6296(5) 31(3)
O(9) 3604(3) 4798(6) 5779(2) 48(1)
O(10) 5836(4) 8308(7) 5698(3) 91(3)
C(1) 11178(5) 3464(10) 6862(3) 55(2)
C(2) 11122(6) 1653(11) 6824(3) 70(2)
C(3) 10828(6) 4117(13) 7309(3) 74(2)
C(4) 12003(4) 5532(11) 6601(3) 56(2)
C(5) 11224(4) 5437(8) 6264(2) 39(1)
C(6) 10642(4) 6959(9) 6249(3) 45(2)
C(7) 10268(4) 7194(8) 5767(3) 45(2)
C(8) 10992(4) 7729(9) 5450(3) 48(2)
C(9) 11741(4) 6514(8) 5516(3) 45(2)
C(10) 11434(4) 5017(8) 5762(2) 39(1)
C(11) 10340(4) 2945(8) 5601(2) 41(2)
C(12) 9274(4) 4761(10) 5701(3) 49(2)
C(13) 8929(4) 1831(9) 5806(3) 44(2)
C(14) 8722(6) 1655(16) 6258(3) 99(4)
C(15) 8206(7) 442(16) 6397(3) 101(4)
C(16) 7864(5) -644(12) 6073(3) 63(2)
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C(17) 8064(5) -453(9) 5604(3) 54(2)
C(18) 8603(4) 805(9) 5475(3) 45(2)
C(21) 4913(5) 3651(13) 6973(3) 63(2)
C(22) 3990(4) 3870(12) 7038(3) 64(2)
C(23) 5458(5) 4371(17) 7366(3) 83(3)
C(24) 5831(6) 1957(14) 6614(3) 81(3)
C(25) 5694(4) 3390(10) 6284(3) 50(2)
C(26) 6517(4) 4388(14) 6193(3) 69(3)
C(27) 6527(4) 4875(10) 5676(3) 50(2)
C(28) 6647(4) 3370(9) 5386(3) 47(2)
C(29) 5934(4) 2142(9) 5504(2) 43(2)
C(30) 5289(4) 2960(8) 5809(2) 42(2)
C(31) 4305(4) 5321(8) 5713(2) 35(1)
C(32) 5422(4) 7080(9) 5667(3) 52(2)
C(33) 4005(4) 8273(8) 5820(3) 42(2)
C(34) 3868(5) 8622(10) 6283(3) 60(2)
C(35) 3331(6) 9931(12) 6391(3) 72(3)
C(36) 2962(5) 10789(10) 6029(3) 58(2)
C(37) 3100(4) 10422(9) 5580(3) 51(2)
C(38) 3633(4) 9134(9) 5464(3) 48(2)
C(41) 6626(14) 910(30) 7854(10) 146(11)
C(42) 7385(15) 1720(30) 7734(11) 133(10)
C(43) 7431(10) 3430(20) 7601(7) 83(5)
C(44) 8240(12) 4040(30) 7398(8) 110(7)












































































































































































































































































































































































Table 5.   Anisotropic displacement parameters  (Å2x 103) for s16sel13.  The anisotropic
displacement factor exponent takes the form:  -22[ h2 a*2U11 + ...  + 2 h k a* b* U12 ]
______________________________________________________________________________ 
U11 U22 U33 U23 U13 U12
______________________________________________________________________________ 
N(1) 29(2) 32(3) 60(3) -6(3) 10(2) 8(2)
N(2) 35(3) 38(3) 67(4) -8(3) 5(3) -2(2)
N(3) 38(3) 30(3) 54(3) -6(2) 5(2) -5(2)
N(4) 30(2) 32(3) 46(3) -3(2) 4(2) -2(2)
N(5) 37(3) 35(3) 61(4) -3(3) 14(2) -4(2)
N(6) 39(3) 36(3) 59(3) 6(3) 16(2) 6(3)
O(1) 44(3) 72(4) 72(3) 21(3) -1(2) -5(3)
O(2) 42(2) 47(3) 57(3) 2(2) 10(2) -4(2)
O(3) 86(4) 49(3) 71(4) -21(3) 12(3) 4(3)
O(4) 56(3) 32(3) 66(3) -8(2) 17(2) 0(2)
O(5) 31(2) 52(4) 115(5) -17(3) 12(3) 3(2)
O(6) 65(3) 75(4) 68(4) 23(3) 12(3) 16(3)
O(7) 41(2) 66(3) 45(3) 4(2) 8(2) 9(2)
O(8) 19(5) 119(12) 23(5) -21(7) -5(4) -5(6)
O(8A) 64(9) 34(7) 25(6) -20(5) 12(6) -24(7)
O(8B) 15(6) 32(7) 45(8) 16(6) -11(5) -1(5)
O(9) 36(2) 45(3) 62(3) -2(2) 3(2) 3(2)
O(10) 58(3) 39(3) 178(8) -22(4) 51(4) -15(3)
C(1) 55(4) 60(5) 52(4) 9(3) 8(3) -2(4)
C(2) 76(5) 61(5) 73(6) 14(4) 24(4) -4(4)
C(3) 85(6) 88(7) 49(4) 1(5) 19(4) -13(5)
C(4) 49(4) 66(5) 55(4) 11(4) -4(3) -11(4)
C(5) 28(3) 43(4) 47(3) 0(3) 3(2) -4(3)
C(6) 38(3) 36(4) 60(4) -6(3) 11(3) -7(3)
C(7) 39(3) 26(3) 70(5) -6(3) 7(3) 2(3)
C(8) 42(3) 34(4) 66(5) 3(3) -1(3) 5(3)
C(9) 31(3) 37(4) 67(4) 4(3) 8(3) 1(3)
C(10) 30(3) 27(3) 60(4) -1(3) 7(3) 1(2)
C(11) 44(3) 28(3) 51(4) -10(3) 10(3) 1(3)
C(12) 30(3) 52(5) 64(5) -5(4) 2(3) -9(3)
C(13) 32(3) 46(4) 55(4) -7(3) 9(3) -9(3)
C(14) 88(6) 146(11) 64(6) -36(6) 32(5) -72(7)
C(15) 114(8) 130(11) 60(5) -26(6) 31(5) -69(8)
C(16) 50(4) 70(6) 69(5) -8(4) 13(3) -19(4)
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C(17) 65(5) 35(4) 62(5) -3(3) 2(4) -4(3)
C(18) 52(4) 33(4) 50(4) -10(3) 1(3) -1(3)
C(21) 50(4) 95(7) 45(4) 10(4) 5(3) 10(4)
C(22) 50(4) 69(5) 75(5) 6(4) 17(4) -4(4)
C(23) 60(5) 141(10) 49(4) -3(6) -2(4) 4(6)
C(24) 83(6) 105(8) 55(5) 24(5) 17(4) 41(6)
C(25) 40(3) 62(5) 49(4) 4(4) 8(3) 12(3)
C(26) 36(4) 111(8) 63(5) -27(5) 12(3) 8(4)
C(27) 39(3) 48(4) 62(4) -8(3) 15(3) -3(3)
C(28) 41(3) 51(4) 50(4) -6(3) 12(3) 4(3)
C(29) 46(4) 32(4) 52(4) -3(3) 3(3) 4(3)
C(30) 40(3) 30(3) 55(4) 4(3) 4(3) 2(3)
C(31) 29(3) 35(4) 42(3) -2(3) 3(2) 3(3)
C(32) 52(4) 28(4) 77(5) -10(4) 21(4) -5(3)
C(33) 37(3) 23(3) 65(4) 3(3) 12(3) 2(3)
C(34) 86(5) 47(5) 47(4) 2(3) 8(4) 21(4)
C(35) 90(6) 64(6) 63(5) 1(4) 15(4) 31(5)
C(36) 62(5) 40(4) 71(5) 4(4) 22(4) 10(4)
C(37) 41(3) 38(4) 74(5) 16(4) 10(3) 4(3)
C(38) 41(3) 48(4) 53(4) 5(3) 7(3) 8(3)
C(41) 112(15) 180(20) 146(18) 87(16) -76(14) -16(15)
C(42) 125(13) 136(14) 137(13) 35(11) 9(10) 25(11)
C(43) 80(9) 97(11) 72(9) -9(8) 6(8) 3(8)
C(44) 98(11) 139(13) 92(11) -14(10) -12(9) -7(10)




Table 6.   Hydrogen coordinates ( x 104) and isotropic  displacement parameters (Å2x 10 3)
for s16sel13.
________________________________________________________________________________ 
x y z U(eq)
________________________________________________________________________________ 
H(2A) 10532 1311 6859 104
H(2B) 11476 1154 7071 104
H(2C) 11321 1310 6516 104
H(3A) 10239 3765 7338 111
H(3B) 10852 5304 7305 111
H(3C) 11166 3708 7577 111
H(4A) 12526 5775 6429 68
H(4B) 11924 6364 6846 68
H(7) 9796 8004 5765 54
H(8A) 11180 8838 5536 57
H(8B) 10795 7739 5118 57
H(9A) 11967 6218 5206 54
H(9B) 12203 7026 5704 54
H(10) 11880 4156 5757 47
H(14) 8942 2397 6485 119
H(15) 8077 333 6720 121
H(16) 7502 -1496 6169 75
H(17) 7836 -1172 5373 65
H(18) 8743 944 5156 54
H(22A) 3853 5029 7035 96
H(22B) 3831 3403 7340 96
H(22C) 3675 3323 6784 96
H(23A) 5343 5536 7390 125
H(23B) 6058 4202 7299 125
H(23C) 5323 3840 7663 125
H(24A) 5854 923 6439 97
H(24B) 6361 2084 6803 97
H(27) 6992 5670 5620 59
H(28A) 7209 2887 5458 57
H(28B) 6619 3646 5048 57
H(29A) 5654 1754 5210 52
H(29B) 6181 1194 5670 52
H(30) 4793 2225 5854 50
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H(34) 4129 7996 6526 72
H(35) 3228 10213 6707 86
H(36) 2597 11669 6098 69
H(37) 2833 11042 5338 61
H(38) 3732 8869 5146 57
H(41A) 6291 677 7568 219
H(41B) 6296 1604 8061 219
H(41C) 6766 -106 8016 219
H(42A) 7627 1101 7472 159
H(42B) 7782 1585 8005 159
H(43A) 7313 4083 7882 99
H(43B) 6968 3639 7369 99
H(44A) 8122 4449 7077 132
H(44B) 8454 4956 7591 132
H(45A) 9435 3237 7267 203
H(45B) 8722 1895 7166 203






























































































































































































































































































Crystal structure data for IV-46
Table 1.  Crystal data and structure refinement for s18sel11.
Identification code s18sel11






Unit cell dimensions a = 5.85700(10) Å = 90°.
b = 11.24590(10) Å = 90°.
c = 19.2255(2) Å  = 90°.
Volume 1266.33(3) Å3
Z 4
Density (calculated) 1.459 Mg/m3
Absorption coefficient 1.145 mm-1
F(000) 584
Crystal size 0.320 x 0.150 x 0.100 mm3
Theta range for data collection 4.555 to 72.989°.
Index ranges -6<=h<=7, -13<=k<=13, -23<=l<=23
Reflections collected 12666
Independent reflections 2529 [R(int) = 0.0299]
Completeness to theta = 67.684° 100.0 % 
Absorption correction Semi-empirical from equivalents
Max. and min. transmission 1.00000 and 0.71709
Refinement method Full-matrix least-squares on F2
Data / restraints / parameters 2529 / 0 / 183
Goodness-of-fit on F2 1.052
Final R indices [I>2sigma(I)] R1 = 0.0258, wR2 = 0.0687
R indices (all data) R1 = 0.0266, wR2 = 0.0696
Absolute structure parameter 0.03(6)
Extinction coefficient n/a
Largest diff. peak and hole 0.224 and -0.173 e.Å-3
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Table 2.  Atomic coordinates  ( x 104) and equivalent  isotropic displacement parameters (Å2x 103)
for s18sel11.  U(eq) is defined as one third of  the trace of the orthogonalized Uij tensor.
________________________________________________________________________________ 
x y z U(eq)
________________________________________________________________________________ 
O(1) 7247(2) 4958(1) 5643(1) 27(1)
O(2) 3528(2) 4947(1) 5364(1) 27(1)
O(3) 6864(2) 2652(1) 4795(1) 21(1)
O(4) 6380(2) 1722(1) 3508(1) 27(1)
O(5) 10542(2) 3266(1) 3829(1) 24(1)
O(6) 8344(2) 6348(1) 4113(1) 26(1)
O(7) 4950(2) 5365(1) 3973(1) 21(1)
F 9300(2) 3186(1) 2691(1) 32(1)
C(1) 6640(4) 5056(2) 6373(1) 37(1)
C(2) 5510(3) 4905(1) 5202(1) 20(1)
C(3) 6286(2) 4693(1) 4446(1) 18(1)
C(4) 5755(2) 3380(1) 4295(1) 18(1)
C(5) 6434(3) 2976(1) 3561(1) 20(1)
C(6) 8739(3) 3452(2) 3363(1) 22(1)
C(7) 9793(3) 4496(2) 3679(1) 22(1)
C(8) 8715(3) 5132(1) 4286(1) 20(1)
C(9) 6053(3) 6496(2) 3863(1) 24(1)
C(10) 6043(4) 6734(2) 3090(1) 41(1)

























































































































Table 5.   Anisotropic displacement parameters  (Å2x 103) for s18sel11.  The anisotropic




U11 U22 U33 U23 U13 U12
______________________________________________________________________________ 
O(1) 28(1) 39(1) 15(1) -2(1) -1(1) -4(1)
O(2) 24(1) 33(1) 25(1) -1(1) 5(1) 1(1)
O(3) 23(1) 24(1) 17(1) 5(1) -1(1) 1(1)
O(4) 33(1) 24(1) 23(1) -4(1) -5(1) 1(1)
O(5) 17(1) 31(1) 25(1) 1(1) -2(1) 4(1)
O(6) 24(1) 22(1) 32(1) 3(1) -4(1) -4(1)
O(7) 19(1) 22(1) 21(1) 3(1) -4(1) 1(1)
F 34(1) 44(1) 18(1) -4(1) 6(1) 2(1)
C(1) 44(1) 53(1) 15(1) -5(1) 1(1) -9(1)
C(2) 24(1) 16(1) 19(1) 1(1) 0(1) -1(1)
C(3) 16(1) 22(1) 15(1) 1(1) -2(1) 1(1)
C(4) 15(1) 21(1) 17(1) 2(1) -1(1) 1(1)
C(5) 19(1) 24(1) 17(1) -2(1) -3(1) 2(1)
C(6) 21(1) 30(1) 16(1) 1(1) 1(1) 4(1)
C(7) 15(1) 30(1) 21(1) 4(1) -1(1) 0(1)
C(8) 17(1) 24(1) 19(1) 2(1) -2(1) -2(1)
C(9) 25(1) 22(1) 24(1) 4(1) -2(1) -1(1)
C(10) 48(1) 50(1) 26(1) 15(1) -7(1) -10(1)




Table 6.   Hydrogen coordinates ( x 104) and isotropic  displacement parameters (Å2x 10 3)
for s18sel11.
________________________________________________________________________________ 
x y z U(eq)
________________________________________________________________________________ 
H(3) 5820(50) 2390(30) 5062(15) 42(7)
H(4) 6790(50) 1440(20) 3875(14) 39(7)
H(1A) 5682 5761 6442 56
H(1B) 8031 5130 6653 56
H(1C) 5797 4344 6516 56
H(4A) 4072 3262 4346 21
H(5) 5289 3306 3227 24
H(7) 10814 4981 3374 26
H(8) 9704 5065 4708 24
H(10A) 6825 6084 2848 62
H(10B) 6833 7484 2995 62
H(10C) 4463 6787 2925 62
H(11A) 5699 8212 4214 56
H(11B) 4972 7242 4782 56






























































Table 8.  Hydrogen bonds for s18sel11  [Å and °].
____________________________________________________________________________ 
D-H...A d(D-H) d(H...A) d(D...A) <(DHA)
____________________________________________________________________________ 
O(3)-H(3)...O(3)#1 0.85(3) 2.33(3) 3.0516(6) 142(2)
O(3)-H(3)...O(5)#1 0.85(3) 2.26(3) 2.9432(16) 137(2)
O(4)-H(4)...O(2)#2 0.81(3) 2.37(3) 3.1320(17) 157(2)
O(4)-H(4)...O(3) 0.81(3) 2.23(2) 2.7026(16) 117(2)
____________________________________________________________________________ 
Symmetry transformations used to generate equivalent atoms: 
#1 x-1/2,-y+1/2,-z+1    #2 x+1/2,-y+1/2,-z+1      
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Methyl (3aR,4R,7R,7aR)-6-fluoro-2,2-dimethyl-7,7a-dihydro-4,7-epidioxybenzo[d][1,3]dioxole-
3a(4H)-carboxylate IV-47
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Methyl (1aS,1bS,2aR,2bS,5aR,5bR)-1a-fluoro-4,4-
dimethyltetrahydrobis(oxireno)[2',3':3,4;2'',3'':5,6]benzo[1,2-d][1,3]dioxole-2b(1aH)-carboxylate
IV-48
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Methyl (3aS,4R,7R,7aR)-6-fluoro-4,7-dihydroxy-2,2-dimethyl-7,7a-dihydrobenzo[d][1,3]dioxole-
3a(4H)-carboxylate IV-49
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Methyl (3aS,4R,7aS)-6-fluoro-4-hydroxy-2,2-dimethyl-7-oxo-7,7a-dihydrobenzo[d][1,3]dioxole-
3a(4H)-carboxylate IV-50
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Methyl (3aR,4R,7aS)-4-((tert-butyldimethylsilyl)oxy)-6-fluoro-2,2-dimethyl-7-oxo-7,7a-
dihydrobenzo[d][1,3]dioxole-3a(4H)-carboxylate IV-54
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